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Abstract
The mortality from septic shock is approximately 50%. Most patients die from the 
ensuing multi-organ dysfunction syndrome rather than the acute septic inflammatory 
process per se. The aetiology of the organ dysfunction is unknown. A characteristic 
phenomenon of an increasing severity of sepsis is a decrease in tissue oxygen extraction 
with a decrease (relative and/or absolute) in tissue oxygen consumption. Two theories 
have been advanced to explain this observed decrease in oxygen extraction. 
Traditionally, this has been ascribed to microvascular shunting of blood away from 
nutrient capillaries. However, findings in both patients and animal models have 
demonstrated a raised tissue PO2, suggesting that the oxygen is available to cells but 
cannot be metabolised, i.e. a state of dysoxia. As mitochondria account for over 90% of 
total oxygen consumption, in the process of oxidative phosphorylation, it has been 
hypothesised that sepsis results in an inhibition of the mitochondrial enzymes involved 
in this process. If severe, this would be expected to lead to energy failure in the organs 
and, possibly, to initiation of apoptotic or necrotic cell death.
Marked over-production of the intercellular messenger nitric oxide is a characteristic 
feature of sepsis; the mitochondrial damage theory has been given additional credence 
by the discovery that nitric oxide and its derivative, peroxynitrite, can inhibit or 
permanently damage mitochondrial enzymes involved in the oxidative phosphorylation 
pathway.
The work leading to this thesis has demonstrated that sepsis is associated with an 
increase in nitric oxide production, a reduction in antioxidant protection, respiratory 
chain enzyme inhibition, and a depletion in tissue ATP levels. These changes were 
shown in both skeletal muscle biopsies obtained from critically ill patients in septic 
shock, and in skeletal muscle and liver biopsies obtained from a long-term septic rat 
model. These changes correlated with the severity of disease and eventual outcome. 
These findings thus demonstrate a mechanism that is present in both ‘non-vital’ and 
‘vital’ organs, and across species. These findings may be epiphenomenal and causation 
needs to be definitively demonstrated. However, this work does suggest that 
mitochondrial dysfunction could be an important pathophysiological mechanism 
underlying sepsis-induced organ failure.
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Chapter 1; 
Introduction
1.1 Definition o f sepsis
Sepsis is the systemic inflammatory response to infection. Together with its associated 
organ dysfunction, it is the predominant cause of mortality in the intensive care unit 
(ICU). It is an increasingly common form of death (1;2) and its incidence is predicted to 
increase still further (3).
As interest in the mechanisms underlying the pathogenesis of sepsis grew, so did a 
plethora of confusing terminology. This complicated interpretation of clinical trials and 
laboratory research. To clarify the situation, a consensus conference in 1992 produced 
definitions that are now widely used (4) (Table 1). A generalized inflammatory 
response, termed the systemic inflammatory response syndrome (SIRS), can follow a 
large number of infectious and non-infectious insults such as trauma, bums, and 
pancreatitis. Sepsis is defined as SIRS resulting from infection. Severe sepsis is defined 
as sepsis associated with acute organ dysfunction, while septic shock is defined as 
severe sepsis associated with hypotension unresponsive to adequate fluid resuscitation.
Systemic inflammatory 
response syndrome 
(SIRS)
The systemic inflammatory response to a variety o f severe 
clinical insults. Requires two or more of:
• core temperature >3 8°C or <36°C
• heart rate > 90 bpm
• respiratory rate > 20 breaths/min or PaC02 < 4.3kPa
• white blood count > 12000/mm3 or <4000/mm3 or >10% 
immature neutrophils
Sepsis The systemic response to infection.
Requires SIRS criteria in the presence of proved or suspected 
infection.
Severe sepsis Sepsis associated with organ dysfunction, hypoperfusion or 
hypotension
Septic shock Sepsis associated with hypotension (despite adequate fluid 
resuscitation) and perfusion abnormalities
Table l:Definitions of sepsis as outlined by the ACCP/SCCM (Society of Critical Care 
Medicine/ American College of Chest Physicians) (4).
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1.2 Epidemiology of sepsis
Various studies have assessed the incidence, aetiology and outcome of patients admitted 
to hospital with sepsis. Unfortunately, direct comparisons are difficult as different 
populations (e.g. surgical patients, emergency admissions, ICU patients) are often 
examined, and data are collected in different ways. However, they do demonstrate how 
common a problem sepsis is, particularly amongst the critically ill, the risk factors for 
its development, and the high associated mortality.
A multi-centre cohort study of 14,364 ICU patients (5) found that 21.1% had an 
established infection on admission, with 80% being classified as septic. Short-stay (<24 
hours) patients (mainly elective surgical admissions) had infection rates of 5.6%, of 
which 61% were community-acquired. Longer stay patients (>24 hours) had a 32.3% 
incidence of infection, with 55.8% being community-acquired. Of these long-stay 
infected patients, 28.3% fitted the ACCP/SCCM criteria for sepsis, 23.9% severe sepsis, 
and 29.9% septic shock. Of the 8353 patients comprising the long-stay group 1581 
(18.9%) developed at least one ICU-acquired infection. This incidence was higher in 
patients admitted with an infection compared to those without (26.4% vs. 15.3%). 
Mortality rates ranged from 16.9% in the non-infected group to 53.6% in patients 
admitted with a nosocomial infection and subsequently developing an ICU-acquired 
infection. A point prevalence study (6) of 10,038 admissions in 1417 Western European 
ICUs revealed 44.8% to have microbiological evidence of infection (13.7% community- 
acquired, 9.7% hospital-acquired, and 20.6% acquired within the ICU). Respiratory, 
urinary tract and bloodstream infections accounted for 64.7%, 17.6% and 12%, 
respectively. Enterobacteriaceae (34.4%), Staphylococcus aureus (30.1%) and 
Pseudomonas aeruginosa (28.7%) accounted for the vast majority of isolates. Prolonged 
ICU stay (>48 hours), mechanical ventilation, trauma and central venous catheters were 
independent risk factors for acquiring an ICU infection. On admission, patients over 60 
years, with evidence of organ dysfunction and with a high APACHE II score had a 
worse prognosis. The APACHE II score (Acute Physiology and Chronic Health 
Evaluation score) is calculated within 24 hours of ICU admission and is used to assess 
the severity of the patient’s illness.
The incidence of bacteraemia and sepsis is rising. A 25 year study from 1971-1995 
conducted in a London teaching hospital ICU showed a slow escalation in bacteraemic
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episodes between 1971 (1.7/100 admissions) and 1990 (1.9/100 admissions), but a more 
dramatic increase by 1995 (3.8/100 admissions) (7). This change was associated with a 
shift in isolates from Gram negative to Gram positive organisms. A study in the US 
found sepsis was responsible for 1.3% of all hospital admissions and that the incidence 
had risen, on average, by 8.7%/year between 1979 and 2000 (1). Again, this was 
associated with an increase in the proportion of Gram positive organisms. A systematic 
review of papers published between 1958 and 1997 also found a decrease from 90% to 
69% in the incidence of Gram negative infections causing sepsis (8). These changes 
have been attributed to an increased use of intra-vascular catheters, (responsible for 
62% of bacteraemic episodes between 1986-95, (7)), selective pressures of antibiotic 
usage, an aging population, the use of immunosuppressants and the emergence of 
HIV/AIDS.
The discharge record of hospitals in seven US states in 1995 (3), noted 6,621,559 
admissions of whom 192,980 had an episode of severe sepsis. This translates to a 
national incidence of 3.0 cases per 1000 population. Over half (51.1%) required 
intensive care. The incidence was higher in men and rose with age, from 0.2/1000 in 5- 
14 year olds to 26.2/1000 in those over 85 years. An Underlying co-morbidity was found 
in 55.5%. The overall mortality was 28.6% but increased with age (38.4% if >85 years), 
ICU care (34.1%) and increasing organ dysfunction (76% with >4 organ failures). On 
average, these patients stayed for 19.6 days in hospital, each case costing $22,100. This 
cost was significantly higher in those treated in intensive care ($29,900). This translates 
nationally to $16.7 billion, 83.1% being used in patients over 65 years. The authors 
predict an annual increase in the incidence of severe sepsis of 1.5%.
A two month study involving 11,828 admissions to 170 adult ICUs in France 
documented severe sepsis in 9% of admissions (9). Mean age was 61.4 years and 63% 
were male. Most cases of severe sepsis were pulmonary (41%), abdominal (32%) or 
urinary tract (11%) in origin. Crude hospital mortality rate was 59%. Independent risk 
factors for an early death (<3 days) were: severity of illness (assessed by the Simplified 
Acute Physiology Score II (SAPS II), a scoring system to assess severity of illness on 
admission to ICU, (10)), two or more organ failures, shock and an arterial blood pH 
<7.33. Mortality beyond 3 days was associated with a high illness severity score, 
multiple organ failure, thrombocytopenia, hypothermia and chronic underlying liver 
disease.
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Another large US study across 8 tertiary care centres (11) prospectively monitored 
12,759 patients over a 15 month period and documented 1,342 episodes of sepsis. This 
produced a hospital incidence of 2 cases per 100 admissions, 55% of whom required 
intensive care. Patients with sepsis were older, more likely to be an emergency 
admission, and had longer ICU and hospital stays compared to non-septic patients. The 
most common sites of infection were respiratory (42%), blood (12%), genitourinary 
(11%) and abdominal (10%). Shock (defined as hypotension at the onset of sepsis) was 
present in 47% of patients with neurological dysfunction (assessed by a Glasgow Coma 
Score (GCS) of<15).
A study performed in a German teaching hospital examined the incidence of severe 
sepsis/septic shock and its associated mortality in 4218 patients admitted to their 
surgical intensive care over a seven year period (12). Both incidence and mortality 
increased with age, being 4.1% and 0%, respectively in those below 20 years, rising to 
10.2% and 79.3% in those over 80 years old. A lower incidence of severe sepsis was 
found in females, though mortality was the same. This sex difference was also described 
by Angus and colleague (3).
A UK study found the median daily cost of treating 36 ICU patients admitted with 
sepsis was $930 compared to $750 for 177 patients admitted over the same period with 
non-septic illnesses (13). This was attributed to the septic patients being both sicker 
(higher APACHE II scores) and requiring more interventions (higher Therapeutic 
Intervention Scoring System (TISS) scores, assessing the nursing workload imposed by 
the patient (14)). Nursing staff ($317/day) drugs ($77/day), consumables ($83/day) and 
medical staff ($84/day) were the main cost items.
Teres and colleagues reported an 11.3% prevalence rate for severe sepsis within ICUs, 
with a 36.3% mortality (15). Patients admitted with severe sepsis were older (63.6 vs.
60.7 years), had a higher mortality (36.3% vs. 15.8%) and a longer length of stay (16.2 
vs. 10.6 days) than those admitted with non-septic conditions. Survivors with a SAPS II 
score in the highest quartile had a significantly longer hospital stay (28.5 days) than 
those with a SAPS II score in the lower quartile (14.5 days). The reverse was true for 
non-survivors; those with the highest SAPS II scores had a shorter duration of stay (8.8 
days) compared to those with a lower SAPS II score (16.4 days). A study of admissions
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to ICUs in Italy (16) found the incidence of SIRS, sepsis, severe sepsis and septic shock 
to be 52%, 4.5%, 2.1% and 3%, respectively, with corresponding mortality rates of 
26.5%, 36%, 52% and 81.8%.
To assess the natural progression of SIRS, Rangel-Frausto conducted a nine month 
study of 3708 admissions to three general wards and an ICU in a tertiary referral centre 
(17). They found that 68% of these patients had evidence of SIRS (fulfilling at least 2 of 
the 4 criteria shown in Table 1). These patients were followed up for a further 28 days, 
or until discharge from hospital. During this period 26% developed sepsis, 18% severe 
sepsis and 4% septic shock. Of those who developed septic shock, 71% had previously 
been classified as having SIRS, sepsis or severe sepsis suggesting a continuum of 
disease. Thirty two percent of patients fulfilling two criteria for SIRS developed sepsis 
within 14 days, while 45% of those meeting all four SIRS criteria developed sepsis 
within 14 days. Higher rates of organ dysfunction were seen in patients who had more 
intense inflammatory responses (Table 2). The mortality rate rose from 3% in patients 
without SIRS, to 6% in those fulfilling two SIRS criteria, 18% in those meeting four 
SIRS criteria, and 46% in those with septic shock. This was the first study to 
demonstrate a progression from SIRS to sepsis and septic shock, which was associated 
with increased rates of organ dysfunction and a higher mortality.
Acute 
respiratory 
distress 
syndrome, %
Disseminated
intravascular
coagulation,
%
Acute renal 
failure, %
Shock, %
SIRS: 2 criteria 2 8 9 11
SIRS: 3 criteria 3 15 13 21
SIRS: 4 criteria 6 19 19 27
Sepsis 6 16 19 20
Severe sepsis 8 18 23 28
Septic shock 18 38 51 100
Table 2: Rates of organ dysfunction in patients with SIRS, culture positive sepsis, severe 
sepsis and septic shock. Adapted from Rangel-Fraustro et al (17)
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Septic patients usually die of the ensuing multi-organ dysfunction rather than the initial 
acute inflammation. Due to the relatively recent introduction of life sustaining 
technology such as mechanical ventilators and inotropes, the syndrome of multiple 
organ failure (MOF) has only been recognised as a distinct entity since the 1970s (18), 
and is now the leading cause of mortality in intensive care.
Organ failure is not an all-or-nothing phenomenon. Rather, it is a spectrum of disease 
which may or may not require support, be it pharmacological (e.g. inotropes) or 
mechanical (e.g. renal replacement therapy, mechanical ventilation). This led to a new 
syndrome - multi-organ dysfunction syndrome (MODS) - being coined in 1992 by Bone 
and colleagues (4). MODS is defined as altered organ function in an acutely ill patient 
such that homeostasis cannot be maintained without intervention. MODS can arise 
from a large number of possible insults, sepsis being the most common (19). Other 
causes include conditions as diverse as trauma (20), bums (21), pancreatitis (22), 
cardiac arrest (23), haemorrhage and surgery (24). Studies investigating the aetiology of 
acute renal dysfunction (25) and the acute respiratory distress syndrome (26;27) cite 
sepsis as the commonest pre-disposing factor.
MODS is considered the end result of severe, persistent inflammation. Patients with a 
more intense inflammatory response are more likely to develop organ dysfunction 
(17;28). This may be highly variable, ranging from predominant and profound 
respiratory failure to renal or cardiovascular failure.
As multi-organ dysfunction reflects a spectrum of disease, a number of scoring systems 
have been constructed to assess severity, follow trends, and allow comparisons. Readily 
available physiological and biochemical variables are used to describe dysfunction of 
the major organ systems. The three most popular scoring systems are SOFA (Sequential 
Organ Failure Assessment (29)), shown in Table 3, LODS (Logistic Organ Dysfunction 
Score (30)) and the Multiple Organ Dysfunction Score (31). The LODS system is 
intended only for the first day of intensive care admission while the other scores have 
been used for sequential scoring and for following disease progression. Though the 
sensitivity of some of the measured variables is not particularly high, these scores are ~ 
simple and easy to use. Table 4 demonstrates the correlation between organ failure 
(defined as a SOFA score for that organ of >3 points) and mortality in an international 
multi-centre study of 1449 patients (32).
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SOFA Score 0 1 2 3 4
Respiration
Pa02/Fi0 2 mmHg
>400 <400 <300 <200 with 
respiratory 
support
<100 with 
respiratory 
support
Coagulation
Platelet count 103/mm3
>150 <150 <100 <50 <20
Liver
Bilirubin pmol/1
<20 20-32 33-101 102-204 >204
Cardiovascular system 
Hypotension
None mean BP 
<70 
mmHg
Dop* <5 
Dob*, any 
dose
Dop >5 
Epi° <0.1 
Norepi+ <0.1
Dop >15 
Epi >0.1 
Norepi >0.1
Central nervous system
GCS
15 13-14 10-12 6-9 <6
Renal
Creatinine pmol/1 
(or urine output)
<110 110-170 171-299 300-440
or
<500 ml/day
>440
or
<200ml/day
*= Dopamine, •= Dobutamine, ° = Epinephrine, + = Norepinephrine
(Doses of adrenergic agents given in pg/kg/min, administered for at least 1 hour) 
Table 3: The SOFA score adapted from (29).
Number o f 
failed organs
% o f patients ICU 
mortality rate (%)
Mean maximum 
SOFA score
0 35.1 3.2 3.1
1 24.9 10.6 7.0
2 16.8 25.5 10.1
3 12.1 51.4 13.7
4 6.5 61.3 16.4
5 3.0 67.4 19.4
6 1.6 91.3 21.3
Table 4: Organ dysfunction and mortality, adapted from (32).
The most common organ system to fail is the respiratory system, affecting 91% of 
patients (29), whereas hepatic dysfunction affected only 24%. Table 5 illustrates the 
incidence of organ dysfunction in the ICU.
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Respiratory 1314(91%)
Cardiovascular 896 (62%)
Renal 775 (53%)
Neurological 702 (48%)
Coagulation 513 (35%)
Hepatic 342 (24%)
Table 5: Incidence of organ dysfunction within the ICU, adapted from (29)
Neurological dysfunction was the earliest apparent (mean time from ICU admission 1.6 
days) followed by respiratory, cardiovascular, renal, coagulation and, finally, hepatic 
(mean 4.9 days). Patients admitted with infection had more severe organ dysfunction 
than those without (19). Seventeen percent of patients with no organ failures had 
infection, as opposed to 74% of patients with four failing organs.
The risk of dying relates to:
• The number and severity of failed organs on ICU admission. A study of 1449 
patients (32) found that the mortality of ICU patients admitted with no failing 
organs, as assessed by the SOFA score, was 3.1%, rising to 91.3% for those with 
six organ failures. Lower SOFA scores (32) were seen in eventual survivors (6.7 
± 4.5) compared to non-survivors (13.6 ± 4.8). The mortality rate exceeded 90% 
for those patients with a SOFA score >15 (19). A high cardiovascular score had 
the largest impact on mortality (odds ratio 1.65) followed by renal, neurological, 
coagulation and respiratory scores (odds ratio 1.18) (32). Hepatic dysfunction 
had no impact on mortality (odds ratio 0.82).
• Increasing organ dysfunction. On average, survivors showed an increase in the 
SOFA score of 2.3±2.7 while non-survivors showed a significantly larger rise of 
5.5±4.1 (32). An increase in the Multi-Organ Dysfunction Score (MODS) 
following ICU admission was also associated with a poor outcome, and was 
more predictive of outcome compared to the APACHE II score taken after 24 
hours (33).
• The pattern of organ dysfunction. In a study of 287 septic ICU patients with 
organ dysfunction (34), Russell found the respiratory system was the most 
commonly affected, though neither the initial severity nor change in respiratory 
dysfunction was related to survival. Similarly, Vincent and colleagues (19) also
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found a combination of respiratory dysfunction and another failing system 
carried a lower mortality than any other combinational9). Mortality ranged 
from 20% in those with cardiovascular and haematological dysfunction to 74% 
for those with cardiovascular and neurological dysfunction (23). Others have 
also demonstrated a worsening in cardiovascular (35) or renal (25) function to be 
associated with a poor outcome.
• Precipitating factor. Patients with MODS resulting from trauma had a lower 
mortality (45%) than those associated with sepsis (75%) or cardiac arrest (80%) 
(23).
• Intensity of inflammation. A study of 2,300 consecutive admissions to a surgical 
ICU, over a 49 month period, had a 49.4% incidence of SIRS (36). Those with a 
higher intensity of inflammation (adjudged by the number of SIRS criteria) on 
admission had longer ICU stays and higher mortality rates. Those patients who 
no longer fulfilled the SIRS criteria by ICU day 2 had a lower mortality (11%) 
than those whose score increased or was unchanged (18%).
Although mortality remains high, survival rates for sepsis and MODS are improving 
(1); this is generally due to better overall supportive care rather than any specific 
treatment. A study investigating trends in the aetiology of MODS looked at 5,677 
patients admitted to 19 ICUs between 1979-1982, compared to 17,440 patients admitted 
to 42 ICUs between 1988-1990 (23). The incidence for multiple organ dysfunction was 
14% in both groups. Patient with 1-2 organ failures had similar survival rates over the 
two time periods. However those with >3 organ failures persisting for >4 days showed 
improved survival (from 2% to 16%). For septic shock, a systematic review of 131 
studies also showed a reduction in mortality, from 61.6% in 1988-91 to 53.1% over the 
period 1994-97 (8).
Therapies aimed at reducing mortality in sepsis and MODS have been generally 
disappointing (37), however there have been some recent exceptions. A large (n=1690), 
multi-centre randomized placebo controlled trial has shown an outcome benefit for 
patients with severe sepsis treated with human recombinant activated protein C (38). 
Activated protein C is an endogenous protein capable of activating fibrinolysis, 
inhibiting thrombosis and having anti-inflammatory effects. Levels of protein C are 
depressed in septic patients and are associated with a poor outcome. Replacement with a 
recombinant version of the activated protein over 96 hours led to a 6.1% absolute
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reduction in mortality at 28 days compared to control patients (1  life saved for every 16 
patients treated). Despite the failure of a number of corticosteroid trials in the 1980s 
(39), a recent multi-centre French study (40) showed that septic shock patients who did 
not show an appropriate cortisol rise following a corticotrophin (ACTH) stimulation test 
fared significantly better when treated with ‘physiological’ doses of hydrocortisone and 
fludrocortisone.
1.3 Inflammation
An invading pathogen normally provokes a complex inflammatory cascade aimed at 
localising and eliminating the infection. However, for reasons as yet unclear, this can be 
excessive and inappropriate, resulting in a generalised activation of macrophages, 
neutrophils, platelets, endothelium, complement, coagulation and fibrinolytic pathways. 
These, in turn, produce many inflammatory mediators such as cytokines, arachidonic 
acid metabolites and large amounts of reactive oxygen and nitrogen species such as 
superoxide (O2*) and nitric oxide (NO). These mediators can consume endogenous 
defences such as antioxidants and antiproteases.
Numerous attempts have been made to modulate the inflammatory response in the hope 
of improving outcome. This includes blocking pathogens (e.g. anti-endotoxin 
antibodies), inflammatory mediators (e.g. anti-TNF antibodies, nitric oxide synthase 
inhibitors) or cells (E-selectin antibodies), or by boosting the body’s own anti­
inflammatory or protective responses (e.g. antithrombin III, anti-oxidants). 
Unfortunately, large multi-centre patient studies have generally failed to show either 
significant survival benefit or a consistent reduction in the number or duration of organ 
system failures (37). The reasons for these failures are not fully understood but may 
include inappropriate timing of drug administration, an inability of the drug to halt the 
inflammatory process, or the use of anti-inflammatory drugs during the period of 
relative immunosuppression (the anergic, Compensated Anti-inflammatory Response 
Syndrome [CARS]) that follows the initial period of systemic inflammatory response 
(41).
In many cases, despite the pro-inflammatory phase having dissipated within days, organ 
failure may persist for weeks or even months afterwards, irrespective of further insults 
such as nosocomial infections or surgery.
29
1.4 Oxygen delivery and utilization
Organ function depends on an adequate supply of oxygen for aerobic ATP generation. 
Oxygen delivery to the tissues is dependent on blood flow, haematocrit and the oxygen 
saturation of the haemoglobin. In addition, the ability of oxygen to dissociate from 
haemoglobin, the diffusion gradient from vessel to mitochondria, and the physical 
resistance to this diffusion are also important but less well appreciated factors.
In normal subjects the basal tissue oxygen delivery (DO2) is sufficient to supply the 
tissues with oxygen and substrate to allow aerobic respiration at rest. Increasing DO2 
only increases tissue utilization (VO2) slightly, due to increased cardiac work. However, 
in the face of an increased demand, tissue oxygen delivery is increased by both an 
elevation in cardiac output, and by more oxygen being extracted from the haemoglobin. 
The oxygen extraction ratio (ERO2), the ratio of VO2 to DO2, can increase from a basal 
level of approximately 0.25 to a maximum of 0.80 at the point of maximum exertion. 
The increase in ERO2 is mainly through nutrient capillary recruitment. However, there 
comes a point where delivery can no longer match supply, and an oxygen debt is 
created. This point, the anaerobic threshold (DC^crit)> occurs at an ERO2 of 
approximately 0.60. At this point VO2 becomes dependent on DO2 and is termed 
physiological supply dependency. Below the DChcnt anaerobic respiration attempts to 
make up the shortfall in ATP production. This applies to severe exercise in healthy 
patients and to patients suffering from cardiogenic or hypovolaemic shock.
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Figure 1: The relationship between oxygen delivery (DO2) and oxygen consumption (VO2).
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1.4.1 Oxygen delivery in the critically ill
Clowes (42) found that high risk surgical patients who maintained high levels of DOo 
fared significantly better than those unable to do so. This has been subsequently 
demonstrated in trauma patients (43) and those with ARDS (44) and sepsis (45). 
Shoemaker found the size of perioperative oxygen debt was related to outcome in high 
risk surgical patients (Figure 2) (46). Non-surviving patients had the largest oxygen debt 
in the early post operative period (33.5 L/m2), while those patients who made an 
uncomplicated recovery had an oxygen debt of only 8.0 L/m2.
jntra Hours postoperative
operative 1 2 4 8 12 24 36 48
Figure 2: Oxygen debt in survivors and non-survivors of high risk surgery (46)
By reducing perioperative oxygen debt in the high risk surgical patient through targeted 
oxygen delivery goals using fluid and inotropes, he demonstrated significant 
improvement in mortality rates from 28% in the control groups to just 4% in the 
treatment group (47). Similar results were achieved by Boyd and colleagues (48).
These results may translate into the treatment of the critically ill in the initial stages of 
their illness. Rivers studied 263 patients admitted to an emergency room (ER) with 
severe sepsis (49). Those randomly assigned to an ‘early goal directed group’ received a
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protocolised fluid, vasoactive and blood transfusion regimen to achieve prespecified 
haemodynamic targets while in the ER. They had a significantly lower hospital 
mortality rate compared to those receiving standard care who otherwise received 
identical treatment (30% vs. 46.5%).
In ICU patients with already established organ dysfunction, the situation is far more 
complex. Attempts to enhance DO2/VO2 have been generally disappointing with only a 
slight benefit (50), no difference (51), or harm (52) being reported. This latter study, a 
randomized, prospective controlled trial of a heterogeneous group of critically ill 
medical and post-operative surgical patients found a 50% mortality in the protocol 
group as opposed to 30% in controls. Non-survivors were characterised by an inability 
to respond to the pharmacological challenge by increasing their VO2 (± DO2). A meta­
analysis (53) and consensus conference (54) suggested that timely resuscitation was 
important, however, ‘driving’ the circulation to achieve set target values is of no benefit 
once the patient is critically ill, though it may be advantageous as ‘prophylactic’ therapy 
in the at-risk patient.
These studies suggest that the way patients utilize oxygen is fundamentally different in 
the early stages of critical illness compared to when organ dysfunction is established.
Sepsis is usually characterized by an increased cardiac output but a decreased 
arteriovenous oxygen difference. This high output state does not appear to be ‘luxury 
flow’ in excess of metabolic needs as there is usually a concurrent lactic acidosis (which 
may or may not be due to tissue hypoxia) and organ dysfunction/failure. Similar to the 
high risk surgical patient, septic patients who can spontaneously maintain high levels of 
oxygen delivery/consumption fare better. However, a number of investigators have 
demonstrated altered body utilisation of oxygen in sepsis compared to health. Kreymann 
and colleagues (55) demonstrated a significant fall in global VO2 in patients with 
increasing severity of sepsis. An endotoxic rabbit model demonstrated a fall in VO2 and 
oxygen extraction in the hind limb despite the maintenance of DO2 and tissue oxygen 
tension (56). An endotoxic feline model demonstrated a fall in ileal oxygen extraction 
despite a rise in DO2 (57). In a faecal peritonitis rat model (58), Yang and colleagues 
found both DO2 and VO2 fell in the liver and small intestine while the kidneys 
maintained their VO2 despite a fall in DO2, thus demonstrating the diverse mechanisms 
by which different organs handle oxygen. However, the contrary was found in a rat CLP
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model where sepsis was associated with an increase in oxygen extraction despite similar 
DO2 values to the sham operated animals (59).
Nelson and colleagues assessed the effect of progressive haemorrhage on DO2 and VO2 
in septic and control dogs (60). The DC^ crit in the septic dogs was twice that of the non- 
septic controls. A decrease in the global oxygen extraction was also noted. They later 
demonstrated that the gut DChcrit was higher that in other organ beds, suggesting that 
different organs had different supply dependencies (61). They hypothesized that sepsis 
disrupted microvascular control, leading to earlier supply dependency. Even during this 
phase, however, recruitment of nutrient capillaries was still possible. They suggested 
that some organs were under-perfused, while others were relatively over-perfused.
Other investigators have also hypothesized maldistribution of blood flow within nutrient 
capillary beds, referring to the underperfused areas as microcapillary weak units (62) 
Eichacker, by contrast, found no evidence of oxygen supply-dependency in septic 
compared to sham-operated dogs (63).
Data from patients are contradictory. Oxygen supply-dependency has been 
demonstrated in septic shock by some groups (64;65) but not by others (66;67). 
Friedman and colleagues reported that supply dependency existed during episodes of 
haemodynamic instability while independence existed during periods of stability (65). 
However, Ronco and colleagues were unable to demonstrate supply dependency in 
septic patients with either normal or raised plasma lactate levels (6 6 ). They also 
investigated supply dependency during withdrawal of treatment in terminally ill patients 
and found no dependence of oxygen consumption on oxygen delivery until the delivery 
dropped below a critical point of 3.8 ml/min/kg. Oxygen consumption at this point was 
2.8 ml/min/kg (67). These parameters were similar in both septic and non-septic 
patients. How representative these figures are in relation to critically ill patients being 
actively treated remains open to question. Considerable debate has also been generated 
by the likelihood (or not) of mathematical coupling when oxygen consumption and 
delivery are both being measured using the same variables (cardiac index, haematocrit 
and oxygen saturation). A big difference or error in one of these variables will be 
translated into both calculated parameters.
Other studies have found oxygen supply-dependency to be patient-specific and 
indicative of eventual outcome. The response to a pharmacological challenge, e.g.
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prostacyclin (6 8 ), dobutamine (69) or n-acetylcysteine (70) was able to distinguish 
between survivors and non-survivors on the basis of the VO2 response to the rise in 
DO2 . Except for the prostacyclin study, whose results have not been reproduced, 
survivors were more likely to show significant increases in DO2 and VO2 on infusion of 
the drug whereas non-survivors had a rise in DO2 but a much smaller rise in VO2 . Hayes 
and colleagues (71) found that the patient response to volume expansion and 
dobutamine targeted at ‘supranormaT physiological values divided into two groups. The 
first group who reached target levels in all three indices responded well to treatment and 
survived to leave ICU. The second group, despite interventions with high dose 
dobutamine, showed a rise in cardiac index and DO2 but no rise in VO2 . Lactate levels 
remained high and the oxygen extraction ratio decreased. Sixteen of the seventeen 
patients in this group subsequently died. Patients with a high cardiac reserve also 
appeared to do well while those with poor reserve, even if artificially enhanced, did 
poorly.
In summary, septic patients who can spontaneously (but not with high dose inotropes) 
elevate oxygen delivery and utilization have an increased chance of survival. The point 
at which DC^ crit occurs appears to be at a higher DO2 value in sepsis. Investigators have 
argued that these findings reflect either: i) a disturbance in the microvasculature that 
leads to blood being shunted away from the nutrient capillary bed, leaving parts of the 
tissues relatively hypoxic or ii) a direct cellular effect that prevents the oxygen from 
being appropriately utilized.
1.4.2 Microvascular derangements
Microvascular derangements are well described in sepsis. Using video microscopy in 
unanaesthetized, decerebrated, hyperdynamic septic rats, Cryer and colleagues (72) 
demonstrated a constriction of large (A1 and A2) arterioles and a dilatation of smaller 
(A3 and A4) arterioles. O’Brien reported decreased catecholamine responsiveness in 
mesenteric arteries isolated from endotoxic rats (73). Using orthogonal polarisation 
spectral imaging, alterations in the sublingual vasculature of eight septic patients was 
demonstrated, with decreased perfusion particularly in the smaller blood vessels (74).
Inter-organ differences in blood flow also exist. Martin (75) demonstrated a marked
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decrease in the contractile ability of pulmonary and coeliac arteries of septic rats 
exposed to a number of different vasoconstrictors while the femoral and renal arteries 
responded as per controls. In a conscious endotoxaemic rat model, blood flow increased 
to the duodenum and jejunum, did not change in the colon, but decreased by 43% in the 
ileal mucosa (76).
The reasons for these alterations are complex and multi-factorial. Mechanisms 
implicated in this derangement include:
• Reactive nitrogen species. Nitric oxide (NO) and its metabolites (e.g.
peroxynitrite, ONOO) have been heavily investigated over the last decade as 
modulators of the vasodilatation and vascular dysfunction seen in sepsis 
(77;78). Unfortunately, despite encouraging pre-clinical (79;80) and early 
clinical data, the inhibition of NO production using a ‘non-specific’ nitric oxide 
synthase (NOS) inhibitor (L-NMMA, N -monomethyl-L-arginine) led to an 
excess mortality in the treatment group in a large phase III trial (81).
• Altered vascular receptor activity. With sepsis, systemic arteries become less
responsive to catecholamines. Lower a-receptor density (82) and activity (73) 
have been found in septic rats. The latter study examined rat mesenteric artery 
and found hyporesponsiveness to the a-receptor agonist phenylephrine, and to 
non-specific NOS and specific iNOS inhibition. ONOO' decreased the affinity 
of human a ia and aid vascular receptors for the agonist prasozin (83). The 
administration of endotoxin to healthy volunteers resulted in a decrease in 
arterial responsiveness to norepinephrine but not to L-NMMA (84). This 
implicates a decrease in the activity of the adrenergic signalling pathway. Tang 
and colleagues demonstrated a relative over-expression of the p-adrenoreceptor 
in the early hyperdynamic phase, but a relative under-expression during the 
hypodynamic phase of sepsis (85). In patients with Gram negative sepsis, an 
increased mortality was seen in those patients with down-regulation and 
desensitization of the a 2 and Pi-adrenoreceptors (8 6 ). Reduced adrenoreceptor 
sensitivity was related to lower levels of cAMP in the hearts of septic patients, a 
decrease in myocardial performance and a loss of responsiveness to epinephrine 
(87).
• Arachidonic acid metabolites. Arachidonic acid metabolites are subgrouped into
cycloxygenase (prostaglandins, thromboxanes) and lipoxygenase (leukotrienes) 
products. These are involved in vascular control, permeability, platelet
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aggregability and immune modulation. Sepsis is associated with a suppression 
of prostacyclin (PGI2) and enhanced thromboxane (TXA2) levels that correlated 
with haemodynamic changes (8 8 ). Infusion of prostacyclin or an analogue 
improved blood flow, acidosis and outcome (89;90). Organ blood flow was also 
improved in a septic rat model by TXA2 synthase inhibition (91). In septic 
patients Pittet demonstrated that prostacyclin, but not phentolamine (an 
arteriolar vasodilator), could increase both whole body oxygen consumption 
and skin microvascular blood flow (92). Cyclooxygenase inhibitors such as 
ibuprofen improved survival in animal models (93) but no outcome benefit was 
seen in septic patients (94).
1.4.3 Cellular oxygen utilization
Using in vivo 31P nuclear magnetic resonance spectroscopy, 18F fluoromisonidazole, and 
microfluorometric enzymatic techniques in a septic rat model, Hotchkiss (95) found no 
evidence of bioenergetic failure or tissue hypoxia in rat muscle, liver, heart and brain 
despite an adequate macrovascular oxygen delivery.
Tissue oxygen tension represents the local balance between oxygen delivery and 
utilisation. Low values indicate inadequate supply to meet local demands whereas 
elevated tensions suggest either an excessive supply and/or decreased consumption. 
Muscle tissue PO2 fell in an endotoxic rat model (96) compared to sham operated 
controls. However, when the experiment was repeated but with intravascular volume 
replacement (16ml/kg/hr i.v. 0.9% saline) the oxygen tension remained similar to 
control values; this highlights the importance of fluid resuscitation in both the treatment 
and investigation of sepsis.
Vallet examined muscle and gut (mucosal and serosal) tissue PO2 in endotoxaemic dogs 
(97). The animals remained unresuscitated for the hour following endotoxin injection 
during which time there was a fall in blood pressure, blood flow, and tissue PO2 at all 
sites. Subsequent fluid resuscitation produced an increase in tissue PO2 except at the gut 
mucosa where it remained at extremely low levels. This may possibly reflect 
irreversible damage during the episode of hypoperfusion and, yet again, highlights the 
important confounding influence of hypovolaemia. Using a well resuscitated pig model,
Van de Meer found that endotoxaemia resulted in an ileal mucosal acidosis despite 
maintenance of perfusion (98). This was associated with a significant rise in ileal PO2 
compared to sham controls.
Using low infusion or high bolus doses of i.v. endotoxin in anaesthetised, well- 
resuscitated rats, Rosser generated models that had either high or low cardiac outputs 
(99). Bladder oxygen tension rose in both septic models compared to sham-operated 
controls, irrespective of haemodynamic status. By contrast, a haemorrhage model of 
similar severity (adjudged by metabolic acidosis) produced a fall in bladder tissue 
oxygen tension (100).
This rise in tissue PO2 has been verified in studies of skeletal muscle in forty intensive 
care patients (101). Half were septic, ten had cardiogenic shock, and ten had limited 
infections but no signs of a systemic reaction. A polarographic, Clark-type needle 
electrode was introduced into the biceps muscle o f each patient and a histogram of 
muscle PO2 constructed over eight minutes. In this manner some 200 individual 
measurements were taken at each data point within 3 crrf blocks of muscle. Septic 
patients displayed significant increases in muscle PO2 compared with patients with 
limited infection or in normal subjects (Figure 3). Patients with cardiogenic shock had 
even lower values.
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Figure 3: Muscle oxygen tensions obtained by Boekstegers and colleagues (101)
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Septic patients also demonstrated an increase in muscle PO2 with an increasing severity 
of sepsis over a seven day period (102). Patients responding to an injection of anti-TNF 
antibody showed a reduction in inflammatory indices and illness severity score, with a 
normalisation of muscle PO2 (103). Non-responders who eventually died maintained a 
high muscle PO2 . In a small study of nine septic ICU patients, Ramnarain (104) found 
subcutaneous tissue PO2 fell with clinical improvement in six patients and rose in the 
two who deteriorated and died. A significant correlation was found between 
subcutaneous PtC>2 and SOFA score.
Sair and colleagues investigated muscle (brachioradialis) and subcutaneous tissue PO2 
in six septic patients, seven healthy volunteers and six patients post cardio-pulmonary 
bypass (105). Subcutaneous Pt0 2  values were significantly higher than muscle, 
reflecting the different supply/utilization characteristics of different tissues. Similar to 
the Boekstegers’ study noted above (101), muscle Pt0 2  was significantly higher (4.4 
kPa) in septic patients compared to both cardiac surgical patients (1.5 kPa) and healthy 
volunteers (1.7 kPa). This raised Pt0 2  was not associated with increased forearm blood 
flow measured by plethysmography. These differences were not seen in the 
subcutaneous tissue. On rendering the forearm transiently ischaemic, muscle Pt0 2  fell 
faster in the septic group but the final value was similar in all three groups. Initial 
differences in muscle Pt0 2  were restored on reperfusion of the limb. The authors 
speculated that these changes may be due to pathological vasodilatation, venous pooling 
of blood with a high oxygen content, or a shift in the haemoglobin-oxygen dissociation 
curve (due to the lower pH) augmenting oxygen release to the tissues.
The findings of decreased oxygen extraction and increased tissue oxygen tensions 
prompted some investigators to explore the alternative possibility of inhibition of 
cellular oxygen utilization rather than an impairment of local oxygen delivery due to 
microvascular redistribution. As over 90% of the body’s oxygen is utilised by the 
mitochondrial respiratory chain in the process of oxidative phosphorylation, a disruption 
to this process with a resultant decrease in ATP production may potentially explain the 
organ dysfunction associated with sepsis. Support for this ‘cellular dysoxia’ hypothesis 
comes from cell culture models. Compared to untreated hepatocytes, maximal oxygen 
consumption was markedly increased in hepatocytes exposed to endotoxin (106) at six 
hours, but was significantly depressed at 24 hours. Likewise, endothelial and smooth
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muscle cells isolated from pig aorta and exposed to endotoxin also demonstrated a 
significant decrease in oxygen consumption (107).
1.5 Mitochondria
Mitochondria are intracellular organelles whose roles include:
• Control of metabolic processes including ATP generation (by the process of 
oxidative phosphorylation), fatty acid oxidation and urea formation.
• Control of cell death by the initiation of apoptotic or necrotic processes.
• Ca and ion homeostasis.
• Intracellular signalling.
• Heat production.
Mitochondria are encased in two specialised membranes, the inner and outer 
membranes. This creates two intra-mitochondrial spaces, the small inter-membrane 
space and the larger internal matrix. The outer membrane is relatively porous thus the 
inter-membrane space has a similar composition to the cytosol with respect to small 
molecules. The inner membrane is highly impermeable due to a high proportion of 
lipids, including cardiolipin, within the membrane. This impermeability is central to the 
process of oxidative phosphorylation. Embedded within the inner membrane are the 
components of the respiratory chain, ATP synthase and several transport proteins. 
Contained within the mitochondrial matrix are enzymes involved in oxidation of acetyl 
CoA.
1.5.1 Energy transduction
The process of mitochondrial oxidative phosphorylation is fuelled by the process of 
glycolysis and the oxidation of fatty acids.
Glycolysis is the catabolic process where a six carbon glucose molecule is metabolised 
by a series of enzymatic reactions to two pyruvate (three carbon) molecules. This 
process results in the net production of two molecules of ATP and, crucially, does not 
require oxygen. The process occurs in the cytoplasm and is the cell’s source of ATP in
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conditions of low/absent O2, anaerobic respiration. Pyruvate can undergo oxidative 
decarboxylation, by pyruvate dehydrogenase, to generate acetyl-CoA and enter the 
tricarboxylic acid (Krebs) cycle.
Fatty acids are oxidized within mitochondria by most cells (except those of the brain 
and intestine). The process of fatty acid oxidation is termed p-oxidation since it occurs 
through the sequential removal of 2-carbon units by oxidation at the P-carbon position 
of the fatty acyl-CoA molecule. Each round of P-oxidation produces one molecule of 
NADH, FADH2 and acetyl-CoA.
The acetyl CoA molecule, produced by these processes, condenses with oxaloacetate (a 
four carbon compound) to generate citrate. Through a series of reactions (comprising 
the tricaboxylic acid cycle) the two carbons from the acetyl group are then released as 
carbon dioxide, and the oxaloacetate is regenerated. During this process NAD+ and 
fumarate are reduced to NADH and succinate respectively. These two compounds then 
provide electron to the mitochondrial respiratory chain. A pyrophosphate bond is also 
generated in the form of guanosine triphosphate. This is readily transferred to ADP to 
form ATP.
1.5.2 The mitochondrial respiratory chain
The respiratory chain is the terminal portion of the oxidative phosphorylation pathway 
and is responsible for the majority of the body’s oxygen consumption and ATP 
generation. The respiratory chain is composed of four individual complexes (Complexes 
I to IV) that transfer electrons down a redox gradient from the NAD+/NADH or 
fumarate/succinate couple to the O2/H2O couple. The chain is located in the inner 
mitochondrial membrane and operates as a series of electron transfers with the 
subsequent oxidation and reduction of the donor and acceptor. These reactions are 
known as redox reactions. The reduced and oxidized versions of a compound are known 
as a redox couple.
The initial transfer of electrons from the tricarboxylic acid cycle within the 
mitochondrial matrix to the membrane bound respiratory chain is performed largely by 
the NADH/NAD+couple. However, some enzymes catalyse dehyrogenations where the
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redox potential is close to 0 mV and therefore will not reduce NAD+. These enzymes, 
which include succinate dehydrogenase and electron transferring flavoprotein, donate 
electrons directly to the respiratory chain at a potential close to 0 mV.
There are about 20 redox-active carriers within the respiratory chain consisting of:
• Flavoproteins e.g. FAD and FMN,
• Cytochromes
• Iron sulphur proteins
• Ubiquinone, a lipophilic, freely diffusible quinone with a side chain of 10 
isoprene units (CoQio)
• Protein-bound copper
Most of these carriers are incorporated into the large mitochondrial enzyme complexes; 
only ubiquinone and cytochrome c are freely mobile.
Electrons cannot be transferred randomly from one complex but must follow a 
sequence. This transfer is not a simple stepwise phenomenon as some undergo one 
electron reduction e.g. iron-sulphur (FeS) centres, while others undergo two electron 
reduction e.g. flavoproteins. This lack of simplicity may be inferred from the ratios of 
the individual complexes. For every molecule of complex I, it is estimated there are 
three of complex III, fifty ubiquinone, nine cytochrome c and seven complex IV.
Electron transfer between redox centres involves the electron tunnelling through the 
surrounding protein matrix. This is only possible if the two redox centres (donating and 
accepting) are in close proximity to each other (<14A), and there is an appropriate fall 
in the redox potential between the two centres (usually 0-100mV). If these conditions 
are not met, electron transfer rates would be too slow. Therefore, the redox active sites 
on two complexes are on (or very close to) the surface of the protein to allow electron 
transfer to occur when the complexes come into apposition.
The transfer of electrons through the series of redox centres allows for the extrusion of 
protons from the matrix to the intermembrane space. This generates a proton motive 
force (Ap) across the membrane, composed of an electrical potential (A\j/) estimated to 
be 200mV and a pH gradient (ApH) of approximately -0.5 unit. However, the 
techniques used to measure these values will often influence them. As such, the actual
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values and relative contributions of A\|/ and ApH to Ap in the living organism are 
unknown. It is estimated that for every molecule of NADH oxidized by the respiratory 
chain, ten hydrogen ions are extruded (four by complex I, two by complex III and four 
by complex IV). However, only six hydrogen ions are extruded with the oxidation of 
succinate (two by complex III and four by complex IV) due to the lower redox potential 
of the fumarate/succinate couple. The physical movement of protons across the inner 
mitochondrial membrane is not fully understood but may involve a proton pump or a 
redox loop. The conformational pump theory suggests a redox activated conformational 
change in the complex, allowing exposure of the redox active site to alternate sides of 
the membrane. The other possibility - the redox ‘loop’ theory - includes a series of 
alternate proton/electron carriers that allow movement of protons across the membrane.
Complex I (NADH-Ubiquinone oxidoreductase) is the largest (approximately 750kDa) 
and least well understood of the respiratory chain complexes. It catalyses the transfer of 
two electrons from NADH to ubiquinone, and in so doing translocates four protons. 
Complex I is composed of at least 14 subunits and contains at least one flavin (FMN) 
and eight FeS centres. Most of these have redox potentials ranging from -300mV to 
-230mV and are therefore thought to be involved in the early steps of electron transfer. 
One of the FeS centres has a redox potential of -20 to -160mV and is therefore 
postulated to be involved later in the transfer of electrons, possibly to ubiquinone.
Ubiquinone receives electrons not just from complex I, but also from three other 
sources:-
1. Complex II (succinate dehyrogenase). This complex is composed of four 
subunits, and oxidizes succinate to fumarate as part of the Krebs cycle. The two 
electrons released pass through three FeS centres into the membrane phase of the 
complex where they reduce ubiquinone.
2. Electron transferring flavoprotein-ubiquinone oxidoreductase (ETF-ubiquinone 
oxidoreductase). This accepts electrons resulting from fatty acid and amino acid 
catabolism. ETF-ubiquinone oxidoreductase contains a FAD and a FeS centre. It 
is anchored to the matrix (n) side of the membrane by hydrophobic residues, 
where the interaction with ubiquinone is thought to occur.
3. Glycerol-3-phosphate dehydrogenase. This is anchored to the outside (p) of the 
membrane and provides a means of electron transfer from cytoplasmic NADH 
directly to the respiratory chain.
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Ubiquinone is lipophilic, freely diffusible within the membrane and can be reduced to 
ubiquinol. The transfer of electrons from ubiquinol to complex III (often referred to as 
the bcj complex), is complicated and is referred to as the Q cycle. Firstly, ubiquinol 
binds to a site on complex III (Qp) and transfers an electron to the FeS contained in the 
Rieske protein of complex III, thus generating a semiquinone radical and translocating 
two protons. This electron subsequently reduces cytochrome C. An electron is then 
donated to the b haem of complex III, which is in close proximity to a second 
ubiquinone binding site (Qn) that has a high affinity for the semiquinone. The 
semiquinone can then be reduced back to ubiquinone by the transfer of two electrons 
(the second electron having come from the oxidation of another ubiquinol molecule, 
described above), thus completing the cycle.
Complex III is thought to be a dimer, with each monomer working to catalyse the 
transfer of electrons from ubiquinol to cytochrome C. Once the FeS centre within the 
Rieske protein has been reduced by the transfer of an electron from ubiquinol, the FeS 
dissociates from the Qp binding site. At the same time, its affinity for cytochrome C is 
increased, and is thus able to shuttle the electron from the Qp to the cytochrome C 
binding site, a distance of approximately 20A. Once the electron has been passed to 
cytochrome C, the affinity reverts back to Qp.
Cytochrome C is a protein located on the p side of the mitochondrial membrane and is 
responsible for the transfer of electrons between complex III and complex IV. 
Cytochrome C is also involved in the apoptotic signalling mechanism.
Complex IV (cytochrome C oxidase) is the terminal component of the respiratory chain 
and is composed of eleven different subunits. Complex IV is responsible for reducing 
one molecule of oxygen to two molecules of water. The mechanism by which this 
occurs is complex and not fully understood, but it is believed to take a number of steps.
1. Oxygen initially binds to a haem centre (a3).
2. The 0 -0  bond is then broken with the formation of a Fe4+=0 and a hydroxyl group 
bound to a closely associated copper moiety (C ub). This reaction requires four 
electrons of which two originate from a3, one from Cub while one is hypothesized to 
come from a tyrosine residue attached to the copper (which also donates the 
required proton).
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3. The Fe4+=0 is then reduced to Fe3+-OH by an electron originating from cytochrome 
C and a proton from the n side of the membrane
4. A further two electrons and two protons are then required to allow the ferric 
hydroxide and the copper hydroxide to return to their original oxidation state with 
the concomitant release of two molecules of water.
The reaction can be summarized by the equation, 4e‘ + 4H* + O2 —» 2 H2O
The reduction of one molecule of oxygen is also associated with the translocation of
four protons from the n to the p side of the membrane.
The Ap generated can then be utilised by the mitochondria in a number of ways:
1. ATP synthesis, using the ATP synthase enzyme {q.v.)
2. Ion and metabolite transport, such as translocation of ATP/ADP and Na+/H+ 
exchange.
3. Thermogenesis. Brown adipocytes, common in newborn mammals, contain 
large numbers of mitochondria. These contain a transmembrane protein known 
as uncoupling protein-1 (UCP1). Triglyceride stores are hydrolysed to free fatty 
acids which, in turn, bind to UCP1. This protein now undergoes a 
conformational change, allowing it to conduct protons thus lowering Ap and 
releasing heat. A further four UCPs have been described, two in the brain and 
two distributed through numerous tissues. UCPs are also thought to be involved 
in controlling metabolic rate and free radical production (108).
4. Proton leak. The inner mitochondrial membrane is not completely impermeable 
to protons and a proportion will ‘leak’ back into the matrix lowering Ap. The 
reason for this is not fully understood. The extent of the leak varies between 
species; anoxia-tolerant animals have less permeable mitochondrial membranes 
than mammals. This may allow them to redirect a greater proportion of Ap 
toward ATP generation when oxygen tensions (and the rate of respiration) fall 
(109).
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1.5.3 ATP synthesis
The ATP synthase enzyme (complex V) utilises Ap to generate ATP from ADP and 
inorganic phosphate (Pj). It spans the inner mitochondrial membrane and is classically 
described as being composed of two fractions. Fraction oligomycin (Fo) is the 
transmembrane portion of the protein that is capable of conducting protons; it can be 
inhibited by oligomycin. Fraction 1 (Fi) has the ATPase activity and controls proton 
entry to F<> Thus, ATP synthase is often referred to as Fj. Fq-ATPase. (Figure 4)
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Figure 4: Schematic representation of ATP synthase (obtained from 
http://pathology.mc.duke.edu/research/postpizzo.html).
The Fi fraction is composed of five different polypeptides a , p, y , 5 , and s. The a  and P 
subunits (of which there are three each) are arranged alternately around the y  subunit. 
The y  subunit extends from the (X3, P3 complex and with the 5 and e  subunits allow for 
interaction with the Fo fraction. The Fo fraction contains three polypeptides, a, b and c. 
The relative proportions of these polypeptides are as yet unknown. The c subunits are 
thought to create a transmembrane ring and interact with the y  subunit of Fj. The b 
subunit is also believed to interact between both fractions while subunit a is believed to 
be contained within the membrane and interact with the c subunits. The mechanism by
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which Fi. Fo-ATPase uses the proton motive force to generate ATP is also yet to be 
hilly elucidated. Current theory suggests the (X3, P3 complex contains binding sites for 
ADP and Pi that then undergo conformational changes to form and then release ATP, 
where one cycle results in the formation of three molecules of ATP.
In the absence of Ap, the Fj. Fo-ATPase is able to run in reverse, hydrolysing ATP and 
generating a proton gradient. An inhibitor protein can be found in mammalian 
mitochondria and this may prevent ATP hydrolysis. However, Beltran inhibited 
mitochondrial respiration by 85% (using NO) and noted that AT actually increased. 
Inhibiting the Fi. Fo-ATPase with oligomycin resulted in a decrease in AT, suggesting 
that, in this cell line at least, the Fi. Fo-ATPase may be able to maintain AT by running 
in reverse (1 1 0 ).
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1.5.4 Control of respiration
Respiration is controlled by the equilibrium between the redox potential across the 
respiratory chain and Ap. If the inner mitochondrial membrane was impermeable to 
protons, respiration would generate a proton gradient of approximately -200mV. At this 
point an equilibrium would be achieved and respiration stops. However, if the proton 
gradient is dissipated (e.g. by ATP synthesis, proton leak, etc) this equilibrium is lost 
and respiration accelerates. This is demonstrated in Figure 5, where mitochondria are 
added to an air-tight flask with an oxygen electrode. As the solution does not contain 
any reducing equivalents or ADP, respiration (and proton translocation) cannot occur; 
this is known as state 1 respiration. The addition of ADP to the solution results in the 
activation of ATP synthase, however respiration is limited by the lack of substrate; state 
2 respiration. On the addition of the substrate succinate (and in the presence of ADP), 
respiration and proton translocation accelerate until the supply of ADP is exhausted; this 
is known as state 3 respiration and is limited by the activity of the respiratory chain 
complexes. Without ADP the translocation of protons through ATP synthase ceases and 
respiration slows to match the dissipation through proton leak; this is known as state 4 
respiration. The ADPiO ratio during state 3 respiration can be calculated if a known 
amount of ADP is added to the flask and the amount of oxygen consumed is measured. 
This can indicate how efficiently respiration is coupled to ATP synthesis. Eventually, 
the oxygen in the flask will have been consumed; thus, without a terminal electron 
acceptor, respiration and proton translocation will cease and the proton gradient will 
dissipate; this is state 5 respiration. In practice, investigators usually only refer to state 3 
and 4 respiration. The ratio of state 3 to state 4 respiration (respiratory control ratio, 
RCR) gives an indication of the proportion of oxygen consumption used for ATP 
synthesis and that lost to proton leak.
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Figure 5: The ‘states’ of mitochondrial respiration
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1.6 Production of reactive species
During normal respiration a proportion of electrons passing though the respiratory chain 
are donated directly to oxygen at sites other than complex IV. This results in the 
formation of the reactive species, superoxide (O2*). O2’ can be dismutated to hydrogen 
peroxide (H2O2) and water by either cytosolic CuZn-superoxide dismutase or 
mitochondrial Mn-superoxide dismutase. It is generally quoted that about 1% of 
reducing equivalents are released as H2O2 during well-coupled respiration (111). It is 
thought that production of O j occurs at both complex I, upstream of the rotenone 
binding site (112), and at complex III on the Qp site (113). However, due to the short 
lived nature of O2*, it is difficult to measure its production accurately. Markers such as 
H2O2 production are often used as a surrogate measure of O2’ production. Thus the 
values obtained depend on the cell type used (114; 115), the antioxidant defences of the 
cell or mitochondria (e.g. reduced glutathione, GSH), and the methods of detection.
Debate continues as to the proportion of reducing equivalents that generates O2*. Recent 
papers suggest this could be significantly less than 1% (115;116) and is dependent on 
the respiratory chain substrate. St Pierre and colleagues (115) demonstrated that 
mitochondria isolated from rat skeletal and cardiac muscle do not produce H2O2 when 
respiring on malate and pyruvate (substrate for complex I) or succinate (substrate for 
complex II). However, mitochondria respiring on palmitoyl carnitine (which donates 
electrons by ETF-ubiquinone oxidoreductase) generate significantly more H2O2 . This 
may be due to reverse flow of electrons through complex I, or through the generation of 
O2* by ETF-oxidoreductase itself. However, this was thought to account for only 0.15% 
of total electron flux. Inhibitors of complexes I and III (rotenone and antimycin A, 
respectively) also increased H2O2 production by forcing these complexes to become 
maximally reduced. Complex III produced more H2 0 2 than complex I but did so on the 
cytosolic side of the inner mitochondrial membrane while complex I produced H2O2 on 
the matrix side.
The proportion of reducing equivalents diverted to 0 2 * production increases when the 
respiratory chain becomes reduced as a result of inhibition (114; 117) or disease. 
Mitochondria exposed to NO (a known inhibitor of mitochondrial respiration) showed a
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decrease in complex I, III and IV activities, and an increase in superoxide production 
(118). A rat caecal ligation and puncture (CLP) model demonstrated that generation of 
mitochondrial H2O2 and hydroxyl radical (OH‘) was significantly higher in livers 
isolated from septic as opposed to control rats (116). However, this increase was only 
seen in succinate-supported respiration and not NAD-linked respiration, raising the 
possibility that complex II may also be involved in producing reactive oxygen species. 
Another rat model demonstrated a 2.5 fold increase in H2O2 production by skeletal 
muscle mitochondria isolated from septic rats (119). Infusion of pro-inflammatory 
mediators, NO or bradykinin into the vasculature of isolated rat hearts led to increased 
production of H2O2 (120). In the case of bradykinin, H2O2 production was decreased by 
the NOS inhibitor, L-NMMA and potentiated by the ACE inhibitor, enalapril, which 
inhibits the breakdown of bradykinin.
The addition of L-arginine (a precursor of NO synthesis) to a suspension of rat liver 
mitochondria resulted in the formation of NO and a decrease in state 4 respiration (117). 
This was also associated with an increase in H2O2 production (42% for glutamate and 
58% for succinate-supported respiration). A direct relationship was seen between the 
reduction of cytochrome b and the rate of H2O2 production.
Other important sources of reactive oxygen species are:
1 . the neutrophil, which produces O2’ as a cytotoxic agent during the respiratory burst.
2 . xanthine oxidase, which is involved in the metabolism of nucleotides to uric acid, 
producing O2* as a by-product.
Both these sources of reactive oxygen species are up-regulated during the septic 
process. A study of 31 children with septic shock and MODS showed evidence of 
increased xanthine oxidase activity compared to 30 control children (121). A study 
involving endotoxic rabbits described a loss of the skeletal muscle total adenine pool 
and an increase in plasma hypoxanthine; this may reflect accelerated purine metabolism 
and hence O2' production (122). Enhanced xanthine oxidase activity and O2* production 
were also seen in dysfunctional hearts isolated from endotoxic rats (123).
An excessive release of O2* is, in itself, pro-inflammatory; this results in a recruitment 
of neutrophils, release of inflammatory cytokines, and cell damage (124). This damage
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includes lipid peroxidation, DNA damage and alteration of protein structure and 
function. These alterations may result in cellular dysfunction, and even cell death.
1.6.1 Antioxidant defences
The cell contains a number of antioxidants to protect itself against damage from reactive 
species. The most important antioxidants within the mitochondria are reduced 
glutathione (GSH), thioredoxin and Mn-superoxide dismutase. Quantitatively, GSH is 
the most important. It is a tripeptide consisting of glutamate, cysteine and glycine. 
Glutathione synthesis initially involves formation of a dipeptide by the enzyme y- 
glutamyl-cysteine synthetase, and then formation of the tripetide by glutathione 
synthase. GSH is synthesized in the cytoplasm and needs to be transported into the 
mitochondria. It acts as a substrate for two enzymes, GSH peroxidase and GSH 
transferase, and is oxidised to GSSG. Glutathione peroxidase uses GSH to detoxify 
H2O2 produced by dismutation of O2*. GSH and reduced thioredoxin both maintain 
protein -SH (thiol) groups in a reduced form, (Figure 6 ). The reduction of GSSG back 
to GSH is via the NADPH-dependent enzyme, GSSG reductase.
There is evidence to suggest that GSH levels are depressed during processes involving 
increased oxidative/reductive stress, such as sepsis (121; 125), ischaemia (126) and 
hyperoxia (127), thus exposing the cell to increased oxidative stress.
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Figure 6: Mitochondrial GSH utilization
1.6.2 NO and other reactive nitrogen species
Nitric oxide (NO) is an important mediator in numerous physiological processes such as 
control of vascular tone, inhibition of platelet aggregation, signalling, memory 
formation and enhancing neutrophil cytotoxicity.
NO is a free radical gas produced by numerous cell types, either by the action of NOS 
on L-arginine, or derived from endogenous NO donors, such as nitrosothiols. There are 
three NOS isoforms, two constitutive (endothelial NOS [eNOS] and neuronal NOS 
[nNOS]) and one inducible (iNOS). The constitutive isoforms maintain a background
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level of NO to carry out normal physiological functions. The inducible isoform has very 
little activity in health, however its production can be markedly and rapidly upregulated 
in response to stress.
All three NOS isoforms generate NO by the oxidation of L-arginine to citrulline. Each 
NOS molecule is a homodimer with each monomer comprising of an oxygenase and a 
reductase domain. These domains are separated by a central region that binds 
calmodulin (a calcium binding protein). Calmodulin (and therefore calcium) can control 
NO production as binding permits the transfer of electrons from the reductase to the 
oxidase domain. iNOS has a much higher affinity for calmodulin than either eNOS or 
nNOS making binding essentially irreversible and therefore persistently active. The 
reductase domain is responsible for transferring electrons from bound NADPH to a 
haem centre within the oxidase domain. The oxygenase region binds L-arginine and this 
is where NO synthesis occurs. The haem centre reacts with molecular oxygen to 
produce an iron-oxygen species that hydroxylates arginine to form a NOH-arginine 
compound that is bound to the enzyme. This is followed by further rearrangements that 
produce free NO and citrulline (128).
Under certain situations it is thought that nNOS, and probably eNOS and iNOS, are also 
capable of producing O2*. Depletion of L-arginine stores in a model of ischaemia 
reperfusion resulted in production of O2 mediated by the constitutive isoforms of NOS 
(129). The reductase domain of iNOS has also been shown to produce O2*, even in the 
presence of high concentrations of L-arginine (130).
To allow dimerisation of the NOS enzyme, the oxidase region needs to bind 
tetrahydrobiopterin (BH4). In situations where BH4 is limited, it is postulated that 
subunits without BH4 may produce 02* instead of NO. Indeed, BH4 deficient mice (hph- 
1 knockout) demonstrated decreased levels of NO production and evidence of enhanced 
vascular O2’ production (131; 132). BH4 levels rise in inflammatory conditions in both 
animals (133) and humans (134). Deliberate depletion of BH4 (and thus iNOS function) 
during the septic process may improve haemodynamic status, though this increases the 
risk of enhanced O2* production. Hoshiari, using a column of polymixin B coated fibres, 
haemoperfused eight beagles 14 hours after an i.v. dose of endotoxin (134). Within 60 
minutes there was an increased blood pressure and lower plasma BH4 levels. However,
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there was no change in plasma nitrite/nitrate levels, suggesting no change in NO 
production, although this is a relatively insensitive marker of acute change.
In a solution where both NO and O2’ are being produced there is rapid formation of the 
powerful oxidant ONOO' (135). A similar situation may exist in the mitochondria of a 
septic organism where there is both enhanced O2* production by the respiratory chain 
and iNOS-generated NO. ONOO'is capable of denaturing proteins, cleaving DNA (136) 
and causing prolonged/irreversible inhibition of the respiratory chain (137), ATP 
synthase (138) and mitochondrial aconitase (139). Evidence of ONOO'production 
during the inflammatory process has been found in several animal models (140; 141) and 
in patients. Three patients with chronic renal failure and septic shock showed elevation 
of an ONOO'marker (nitrotyrosine) in their plasma (118±22pM), compared to ten 
patients with chronic renal failure (28±12.3pM) and ten healthy volunteers 
(undetectable) (142). Rectus abdominis biopsies obtained from 16 septic patients 
demonstrated increased levels of nitrotyrosine compared to 2 1  elective surgical cases 
(143). Colocalization was noted between the iNOS protein and nitrotyrosine production. 
Human granulocytes and monocytes stimulated, ex vivo, with endotoxin demonstrate the 
ability to produce ONOO' (assessed by the oxidation of dihydrorhodamine-123) (144).
Though ONOO’ has numerous harmful effects, it has an important role in the 
bactericidal properties of neutrophils and macrophages (145), and may also play a role 
in cell signalling. ONOO' has the ability to nitrate tyrosine residues on the iNOS 
enzyme, thereby reducing its activity and acting as a negative feedback mechanism. 
iNOS isolated from the muscle of three septic patients had evidence of nitrated tyrosine 
residues on the iNOS protein; this was not present in surgical controls (146). Addition 
of exogenous ONOO'to the iNOS protein resulted in nitration of similar residues and 
led to a decrease in NOS activity.
NO may also be produced in mammalian cells by non-enzymatic pathways such as the 
reduction of nitrite (NO2') to NO by the mitochondrial respiratory chain (147).
NO is rapidly deactivated by binding to haemoglobin (148) (for which it has a high 
affinity), reaction with thiol residues to form nitrosothiols, (these may then act as a NO 
reservoir) (149), auto-oxidation to nitrite, or by reacting with reactive oxygen species 
(ROS) to form ONOO" and other derivatives (150).
54
1.6.3 Mitochondrial NOS
NOS activity has also been found within mitochondria. However, it is not yet certain 
whether this is due to a fourth NOS isoform (mtNOS), the result of one of the other 
isoforms being translocated into the mitochondria or contamination. Frandsen 
demonstrated co-localization of nNOS and mitochondria in human muscle biopsies 
(151). However, Kobzic and colleagues found co-localization of eNOS with the 
mitochondria of skeletal muscle isolated from the diaphragm and leg of a rat (152). 
Bates and colleagues found immunolabelling for eNOS in mitochondria isolated from 
rat skeletal muscle, liver and kidney (153). These mitochondria demonstrated calcium 
dependent NOS activity sufficient to inhibit respiration. NOS activity has also been 
detected in mitochondria and sub-mitochondrial particles isolated from rat liver (154). 
The activity required L-arginine and was sensitive to inhibition by L-NMMA. The 
authors estimated the production of NO would sustain an NO concentration of 0.1- 
0.5pM. The enzyme has also been shown to be localized to the mitochondrial 
membrane (155;156). Its enzymatic characteristics are similar to other constitutive NOS 
isoforms; it requires tetrahydrobiopterin, NADPH and free calcium. However, its 
molecular weight and cross-reactivity with an iNOS antibody make these findings less 
easy to interpret. Conversely, a cross-reactivity with eNOS antibodies (and not iNOS) 
has been reported while, at the same time, being constitutively active and dependent on 
calmodulin (157). The role of mtNOS remains unclear. It may be organ-specific, though 
the relatively large quantities of mtNOS found in the liver may control respiration. Very 
low quantities and activity have been found in heart mitochondria (158), with no effect 
on respiration. Others have hypothesized mtNOS is involved in calcium handling (159), 
control of the mitochondrial membrane potential (160), initiation of apoptosis (161) and 
in the response to hypoxia (157).
1.6.4 NOS inhibitors
A large part of our understanding of NO production and action has been developed 
through the use of inhibitors of the constitutive and inducible forms of the NOS 
enzyme. Most of these inhibitors act as arginine analogues competing for the binding 
site on the NOS enzyme. Generally, they are referred to as ‘non-specific’ (inhibiting
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both eNOS and iNOS) or ‘specific’ inhibitors (which usually inhibit just iNOS). This 
nomenclature is confusing as commonly used ‘non-specific’ inhibitors such as L- 
NAME, L-NMMA and L-NA have a much lower in-vitro affinity for iNOS than for 
eNOS (ratios of 0.05, 0.1 and 0.03, respectively) (162).
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1.7 NO and sepsis
Macrophage activation is an early event in the septic process, resulting in upregulation 
of iNOS production and the release of pro-inflammatory cytokines such as tumor 
necrosis factor (TNF) and interleukin-1 (IL-1). These cytokines have the ability to up- 
regulate iNOS at distant sites. This is generally thought to occur within four hours of the 
cell being stressed (79). However, we have recently demonstrated that an increase in 
iNOS-generated NO occurs within two hours of an endotoxic insult (paper submitted).
A 24 hour incubation of IL-1 and rat cardiomyocytes led to increased levels of iNOS 
RNA and nitrite levels (163). The increased level of nitrite could be prevented by 
addition of the NOS inhibitor NMA (Nu-monomethyl-L-arginine). The addition of LPS 
to rat hepatocytes or a co-culture of hepatocytes and macrophages for 24 hours led to an 
increase in media nitrite concentration, and to formation of iron-nitrosyl complexes 
within the hepatocytes (detected by electron paramagnetic resonance spectroscopy,
EPR) (164). These changes were prevented by a NOS inhibitor.
An i.v. injection of endotoxin (12.5mg/kg) to mice resulted in a rapid increase in the 
pro-inflammatory cytokines TNFa and IL- 6  within one hour (79). Nitrite and nitrate 
levels were detectable in the plasma by two hours and evidence of iNOS activity by four 
hours. The rise in NO production was associated with a fall in blood pressure. Both 
changes in nitrite/nitrate levels and blood pressure could be prevented using L-NMMA, 
or by using iNOS knockout mice. In rats treated with i.v. endotoxin (1 mg/kg), a 
significant rise in plasma nitrite/nitrate levels were seen at six hours (164). Similar 
values were also seen in rats treated with C.parvum for 6  days (a model of chronic 
infection), though the addition of endotoxin at this point led to a marked (480%), further 
increase in nitrite/nitrate levels and the generation of nitrosylated haemoglobin, Hb-NO 
(detected by EPR). In a short term (four hour) rat model of endotoxaemia, we have 
demonstrated a significant rise in the Hb-NO signal (detected by EPR) at one hour; 
pharmacological manipulation with L-NAME and 1400W implicated eNOS rather than 
iNOS in this early increase in NO production. By two hours there was pharmacological 
evidence of iNOS activity which became the predominant producer of NO by four hours 
(Dr Nathan Davies, personal communication). Evidence of iNOS induction and NO 
production were seen at one and two hours, respectively in another endotoxic rat model
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(165). Other animal models have reported increased levels of iNOS in the ileal mucosa 
at four hours (166), and the thoracic aorta at six hours (167).
The initial focus of NO research in sepsis was on its cardiovascular properties (168).
NO acts on soluble guanylate cyclase to increase intracellular levels of cGMP, leading 
to vascular smooth muscle relaxation and vasodilation. Under normal physiological 
circumstances this allows microvascular adaptation to local requirements. However, 
excessive production of NO leads to a generalized vasodilated state mediated through 
cyclic GMP-dependent and independent mechanisms (73;78). There is loss of vascular 
integrity through NO-mediated damage to the vascular endothelium and decreased 
smooth muscle reactivity to catecholamines. Both these mechanisms result in a loss of 
vascular control and hypotension that is often refractory to fluid and vasopressors (169). 
By inhibiting nitric oxide synthesis, or the action of NO on guanylate cyclase (170) the 
circulation could be restored and the hyporesponsiveness to vasopressors reversed (171- 
174). However, in 797 septic shock patients multicentre phase III trial investigating L- 
NMMA (a ‘non-specific’ NOS inhibitor) was terminated early through an excess 
mortality in the treatment group (81). This was seen in patients receiving higher doses 
of the drug or those with low cardiac outputs at baseline (Dr Richard Knowles, personal 
communication). A trial involving a specific iNOS inhibitor may be of more benefit 
(175).
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1.7.1 NO and organ dysfunction
NO is produced in large quantities during the septic process. This is frequently 
associated with hypotension that can be reversed with a NOS inhibitor (79; 176; 177). 
These finding have implicated NO as being causal (at least in part) of the cardiovascular 
failure seen in human sepsis.
The fall in blood pressure in an endotoxic rat model could be prevented with the either 
non-specific (L-NAME) or specific iNOS (N6-(-l-iminoethyl) lysine (L-NIL)) 
inhibitors (167). However, only the use of L-NIL prevented the development of 
hypoglycaemia and a metabolic acidosis. The infusion of L-NMMA to a faecal 
peritonitis pig model led to maintenance of blood pressure, a fall in plasma nitrites and 
an improvement in survival (at nine hours) compared to untreated septic animals (80). 
Similar findings were noted by Saetre and colleagues, using the NOS inhibitor, 
aminoethyl-isothiourea (178). Myocardial systolic and diastolic dysfunction in a septic 
rat model was associated with increased levels of myocardial NO at 48 hours (179). 
Another endotoxic rat model demonstrated a decrease in myocardial contractility at 16 
hours that was associated with raised levels of myocardial NOx and 3-nitrotyrosine, and 
a depression in tissue GSH (180). Rats surviving to 48 hours showed clinical 
improvement and myocardial contractility similar to baseline levels. This was 
associated with a normal GSH level, though NOx and 3-nitrotyrosine remained 
elevated. iNOS inhibition (l-amino-2-hydroxyguanidine) prevented the hypotension, 
acidosis and liver (but not kidney) dysfunction seen in yet another endotoxic rat model 
(181). In a similar experiment, iNOS inhibition reduced the level of renal, liver and 
pancreatic dysfunction (177). The hypotension, and increases in urea and aspartate 
aminotransferase witnessed in an endotoxic rat model was largely ameliorated by 
concomitant use of the iNOS inhibitor L-canavanine (182).
Finkel demonstrated that addition of pro-inflammatory cytokines (TNF-a, IL-2 and IL- 
6) to hamster cardiac papillary muscle resulted in a concentration-dependent decrease in 
inotropic activity (183). This could be prevented by L-NMMA which, in turn, could be 
overcome by increasing doses of L-arginine.
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El-Dwairi and colleagues examined the effect of LPS on the contractile dysfunction of 
rat diaphragm, intercostal, gastrocnemius and soleus muscles at 6,12 and 24 hours 
following an i.p. injection of LPS (140). Compared to control animals there were 
significant but differing (gastrocnemius>intercostals>diaphragm>soleus) rises in NOS 
activity (mainly Ca2+ dependent) at 12 and 24 hours in all muscle groups other than the 
soleus group. This was associated with an increase in expression of all NOS isoforms.
In the diaphragm eNOS rose two-fold 24 hours after injection, nNOS 5-fold at 12 hours 
and iNOS 100-fold at 12 hours. iNOS levels returned to baseline values by 24 hours. 
Using anti-nitrotyrosine antibodies, they demonstrated evidence of significant ONOO' 
production in the diaphragm at 12 hours, which decreased by 24 hours. The 
diaphragmatic contractile response to electrical stimuli decreased in a time dependent 
manner. At 24 hours this contractile dysfunction could be restored by the use of a NOS 
inhibitor (S-methylisothiourea), implicating NO in the failure of the skeletal 
musculature associated with sepsis (184).
Another rat model injected with an i.p. dose of endotoxin demonstrated significant 
increases in both iNOS protein and activity in the diaphragm up to 24 hours but not at 
48 hours (185). Staining the diaphragm for iNOS revealed that its expression between 6- 
12 hours was confined to inflammatory cells while expression between 12-24 hours was 
also seen in myocytes. These findings were associated with a decrease in the force of 
contraction of the myocytes isolated from the septic animals. Administration of L- 
NMMA 90 minutes after injection of endotoxin resulted in a decrease in iNOS activity, 
but not in protein levels, and a preservation of contractile function at 24 hours, 
compared to rats treated with endotoxin alone. Administration of dexamethasone, which 
has multiple anti-inflammatory actions including the inhibition of iNOS transcription, 
prevented the rise in both iNOS protein and activity as well as preserving contractile 
function. iNOS activity was significantly raised in the myocardium but not in 
intercostals, soleus, abdominal and extensor digitorum longus. iNOS protein has also 
been seen to peak at 12 hours in the hearts of mice injected with LPS (79).
Contractile failure of diaphragmatic muscle was also seen in a similar endotoxic rat 
model at 24 hours (186). This could not be prevented by co-administration of the 
specific iNOS inhibitor aminoguanidine. The role of eNOS and nNOS, as implicated by 
El Dwairi (140), was not evaluated.
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1.8 Mitochondria in cell models of sepsis
NO was recognised as an inhibitor of the mitochondrial respiratory chain before its 
discovery as a biologically active molecule. Interest has grown in the past decade on 
finding that NO is involved in both physiological and pathological inhibition of 
respiration (187).
The addition of a NO donor (sodium nitroprusside) to a culture of rat synaptosomes led 
to a rapid inhibition of oxygen consumption (188). This inhibition could be reversed by 
addition of haemoglobin (acting as an NO scavenger). The inhibition in respiration 
occurred at complex IV and was found to be competitive with oxygen. The Ki (the 
concentration of NO required to inhibit complex IV activity by 50%) was estimated to 
be 60nM at an O2 concentration of 35pM (assumed by the authors to be the O2 
concentration in the cell). Koivisto also demonstrated the competitive nature of oxygen 
and NO for complex IV in brown adipose tissue (189). Both sets of authors suggested 
that NO may inhibit respiration at physiological levels. A dose-dependent suppression 
of cardiomyocyte oxygen consumption was also seen with the NO donor, S-nitroso-N- 
acetylpenicillamine (SNAP). The concurrent addition of a superoxide generator, 
pyrogallol, had an enhanced inhibitory effect on oxygen consumption (190). To 
investigate whether endogenously produced NO could cause respiratory inhibition, 
Bolanos and colleagues used a primary culture of rat astrocytes and exposed them to 
increasing doses of IFNy and/or LPS (191). Either IFNy or LPS resulted in a dose 
dependent increase in total nitrite/nitrate levels, while the combination was synergistic. 
Significant reductions were achieved by addition of the NOS inhibitor L-NMMA. The 
rise in NO production was also associated with a time dependent decrease in complex 
IV activity (25% inhibition at 18 hours and 56% inhibition at 36 hours). At 18 hours, 
complex IV was the only respiratory chain complex to be affected, but by 36 hours 
complex II/III activity was also depressed by 35%. Importantly, there was no evidence 
of increased cell death. These changes could also be prevented by the use of L-NMMA. 
Borutaite incubated rat aortic rings for 24 hours in LPS and y-IFN, resulting in a marked 
decrease in respiration, the rate of which was dependent on the oxygen concentration 
(192). They also demonstrated reversal by scavenging NO (with oxyhaemoglobin) or 
inhibiting iNOS activity (with 1400W). NO also decreases oxygen consumption in heart
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mitochondria (138), liver mitochondria (193), brain mitochondria (194), renal tubules 
(195), macrophages (196), and skeletal muscle mitochondria (197).
Rapid inhibition of respiration is believed to be due to inhibition of complex IV. This 
inhibition is competitive with oxygen and raises the apparent Km (for oxygen) of the 
complex. The mechanism of inhibition is dependent on the redox state of the metal 
centres of the complex (198). NO can inhibit an oxidized Cub centre, but is rapidly 
oxidized to nitrite and expelled (199), and thus transiently prevents the reaction with 
oxygen. When the metal bi-nuclear centre is reduced, NO can rapidly inhibit the Fe2^  of 
the cytochrome a3 (200). Both these mechanisms are rapidly reversible thus changes in 
NO concentrations will have rapid effects on the rate of cellular respiration.
NO and its metabolites can also inhibit other complexes within the respiratory chain. 
Co-culture of hepatocytes and macrophages exposed to endotoxin for 24 hours led to an 
increase in NO production (evidenced by increased nitrite/nitrate levels and formation 
of iron nitrosyl groups) and a 30% decrease in complex I mediated respiration (164). 
These changes were prevented by the NOS inhibitor N“-nitro-L-arginine.
Orsi and colleagues showed that respiratory inhibition of a murine macrophage cell line 
by NO (using DETA-NO) was initially reversible using oxyhaemoglobin, but more 
prolonged exposure resulted in increasingly irreversible inhibition (196). They 
hypothesized this was due to direct inhibition of complex I by NO. High levels of NO 
(2mM) can also directly inhibit purified complex II (possibly due to destruction of the 
iron-sulphur centres) and, to a lesser extent, complex III activity (201).
The possibility of NO reacting with O2’ in the mitochondria to produce ONOO' 
prompted investigators to study the effects of ONOO’ on the respiratory chain. Addition 
of exogenous ONOO' (0-2mM) for 5 minutes to a suspension of rat heart mitochondria 
resulted in a dose-dependent inhibition of both NADH and succinate mediated state 3 
and 4 respiration (202). This was supported by an associated decrease in complex I and 
II activity (but not complex IV). ONOO’ induced inhibition of the respiratory chain also 
resulted in enhanced succinate-dependent production of H2O2 and, presumably, O2*. 
ONOO' decreased cardiac muscle O2 consumption (190), but this could be reversed 
with the ONOO' scavenger, urate. ONOO' also caused a dose dependent decrease in the 
oxygen consumption of mitochondria isolated from rabbit type II pneumocytes (203).
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This degree of inhibition (up to 67%) was not seen if the pneumocytes were co-cultured 
with equivalent concentrations of O2’, H2O2, or OH' in the presence of Fe^ (33% 
inhibition).
Co-culture of activated astrocytes and neurones separated by a membrane permeable to 
NO (but not to ONOO' and other reactive nitrogen species) demonstrated an initial 
reversible inhibition of complexes II/III and IV after 24 hours (204). However, after 48 
hours of co-culture, the activity of neuronal complexes II/III demonstrated recovery but 
the activity of neuronal complex IV remained suppressed. This inhibition could be 
prevented by the use of a NOS inhibitor (L-NAME). These results suggest that, at least 
initially, the mitochondrial inhibition was due to a direct action of NO on the respiratory 
chain complexes and not due to other radicals or oxidants. The findings at 48 hours, 
may however, represent inhibition by ONOO' or other agents generated by the neurones 
themselves.
When neurones were placed in co-culture with stimulated NO-producing astrocytes, a 
non-significant 31% loss of complex IV activity was seen. There was also a 14% 
decrease in ATP concentration that could be prevented by addition of L-NMMA (205). 
Others have also found that ATP can be depleted by NO. Addition of NO to isolated, rat 
brain mitochondria led to a rapid (within three minutes) reduction in ATP synthesis 
which had recovered to 72% of controls within 12 minutes as the NO decomposed 
(206). Chondrocytes demonstrated a progressive fall in ATP levels with increasing 
doses of an NO donor (NOC-18) (207). NO also decreased ATP concentrations in 
lymphoma cells (208) and type II pneumocytes (209).
Bolanos and colleagues also investigated the effects of exogenous ONOO' on the 
respiratory chain in both primary neuronal and astrocyte cell cultures (137). ONOO' 
produced a dose-dependent inhibition of neuronal complexes II/III and IV and increased 
levels of cell death. No change in complex I activity was noted. Astrocytes were 
unaffected by the addition of up to 2mM ONOO' with no evidence of respiratory chain 
inhibition or cell death, demonstrating the differing susceptibility of cell types to 
oxidant/nitrosative stress. Exposure of neurones to a nitric oxide donor (ImM SNAP) 
for 24 hours resulted in a decrease in activity of all complexes; this was also associated 
with a 57% decrease in GSH concentration (205). Deliberate depletion of neuronal GSH 
with L-BSO (L-buthionine-[SR]-sulfoximine), an inhibitor of y-glutamyl-cysteine
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synthetase, resulted in a 93% decrease in GSH levels and an associated loss of all 
complex activities. These findings suggested GSH protected the respiratory chain 
against inhibition by reactive species. Other investigators have studied the effect of 
reactive nitrogen species on GSH concentrations. Phelps and colleagues stimulated 
pulmonary artery endothelial cells with TNF-a, for six hours (210). This resulted in a 
32% decrease in GSH levels and a decrease in the GSH:GSSG ratio, indicating that 
GSH was becoming increasingly oxidised. They proposed this was due to an increase in 
ONOO' production as these changes were prevented by addition of L-NMMA, SOD or 
urate.
Murine J774 macrophages demonstrated NO-dependent inhibition of respiration that 
was initially reversible on addition of oxyhaemoglobin (196). However, after five hours, 
this inhibition had become irreversible, with a decrease in both complex I mediated 
respiration and activity. This was associated with a 50% decrease in GSH concentration. 
The use of FCCP (carbonyl cyanide p-(irifluoromethoxy)phenylhydrazone) to uncouple 
the respiratory chain did not alter respiration in the treated cells, though a 55% increase 
in O2 consumption was seen in control cells. The use of glucose-free media (with the 
addition of pyruvate) and the use of the Krebs’ cycle inhibitor, 3-nitropropionic acid 
(with the addition of P-hydroxybutyrate), did not alter respiration in the treated cells, 
suggesting the site of action of NO was only on the respiratory chain. T-lymphocyte 
(Jurkat) and fibroblast (L929) cell lines demonstrated very similar responses on 
exposure to DETA-NO (211). Incubating cells with exogenous GSH (GSH-ethyl-ester) 
and light delayed the onset of the irreversible inhibition and partially restored the 
responsiveness to oxyhaemoglobin at five hours (196). Beltran (211) demonstrated the 
persistent inhibition of complex I mediated by ONOO' could be reversed by the addition 
of GSH-ethyl-ester or light. The reversal with light (212) and reducing agents suggest 
the inhibition may be a result of the formation of a nitrosothiol group on complex I.
Addition of a NO donor (DETA-NONOate, maintaining a NO concentration of 1 jiM) to 
mitochondria and submitochondrial particles (SMP) isolated from rat brain, liver and 
heart resulted in a rapid decrease in NADH (but not succinate)-supported respiration 
(114). This inhibition lasted for at least two hours and was not restored by addition of 
5mM GSH. SMPs derived from the three tissues demonstrated evidence of H2O2 
production when exposed to the NO donor, with the heart producing more than the liver 
or brain (-0.17, 0.12 and O.Olnmol/min/mg protein, respectively). A time-dependent
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increase in protein nitration was also seen in the SMPs. Complex I activity was 
decreased by 78% within 20 minutes. However, activity could be almost maintained by 
co-incubation with SOD and uric acid, suggesting that ONOO* is required for complex I 
inhibition. Co-incubation with GSH (5mM) also prevented the decrease in complex I 
activity, however the addition of 5mM GSH at the end of the two hour experiment did 
not reverse the inhibition.
Addition of exogenous GSH prevented the NO-mediated decrease in oxygen 
consumption in liver mitochondria (193) and the decrease in ATP in type II 
pneumocytes (209). However, Lizasoain (194) found that exogenous GSH or glucose 
could not prevent the initial inhibition of respiration by NO, but could prevent the 
inhibitory effect of exogenous ONOO*. ONOO* mediated inhibition of complex I was 
also reversed by light, dithiothreitol (a reducing agent) and GSH-ethyl-ester (213), again 
implicating s-nitrosylation of complex I as the mechanism of inhibition. The s- 
nitrosylation of proteins by NO is well recognized (149), it may regulate a large number 
of different enzyme functions including glyeraldehyde-3-phosphate dehyrogenase 
(GAPDH), glutathione reductase (211), caspases (214) and NFkB (215).
These studies are supported by the findings that oxygen consumption is decreased in 
hepatocytes (106), aortic endothelial cells and smooth muscle cells (107) exposed to 
endotoxin. In the latter study, pre-incubation with N-acetyl-L-cysteine, an antioxidant 
that also provides substrates for GSH synthesis, prevented this endotoxin-mediated 
decrease in O2 consumption.
Techniques other than oxygen consumption and respiratory chain complex activities 
have been used to assess the effects of NO on mitochondria. Szabo and colleagues used 
reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to 
formazan as a marker of mitochondrial respiration in a macrophage cell line (J774) 
(216). Addition of NO donors (3mM, SNAP or 3mM DNO for 24 hours), peroxynitrite 
(ImM for 1 hour) or stimulation with LPS (± IFNy for 24 hours) resulted in a decrease 
in mitochondrial respiration. MnTBAP (Mn (III) tetrakis(4-benzoic acid)porphyrin), 
which has the properties of both superoxide dismutase and a ONOO* scavenger, 
partially prevented these changes. The combined use of MnTBAP and a NOS inhibitor 
(3mM L-NMA) in the immunostimulated cell had an additive effect. NO also mediated 
a decrease in mitochondrial reduction of MTT in cardiomyocytes stimulated by IL-1 p
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(163). Addition of NO (4mM SNAP) to human hepatocytes led to a 66% reduction in 
respiratory function (assessed by MTT), and the development of DNA damage 
(mitochondrial DNA in particular) (217).
Rhodamine-123 is a fluorescent dye that localizes to mitochondria by utilizing the 
membrane potential. The higher the potential the greater the accumulation and 
fluorescence. This allows investigation of the ‘energization’ of the mitochondria in 
individual or small groups of cells. Hepatocytes loaded with rhodamine-123 were 
placed in co-culture with Kuppfer cells isolated from a rat (218). Thirty minutes after 
the addition of endotoxin to the co-culture, a rapid and marked decrease in fluorescence 
was noted in approximately 20% of mitochondria (the remaining 80% being only 
slightly affected). At 60 minutes 85% of hepatocytes showed a decrease in fluorescence. 
These changes could be inhibited by L-NMMA but not by SOD. These results suggest 
that NO (or a NO-mediated process) was causing a dissipation of the mitochondrial 
membrane potential. Possible mechanisms include inhibition of the respiratory chain, 
increased proton leak, and uncoupling of proton translocation. Addition of a NO donor 
to a human rhabdomyosarcoma cell line loaded with rhodamine-123 resulted in a rapid 
decrease in fluorescence that recovered within ten minutes after the disappearance of the 
NO donor (219). The addition of a NOS inhibitor (L-NA) led to an increase in 
fluorescence, suggesting a level of NO control under ‘normal’ conditions (albeit in a 
tumour cell line).
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1.9 Mitochondria in animal models o f sepsis
Numerous investigators have studied mitochondrial dysfunction in organs isolated from 
animal models of sepsis and inflammation. Unfortunately, due to the complexity of the 
living organism and to important variations in experimental design, there is a large 
amount of conflicting data. The use of different species, anaesthesia, fluid resuscitation 
regimens, type, severity and timing of insult, duration of sepsis, organs studied, and 
method of analysis may all be potentially confounding variables (220).
1.9.1 Mitochondrial morphology in sepsis
Livers isolated from septic rats showed a large degree of ultrastructural heterogeneity, 
with evidence of mitochondrial swelling, loss of crystal structure and disruption of the 
matrix (221). Two hours following the induction of sepsis in a neonatal rat model, 
hepatic mitochondria appeared swollen and pale compared to control rats (222). The 
severity of ileal mitochondrial injury correlated with the defect in oxygen utilization 
(57); these changes could be prevented by pretreatment with cyclosporin-A (which, 
among other properties, can inhibit the opening of the mitochondrial transition pore and 
prevent apoptosis) (223).
Welty-Wolf and colleagues (224) took serial skeletal muscle biopsies in baboons before 
bacterial challenge with E coli, at 12 hours and 24 hours after injection, and at death 
(mean time 36 hours post-insult). The mitochondria became enlarged with distorted 
cristae and electron lucent areas within the matrix. With advanced injury the inner 
mitochondrial membrane became fragmented. Quantitative morphometric analysis 
showed significant increases in cristal membrane surface density and the intermembrane 
space with a decrease in matrix volume density. They suggested the damage was severe 
enough to compromise muscle oxidative metabolism.
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1.9.2 Mitochondrial function
Data obtained from animal models are often contradictory, with some models showing 
an increase in mitochondrial activity while others show a decrease. As demonstrated by 
Kantrow and colleagues (221) this may be partly explained by the different techniques 
used to examine mitochondrial activity.
Enhanced mitochondrial function
Perfused livers isolated four days after the induction of faecal peritonitis in a rat model 
showed enhanced oxygen consumption at rest when compared to control livers (225). 
Further increases in oxygen consumption occurred in response to a metabolic load by 
adding further pyruvate and lactate (stimulating gluconeogenesis), or by the addition of 
ammonium chloride and ornithine (to stimulate urea formation). The response was 
similar in both septic and control animals. Though this model had a significant mortality 
(50% at 5 days), there was no evidence of hepatic dysfunction, with normal levels of 
glucose and albumin synthesis. As such, the liver may not be reflective of other failing 
organs in this model. A further rat model demonstrated significantly elevated hepatic 
mitochondrial state 3 respiration at 3 hours and 24 hours after the administration of 
TNFa and IL-ip (226).
Rats treated for seven days with C.parvum and then exposed to endotoxin for a further 
six hours demonstrated evidence of marked NO generation (164). However, despite this, 
there was an increase in hepatic mitochondrial state 3 and 4 respiration. Hepatic 
mitochondria isolated from untreated rats and then exposed to endotoxin did exhibit a 
reduction in state 3 respiration. The authors argue this discrepancy is due to the rapid 
scavenging of NO by blood in vivo. Enhanced mitochondrial function has been seen in 
other studies. Dawson injected rats with a large dose of i.v. endotoxin (70 mg/kg) and 
observed them until death (mean duration of four hours) (227). Once dead, they isolated 
mitochondria from liver, skeletal and cardiac muscle and then determined mitochondrial 
function for a further 4 hours. Hepatic mitochondria ceased functioning within 30 
minutes of death but, up to this point, there was no significant difference in respiratory 
control ratio (RCR) or ADPiO ratio between septic and control animals. Both skeletal 
muscle and cardiac mitochondria isolated from the septic animals demonstrated a raised
RCR compared to controls, and both groups maintained function throughout the 4 hour 
post-mortem period.
Mixed findings
In a rat caecal ligation and puncture model, Kantrow found that hepatocyte oxygen 
consumption was reduced at 16 hours, when compared to sham controls (221). This 
could not be reversed by a 5-minute incubation with L-NAME and so may reflect a 
more persistent inhibition of respiration. The investigators then permeabilized 
hepatocytes isolated from the septic rats and showed a significant decrease in complex 
II supported respiration and a near significant (p=0.09) increase in complex I mediated 
respiration. Following, this, they went on to examine the respiration rate of 
mitochondria isolated from the septic hepatocytes and demonstrated a significant 
increase in both complex I and II mediated respiration in both state 3 and 4. Incubation 
with a NO donor then led to a reduction in respiration rates. These results typify the 
difficulty in interpreting data obtained from animal models. The authors suggest that 
techniques (centrifugation down a Percoll gradient) used to purify mitochondria may 
only isolate ‘robust’ mitochondria from the septic animals, with dysfunctional 
mitochondria being destroyed or excluded.
Kurose used isolated rat livers and perfused them with rhodamine-123. Microcirculatory 
units on the surface of the liver were then observed using a digital imaging fluorescence 
microscope (218). The dye labelled hepatocytes predominantly in the region of the 
portal veins. The liver was then perfused with a range of endotoxin concentrations (0.1- 
l.Opg/ml) for 60 minutes. Livers perfused with l.Opg/ml of endotoxin showed an initial 
increase in fluorescence at 10 minutes, but then a progressive fall until the end of the 
experiment at 60 minutes. This fall, though significant in all regions, was most 
pronounced in the central regions and could be prevented by infusion of the NOS 
inhibitor, L-NMMA.
Similar findings of an initially enhanced mitochondrial function followed by a decrease 
were inferred by Tanaka and colleagues (228). They investigated rats injected with 
either a lethal (at 24 hours) or sub-lethal i.v. dose of E.coli. At six hours both septic 
groups had higher NAD:NADH ratios compared to controls, though by 12 hours this 
ratio had fallen in the lethal group while remaining elevated in the non-lethal group.
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These findings suggest an initial acceleration of mitochondrial activity followed by a 
later decrease in the sicker animals.
Diminished mitochondrial function
Infusion of TNFa and IL-1 p into conscious rabbits resulted in a decrease in global 
oxygen utilization, an increase in glucose oxidation and reduced activity of hepatic 
pyruvate dehyrogenase (229). The authors proposed that the cytokines altered 
intermediary metabolism by an effect, at that point unknown, on mitochondrial function.
Infusion of a NO donor (s-nitrosoglutathione) into the coronary vasculature of an 
isolated, beating rat heart (Langendorff preparation) resulted in a dose-dependent 
decrease in myocardial oxygen consumption (118). This returned to baseline values 
within 10-15 minutes of stopping the infusion. The infusion of the pro-inflammatory 
mediator, bradykinin, also resulted in a depression in myocardial O2 consumption that 
could be partially restored with L-NMMA. A rat liver perfused with a NO-saturated 
solution demonstrated a fall in rhodamine-123 fluorescence (218); this was associated 
with a rise in NADH autofluorescence, particularly in the peri-central area. These 
changes could be prevented when L-NMMA (but not SOD) was also infused.
An endotoxic rat model demonstrated a significant, 44% decrease in state 3 respiration 
in mitochondria isolated from the diaphragm at 48 hours, but not at 24 hours (230).
State 4 respiration and the ADP:0 ratio were unaffected. Administration of a NOS 
inhibitor (L-NAME) or a superoxide dismutase mimetic (PEG-SOD) to the rats 
prevented these changes. A short-term endotoxic, neonatal rat model also showed a 
decrease in hepatocyte mitochondrial oxygen consumption at two hours (222).
Crouser exposed a segment of ileum from anaesthetised cats, cannulated the superior 
mesenteric artery and connected it to the carotid artery (57). The mesenteric vein was 
also cannulated and diverted to a reservoir where the pressure could be maintained at a 
constant 0 mmHg and blood could be added as required to maintain a constant 
haematocrit; this reservoir was then connected to the femoral vein. In this fashion, the 
investigators could ensure a steady oxygen delivery to that segment of ileum and their 
observations were not compounded by tissue hypoxia. Half the cats received a dose of
i.v. endotoxin (3 mg/kg). Two hours following administration of endotoxin, the DO2- 
VO2 relationship was assessed and the ileum then excised for histological analysis of
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the mitochondria. Although oxygen delivery to the ileal segment was maintained at a 
level similar to controls, there was a decrease in oxygen extraction and an elevation in 
DC^ crit- The endotoxin-treated animals displayed significant mitochondrial damage that 
was not seen in controls. This damage ranged from mild to severe with evidence of 
mitochondrial swelling to disruption of the membrane. There was also a significant 
negative correlation between oxygen extraction ratio and the degree of damage, thus 
implicating the damaged mitochondria in the defect in oxygen utilization. Using the 
same model, Crouser then investigated the temporal relationship between ultrastructural 
damage to mitochondria and upregulation of iNOS protein (166). Despite evidence of 
mitochondrial (and cell) damage at two hours, iNOS protein and 3-nitrotyrosine staining 
was only seen at 4 hours. Unfortunately, they did not measure constitutive NOS or 
iNOS activity at either time point. In a further study using a well-monitored and 
resuscitated endotoxic cat model, they examined the relationship between hepatic 
mitochondrial oxygen consumption and ultrastructural damage (231). State 3 respiration 
was significantly depressed in the septic animals, regardless of substrate used. However, 
state 4 respiration was significantly elevated in the septic animals, thus the respiratory 
control ratio, (RCR) was low. This elevation was sensitive to addition of oligomycin, 
suggesting that the Fo-Fi-ATPase may be consuming ATP or dissipating the membrane 
potential. There was also a strong correlation between the RCR and the degree of 
ultrastructural damage.
Schaefer examined in vivo changes in cytochrome aa3 redox state in endotoxaemic rats 
using near-infrared spectrophotometry (232-234). Endotoxin induced direct (or rapidly 
mediated indirect) impairment of oxidative phosphorylation. There was a dose-response 
relationship between endotoxin and reduction of cytochrome aa3 (233). At higher doses 
(5 and 20 mg/kg) this change occurred within 5 minutes, for the lower dose of 
1.25mg/kg, cytochrome aa3 reduction did not reach significance until 30 minutes. No 
change was seen at the lowest doses of 0.3 and 0.08 mg/kg. Maintenance of blood flow 
to the superior mesenteric artery with fluid loading did not prevent the decrease in the 
aa3 redox state, suggesting this change was not the result of ischaemia (232). Endotoxin 
also induced an increase in the reduced cytochrome aa3 concentration within the 
brain(234). However, this change was related to impaired blood flow and was 
proportional to the decrease in tissue HbC>2 . The difference between organs may be 
related to the inability of endotoxin to cross the blood-brain barrier and stimulate local 
NO production.
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Further evidence for mitochondrial dysfunction also comes from a primate model of 
hyperdynamic Gram negative sepsis (235). Though O2 delivery and consumption 
remained unchanged over 24 hours, skeletal muscle cytochrome aa3 became 
progressively reduced (as assessed by near infra-red spectroscopy). This correlated with 
myocyte mitochondrial structural changes, namely progressive swelling and distortion, 
with membrane fragmentation prior to death. An early defect in oxygen provision to 
mitochondria followed by a progressive loss of functional cytochrome aa3 was 
proposed.
Myocardial mitochondria isolated from rabbits, 24 hours after the administration of. 
endotoxin (lOOpg/kg s.c.) demonstrated significantly lower state 3 respiration and RCR 
when compared to controls. This was associated with lower complex I activity. Skeletal 
muscle mitochondria isolated from the same rabbits did not show any inhibition of 
respiration until the dose of endotoxin had been increased by 50% (236). Myocardial 
complex I and II activities have also been seen to decrease with increasing doses of 
E.coli administered to baboons (237).
1.9.3 ATP production
ATP is utilised by the cell to drive energetically unfavourable reactions including 
protein and DNA synthesis, and pumping ions up a concentration gradient. Cells 
hydrolyse ATP to ADP and Pi with resultant release of energy. ADP, under normal 
circumstances is rapidly converted back to ATP by the mitochondria, thus maintaining a 
high ATP:ADP ratio. However, in times of stress, ADP may be hydrolysed to AMP 
with loss of another phosphate and further energy release, albeit less than that released 
by hydrolysis of ATP. For short periods of time, muscle ATP levels can be maintained 
using phosphocreatine; this can act as a ‘phosphate reserve’ allowing rapid 
phosphorylation of ADP back to ATP (phosphocreatine + FT + ADP <-» creatine + 
ATP). Due to its relatively short half-life, ATP levels are difficult to measure. However, 
a number of studies have attempted to do so though with conflicting results. This 
variation can, in general, be explained by the severity of the insult, the duration of 
sepsis, or the organ studied. Most investigators studying energetics in vivo have utilised
<1 1
P nuclear magnetic resonance spectroscopy. This technique is non-invasive and allows
72
temporal monitoring of ATP, Pi and phosphocreatine. Various biochemical methods 
may also be used, such as HPLC. These require careful preparation of the tissue, but can 
give quantitative information on ATP and other nucleotides such as ADP and AMP.
Nitric oxide mediated inhibition of the respiratory chain has been shown in cell models
to deplete ATP concentrations (206;207). Similar findings have been made in sepsis.
<> 1
Jacobs used P-NMR to examine changes in PCr:Pi and ATP:Pi ratios in the skeletal 
muscle of a CLP rat model (238). By 24 hours, septic rats had a 40% decrease in PCr:Pi 
ratio compared to pre-sepsis levels, and an approximate 60% decrease by 48 hours. 
There was a corresponding, but less dramatic, fall of 37% in ATP:Pi ratio at 48 hours, 
suggesting the PCr pool buffers change in the ATP pool. A further set of rats were 
fasted for 48 hours to control for the lack of food intake by the septic animals; no 
changes were seen in either PCr:Pi or ATP:Pi ratio over 48 hours.
In a milder model of endotoxaemia (4mg/kg i.p.), Pelias and Townsend used both NMR 
and biochemical techniques (a spectrophotometric assay) to measure hepatic ATP 
content (239). ATP levels progressively fell, becoming significantly lower than controls 
at 4 and 6 hours. The NMR method of ATP determination correlated well with the 
biochemical technique.
A further rat model used an i.p. injection of endotoxin (15mg/kg) which showed signs 
of severe disease and a mean survival time of 19 hours (240). At 8 hours the animals 
were anaesthetized and a remote control clamp placed around the abdominal aorta. P- 
NMR was used to investigate changes in the skeletal muscle of the hind limb. At this 
time point there were no significant differences between septic and control animals with 
respect to ATP, phosphocreatine or Pi. However, once the clamp was applied (and the 
limb rendered ischaemic), phosphocreatine (though not ATP) fell faster in the septic 
group. On reperfusion, the rate of recovery was similar in both groups, indicating no 
defect in phosphorylating mechanisms of creatine kinase or mitochondria.
In another study, gastrocnemius muscle PCr:Pi and ATP:Pi ratios were lower in rats 48 
hours after the induction of sepsis by CLP when compared to sham operated animals 
(241). To investigate whether this was due to impaired mitochondrial function, the 
authors electrically stimulated the muscle and measured the time of recovery for PCr 
and ATP. This time was shorter in the septic animal at 24 hours compared to controls
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but was prolonged by 48 hours; the authors thus concluded that mitochondrial function 
was initially enhanced during sepsis, but later fell.
Twenty four hours after the injection of TNFa and IL-1 p to a group of rats, hepatic ATP 
levels were significantly lower compared to controls (226). There was also a significant 
increase in AMP and a decrease in total adenine pool (ATP+ADP+AMP). This was 
associated with a rise in NAD:NADH ratio and an enhanced state 3 respiration in 
isolated mitochondria. These authors felt that the fall in ATP levels was more likely a 
result of enhanced metabolic requirement rather than a problem of mitochondrial 
production.
ATP levels were significantly lower in rats injected with a lethal dose of E.coli 
compared to either those injected with a sub-lethal dose or the control group (228). This 
was associated with significantly raised ADP and AMP levels and a fall in the 
NAD:NADH ratio, suggesting an impairment in mitochondrial respiration. It is 
interesting to note that at six hours both septic groups had higher NADiNADH ratios 
compared to controls, though by 12 hours this ratio had fallen in the lethal group while 
remaining elevated in the non-lethal group. These findings of an initial accelerated 
mitochondrial activity followed by a decrease in the sicker animals are compatible with 
the findings of Mizobata and colleagues (241).
An endotoxic rabbit model (with a mortality rate of 39%) was studied for up to seven 
hours to investigate the effects of sepsis on hepatic energetics (242). The septic group 
demonstrated a significant reduction in arterial and intracellular pH, blood pressure and 
hepatic ATP at 3 hours compared to sham controls. The infusion of a NO scavenger, 
carboxy-PTIO 50 minutes after the infusion of endotoxin, attenuated the fall in all of 
these variables. Liaudet also found that the ATP concentrations could be maintained in 
the liver, kidney and jejunum of endotoxic rats by the use of a specific iNOS inhibitor 
(L-canavanine) (182).
In a heavily instrumented, three hour, endotoxic pig model, Revelly demonstrated lower 
ATP levels in jejunal mucosa compared to sham-operated controls (243). This was 
despite enhanced mucosal blood flow resulting from a redistribution of blood flow away 
from the muscularis where the ATP content was maintained. Norepinephrine was used 
in a second group of endotoxic pigs to maintain mean arterial pressure similar to
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baseline. This resulted in mucosal blood flows similar to baseline and ATP levels 
similar to sham controls.
In a hypodynamic rat model of endotoxic shock, Levy and colleagues demonstrated a 
significant rise in plasma nitrate levels and a fall in hepatic NAD:NADH ratio (assessed 
by the arterial ketone body ratio) at three hours (244). Though there was no change in 
skeletal muscle or gut ATP levels, ATP was significantly lower in kidney, liver and 
hearts of the endotoxic animals when compared to sham-operated controls. As opposed 
to Revelly’s results mentioned above, maintenance of blood pressure with either 
epinephrine or norepinephrine led to a further decrease in ATP levels in the affected 
organs.
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1.10 Other mechanisms o f bioenergetic failure
There are a number of other mechanisms that may prevent the cell from utilizing 
oxygen during the septic process.
1.10.1 PARS and sepsis
There is a growing literature on the role of the enzyme poly-(ADP)-ribosyl synthetase 
(PARS) in sepsis. PARS is a nucleotide polymerizing enzyme involved in repair of 
DNA. It cleaves NAD to ADP-ribose and nicotinamide, attaching the ADP-ribose group 
to a protein before extending this group into a nucleic acid-like polymer, poly-ADP- 
ribose. Activation of PARS can rapidly deplete the cell of NAD, thus limiting glycolysis 
and the Krebs cycle of substrate. ATP is also required for the cell to resynthesise NAD. 
Zingarelli and colleagues demonstrated that a J774 murine macrophage cell line 
stimulated with endotoxin showed evidence of DNA strand breakage that was 
associated with evidence of NO and ONOO' formation (245). These changes were also 
associated with a decrease in cellular NAD content and a decrease in mitochondrial 
respiration (assessed by the conversion of MTT to formazan). These changes could be 
prevented with NOS inhibitors (L-NMA or SMT) or PARS inhibitors (3- 
aminobenzamide or nicotinamide). The group also examined macrophages isolated from 
the peritoneal cavity of rats injected with 15mg/kg endotoxin. They found an inhibition 
of respiration with NAD and ATP depletion as early as one hour after injection, 
associated with a rise in NO and ONOO' formation. These changes could again be 
attenuated by the use of PARS inhibitors.
Vascular smooth muscle cells exposed to a variety of NO and ONOO' donors exhibited 
evidence of respiratory inhibition (136). ONOO' also mediated a loss of cellular GSH, 
NAD and ATP levels. 3-aminobenzamide was able to partially protect cells against the 
loss of NAD. However, 3-aminobenzamide was less effective in reversing the 
respiratory inhibition resulting from the exposure of a NO donor (SNAP). Rat aortic 
rings exposed to ONOO' showed a dose-dependent decrease in contractile response to 
norepinephrine, which was associated with an increase in PARS activity (136). This
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responsiveness could be partially restored and PARS activity completely abolished by 
the use of 3-aminobenzamide. The use of 3-aminobenzamide prevented the onset of 
hypotension in an endotoxic rat model (136) and improved mortality in an endotoxic 
mouse model (136). PARS knockout mice with faecal peritonitis demonstrated an 
improved survival compared to wild type mice (246). CaCo-2 cells (an enterocyte cell 
line) exposed to IL-lp, TNFa and IFNy for 24 hours showed a fall in oxygen 
consumption and NAD/NADH levels (247). These could be restored with the addition 
of liposomal NAD or a PARS inhibitor (3-aminobenzamide).
Other studies have also demonstrated the benefits of PARS inhibition, though their 
results suggest that the inhibitors used may have more wide-ranging effects. 
Administration of 3-aminobenzamide prevented endotoxin-induced inhibition of 
myocyte Ca2+-ATPase and partially suppressed ONOO' production in a rat model (248). 
This last observation suggests 3-aminobenzamide may be more than a pure PARS 
inhibitor. Another PARS inhibitor (PJ734) significantly improved survival in a 
bacteraemic pig model (249). Poly-ADP-ribose staining was seen in the heart and lungs 
of the septic animals at six hours, but not in those treated with the PARS inhibitor.
There was also a significant reduction in TNF levels in the treated group which suggests 
that this inhibitor may be having other ‘non-specific’ anti-inflammatory actions. A CLP 
rat model showed that 3-aminobenzamide reduced the level of ileal apoptosis but also 
reduced the level of iNOS staining and serum nitrite/nitrate levels (250).
Despite these encouraging results, not everyone has demonstrated that inhibition of 
PARS improves mortality/morbidity in sepsis. Wray and colleagues investigated the 
effects of three PARS inhibitors (3-aminobenzamide, nicotinamide and 1,5- 
dihyroxyisoquinolone) in an endotoxic rat model (251). None of the inhibitors 
attenuated the fall in blood pressure or the rise in heart rate, serum urea, creatinine, y- 
glutamyltransferase, lactate or nitrite levels. However, 1, 5-dihyroxyisoquinolone did 
prevent the rise in serum bilirubin and aspartate aminotransferase.
PARS has also been implicated in controlling the cell cycle (252), induction of cell 
differentiation (253), suppression of iNOS induction (254) and suppression of 
tumorgenesis (255). PARS inhibition may therefore have an important impact on the 
mid- to long-term survival of the organism with respect to organ repair and the later 
development of neoplasia.
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1.10.2 Cell death
Any insult, if severe enough, may cause cell death, with a consequent reduction in 
oxygen consumption. The mechanisms by which a cell may die are numerous but can be 
roughly divided into those causing necrotic or apoptotic cell death. These are two 
extremes on a continuum which depends on the extent of the injury. In sepsis cell death 
may result from ischaemia, oxidant damage, ATP depletion, DNA damage and 
disruption of calcium homeostasis among others.
A number of studies have tried to address whether cell death is an important component 
of sepsis-associated MODS. Numerous cell models exposed to endotoxin, 
inflammatory cytokines or NO have either exhibited evidence of cell death (217;256- 
258) or no/minimal evidence (191;205;257). These contrasting results relate to the 
severity and duration of insult, and the varying susceptibility of different cells under a 
range of culture conditions.
Likewise, animal models of sepsis also show variable evidence of cell death; this is also 
heavily dependent on the experimental design. A CLP mouse model showed evidence 
of both hepatic apoptotic and necrotic cell death. The administration of soluble TNF 
receptors significantly reduced the number of apoptotic cells. (259). Apoptosis and cell 
damage has also been seen in the ileum (166;250), A further mouse CLP model found 
evidence of marked lymphocyte apoptosis at 18-24 hours, particularly in the spleen and 
thymus (260). Apoptosis was also found in the columnar epithelium of ileum and colon. 
The kidney, however, was relatively spared and the liver showed no evidence of cell 
death. Similarly, despite an endotoxin-induced alteration in renal function, renal tubular 
death is minimal or absent (261;262). These findings are comparable to those in 
patients dying from MODS (see later).
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1.11 Mitochondrial dysfunction in human sepsis
Little data are available on mitochondrial dysfunction in human sepsis. A small study 
investigating the effect of shock on tissue oxygenation, complex III and complex IV 
activity found a raised tissue oxygen tension in the single septic patient studied 
compared to normal subjects or patients with either cardiogenic or haemorrhagic shock. 
All the shock patients showed a low activity of both complexes measured (263). A 
study performed by Poderoso on mitochondria isolated from skeletal muscle of patients 
with septic shock demonstrated a lower respiratory control ratio in the presence of 
malate-glutamate when compared to control patients (264). Succinate-derived 
respiration showed no difference between the septic and control patients. These findings 
suggest that the function of Complex I is impaired in human sepsis.
Mitochondrial dysfunction has been inferred from studies investigating the change in 
arterial ketone body ratio. The decrease in the ratio of acetoacetate to B-hydroxybutyrate 
seen in sepsis reflects a fall in the ratio of hepatic NAD/NADH, inferring that the 
respiratory chain is inhibited at Complex I. This ratio progressively falls in patients 
dying of sepsis (265). A decrease in this ratio also correlated with a rise in plasma 
nitrite, an indicator of NO production (266). Human endothelial cells (HUVEC) were 
exposed to serum taken from 20 septic patients for up to two hours (267) and compared 
to control cells incubated with serum obtained from healthy volunteers. The septic sera 
caused an approximate 44% lower rate of mitochondrial respiration (assessed using 
MTT) compared to those exposed to healthy serum. Respiratory rate also showed a 
significant correlation with the patient’s SvC>2 . Respiration could be increased in cells 
exposed to septic serum (but not controls) with the addition of the NOS inhibitor, L- 
NMMA or the PARS inhibitor, 3-aminobenzamide.
Nucleotide measurements from septic humans are again scarce; in three septic patients a 
fall was noted in skeletal muscle ATP, total adenine nucleotide and phosphocreatine 
levels (268). In another study, Liaw took muscle biopsies in different patient groups 
(269). Severe trauma (n= 12) was associated with a marked loss of phosphocreatine, a 
smaller loss of ATP and the total adenine nucleotide pool, and a rise in AMP as 
compared to normal volunteers, patients undergoing total hip replacement or those who
had suffered moderate trauma. Four of the severe trauma patients subsequently became 
septic; their muscle biopsies revealed much larger falls in ATP, phosphocreatine and 
ADP, and larger rises in AMP. Another study found lower ATP levels in muscle 
biopsies taken from septic patients, compared to patients with evidence of malnutrition 
(secondary to disease states such as oesophageal carcinoma) or patients undergoing 
elective hip surgery (270).
As an interesting parallel to the animal model studies demonstrating minimal 
histological evidence of cell death, Hotchkiss and colleagues compared post-mortem 
samples obtained from patients who died of sepsis-induced MODS with those obtained 
from patients dying from other causes such as cardiac arrest (271). In the septic patients, 
apoptosis was noted in lymphocytes and ileal and colonic columnar epithelial cells. 
However, minimal cell death was found in all other vital organs studied, including 
brain, liver, kidney, heart, lung and muscle, despite evidence of biochemical and 
physiological organ dysfunction.
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1.12 Summary
The incidence of sepsis is rising and is the commonest cause of mortality on the ICU. 
Most patients dying of sepsis die from the associated organ dysfunction rather than the 
initial acute inflammatory episode. The mechanism by which the organ dysfunction 
occurs is yet to be established, but a decrease in oxygen extraction and a rise in tissue 
oxygen tension suggests an inability of the cells to utilize oxygen. Over 90% of VO2 is 
utilised by the mitochondrial respiratory chain in the process of oxidative 
phosphorylation, suggesting that a failure of this process may be central to the 
pathophysiology of MODS. Increased amounts of NO and its metabolites (e.g. ONOO') 
are produced during the septic process and are associated with increasing levels of 
organ dysfunction. Cell and some animal models of sepsis have demonstrated that these 
reactive nitrogen species are able to inhibit the complexes of the respiratory chain, and 
thus ATP production. Inhibiting NOS or scavenging free NO can prevent or reverse 
these changes. The antioxidant GSH has been implicated as having a protective role 
against this inhibition, in particular for complex I. Human data are scarce but are 
supportive of the above findings. Other possible causes for cellular dysoxia include the 
activation of the enzyme PARS, the subsequent depletion of the NAD pool or an 
increase in cell death. Proposed mechanisms for cellular dysoxia in sepsis are depicted 
in Figure 7.
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Figure 7: Schema of proposed mechanisms of dysoxia
1.13 Hypothesis
MODS is a result of mitochondrial respiratory chain inhibition by reactive nitrogen and 
oxygen species generated during severe, generalised inflammation. This is laid out in 
the schema below (Figure 8). This illustrates a progression of events leading to organ 
dysfunction, and outlines the measurements performed to test each step. The possibility 
of an undesirable positive feedback in response to sepsis should be noted. For example, 
inhibited mitochondrial electron flow can increase O2* levels, and hence deplete 
antioxidant (GSH) levels, allowing NO to inhibit complex I. This, in turn, will inhibit 
respiration further, and increase ATP breakdown.
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Figure 8: schema for proposed mechanism of sepsis induced organ dysfunction and the 
measurements undertaken in the investigation.
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1.14 Aims
The aims of this study were to:
1. Assess whether mitochondrial dysfunction occurs in human sepsis.
2. Assess whether the degree of mitochondrial dysfunction relates to the severity of 
sepsis and outcome.
3. Assess how this dysfunction changes with time and the patient’s condition
4. Investigate the relationship between NO production, GSH depletion and 
mitochondrial dysfunction.
5. To develop a long term (3 day) rodent model of sepsis with evidence of MODS to 
simulate the human condition. Using this model, to correlate any changes in 
mitochondrial dysfunction (and recovery) with the time course of sepsis, and to 
compare inter-organ differences of mitochondrial function.
6. Assess if animal or human studies suggest any possible therapeutic targets with a 
view to first testing putative therapies in the rodent model.
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1.15 Approaches
1. Mitochondrial function was assessed by:
i) the maximally stimulated activities of isolated complexes I, II/III and IV.
ii) ATP, ADP, AMP, phosphocreatine and creatine concentrations.
2. Reduced glutathione (GSH) concentration was measured to assess its protective 
effect on complex I, and as a marker of oxidant stress.
3. Tissue total nitrite (NOx) concentration was determined as a marker of NO 
production.
4. Physiological observations.
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Chapter 2; 
Patient Study
2.1 Methodology
2.1.1 Overview
This study examined the effects of sepsis on mitochondrial respiratory chain activity, 
NOx, GSH and ATP levels in muscle biopsies obtained from patients admitted to the 
intensive care with severe sepsis or septic shock. Sequential biopsies investigated the 
change in these variables over time and allowed comparison with the patient’s 
condition. Comparison was made with biopsies obtained from patients undergoing 
elective hip surgery (acting as ‘normal’ controls) and those with cardiogenic shock 
(allowing control for a shock state and critical illness).
2.1.2 Definitions, inclusion and exclusion criteria
Ethics committee (University College London Hospitals Joint Ethics Committee on 
Human Research) approval was obtained for the study. Prior to enrolling each patient, 
their informed consent or agreement from the next of kin was obtained. ICU patients 
recruited to the study had to either have a diagnosis of severe sepsis, septic shock (4) or 
cardiogenic shock (defined as a low cardiac output requiring inotropic support).
Patients undergoing elective hip surgery for degenerative arthritis acted as ‘normal 
controls’. Muscle biopsies were obtained from the vastus lateralis (thigh) muscle, an 
easy and safe procedure in the critically ill (272). Each patient had to fit the following 
inclusion and exclusion criteria:
Inclusion criteria:
• Over 18 years old.
• Severe sepsis or septic shock.
• Cardiogenic shock.
• Elective total hip replacement surgery for degenerative arthropathy.
• Within 24 hours of ICU admission for septic and cardiogenic shock patients.
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Exclusion Criteria:
• Co-existing inflammatory condition (e.g. pancreatitis or rheumatoid arthritis).
• Coagulopathy (INR>2, Platelet count < 20,000).
• Immunosuppression (e.g. Lymphoma or leukaemia).
• Pregnancy.
2.1.3 Clinical scoring
Physiological, haematological and biochemical data were collected to construct SAPSII 
(Table 6 (10)) and SOFA scores (29). These are clinical scoring systems that enable 
comparison between patients with respect to severity of illness (and risk of death) and 
the degree of organ dysfunction, respectively.
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Variable Finding Score
Age (years) <40 0
40-59 7
60-69 12
70-74 15
75-79 16
>80 18
Heart rate (bpm) <40 11
40-69 2
70-119 0
120-159 4
> 160 7
Systolic blood pressure <70 13
(mmHg) 70-99
100-199
5
0
>200 2
Temperature (°C) <39 0
>39 3
P a 0 2/F i0 2 ratio (mmHg) <100 11
(if on advanced respiratory 
support)
100-199
>200
9
6
Urine output (1/24 hours) <0.5 11
0.5-0.999 4
>1.0 0
Serum urea (mmol/1) <10
10-30
0
 JV
>30 10
White cell count (xl03/pl) <1.0 12
1.0-19.9 0
>20 3
Serum potassium (mmol/1) <3.0 3
3.0-4.9 0
>5.0 3
Serum sodium (mmol/1) <125 5
125-144 0
>145 1
Serum bicarbonate (mmol/1) <15 6
15-19 3
>20 0
Serum bilirubin (mg/dl) <4.0 0
4.0-5.9 4
>6.0 9
Glasgow Coma Score <6 26
6-8 13
9-10 7
11-13 5
14-15 0
Chronic illness Metastatic carcinoma 9
Haematological malignancy 10
AIDS 17
Type of admission Scheduled surgery 0
Medical 6
Unscheduled surgery 8
Table 6: The SAPSII scoring system.
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2.1.4 Performing and processing the muscle biopsies
For the septic/cardiogenic shock patients, biopsies were performed on the ICU using an 
aseptic technique. The skin was cleansed with a 0.5% chlorhexidine solution and the 
area draped with sterile towels. The skin was infiltrated with a 1% lidocaine and 
1:200,000 epinephrine solution. The requirement for local anaesthetic was often 
lessened in these patients by the intravenous opiate and sedative required to tolerate 
mechanical ventilation. A 5mm skin incision was made in the lateral thigh. Artery 
forceps were then used to dissect down to and through the muscle capsule. The muscle 
biopsy was then obtained using a pair of Henkel Tilley forceps. Having obtained a 
sufficient amount of tissue (approx 500mg), local pressure was applied to assist 
haemostasis. The wound was closed with a single 2/0 Mersilk suture (if required) and 
dressed with Mepore. The suture was removed at five days.
Biopsies were repeated at five day intervals until death, discharge from ICU, a 
maximum of five biopsies, or the request for withdrawal from the study by the patient or 
relative. If further biopsies were taken, legs were used alternately.
For those patients undergoing elective hip surgery, the biopsy was performed by the 
surgeon, at the start of surgery, through the surgical incision.
The biopsy was processed immediately at the bedside prior to analysis in the following 
manner:
Muscle nucleotide and phosphocreatine analysis: Flash frozen into liquid nitrogen, 
within five seconds of the biopsy being obtained. The sample was then placed rapidly 
into a cooled and labelled Eppendorf tube and replaced in liquid nitrogen.
Muscle complex activities, [GSH] and [NOx]: samples were placed in labelled 
Eppendorf tubes and flash frozen in liquid nitrogen. These samples were processed after 
those for nucleotide analysis, but were frozen within forty five seconds of being 
obtained. In all cases, care was taken to ensure holes were made in the lid of the
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Eppendorfs to allow safe pressure equalistaion between the inside of the tube and the 
local environment. All samples were stored in liquid nitrogen prior to analysis.
2.2 Tissue analysis
2.2.1 Overview of techniques used
High Performance Liquid Chromatography.
High performance liquid chromatography (HPLC) uses a liquid (mobile phase) to 
separate components according to their physical properties. These components are 
initially dissolved within the mobile phase and then introduced into the system via the 
injector, this may be performed manually or using an autosampler. The solution is 
pumped initially through an in-line degasser (Figure 9) to remove bubbles and dissolved 
gases (which could affect the interaction of the components with the column) and then 
through a pre-column (or guard column) and into the chromatographic column. The pre- 
column is used to remove debris that may have been accidentally introduced and thus 
prevent blockage of chromatographic column. The interaction of the components with 
the mobile phase and the immobile packing of the column (the stationary phase) 
determine the degree of separation (or resolution) of these components. This interaction 
can be altered using different mobile and stationary phases to allow separation of a large 
number of different components. The term “reverse phase” refers to the technique used 
to enhance resolution by utilizing a polar mobile phase and the non-polar stationary 
phase. Following separation on the column, the components may be detected by several 
different methods. In this, study electrochemical detection was used for analyzing GSH 
while UV detection was used to analyze adenine nucleotides, phosphocreatine and 
creatine.
Electrochemical detection relies on the compound undergoing an oxidation/reduction 
reaction when a potential is applied across it. The resulting current is proportional to the 
concentration of the component (Figure 14). UV detection works in a similar way to the 
spectrophotometer (see below), analysing how the compound absorbs light of a given 
wavelength.
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Figure 9: Schematic representation of the equipment used for HPLC
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Principles of spectrophotometry
Spectrophotometers apply the principles that atoms exist in only a limited number of 
energy levels, which represent the energy states of electrons within the atom. When one 
of these electrons absorbs radiant energy (i.e. light from the spectrophotometer), it 
undergoes a transition from a lower energy state to a higher energy state, causing the 
electron to jump from a low to a high orbit. Only the exact amount of energy that is 
equivalent to the difference in energy levels of an excited and ground state electron will 
be absorbed by an atom or molecule. After absorption, these excited electrons return to 
their ground state with loss of energy, either as heat, or in certain cases, as light.
A spectrophotometer is used to study the absorption of light by a sample. The 
spectrophotometer used in this study was a Uvikon XS, double beam, UV/visible 
spectrophotometer (Secomam, Domont, France). Spectrophotometers (Figure 10) 
generally consist of a:
• Light source. UV/visible spectrophotometry requires two light sources: the 
deuterium arc lamp for generating light in the UV range (190 to 380 nm) and a 
tungsten-halogen lamp for generating light in the visible spectrum (380 to about 
800 nm).
• A monochromator, to select the desired wavelength of light. This is performed 
by a grating that can split light by diffraction (some spectrophotometers utilise a 
prism and work by refraction).
• Mirror system, to allow the monochromatic light to be passed alternately 
through the sample and reference cuvettes (for double beam only).
• A cuvette holder, in this study a 6x6 autochanger was used to allow up to 6 
samples and their reference to be compared during one run
• Detector. The Uvikon XS uses a photodiode consisting of a semiconductor and 
a capacitor to charge the semiconductor. As light hits the semiconductor, 
electrons flow through it, thereby lowering the charge on the capacitor. The 
intensity of light of the sample is proportional to the amount of charge needed 
to recharge the capacitor at predetermined intervals.
• Data acquisition system to allow data to be interpreted and plotted.
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The absorbances for a range of known concentrations of a substance can be determined 
to generate a standard curve. This can then be used to determine the concentration of 
unknown samples. It is also possible to measure how these concentrations change over 
time. Thus it is possible to measure the rate of disappearance of an enzyme substrate 
(or appearance of product), thereby reflecting the activity of the enzyme.
The plate reader used for the analysis of tissue NOx uses the same principles.
Ligl' i Sample
Detector
Diffraction
grating
Figure 10: Schematic representation of a spectrophotometer.
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2.2.2 Tissue homogenisation
To enable analysis each biopsy was homogenised in 9x their weight of isolation buffer 
(appendix 1). For the patient samples this was done using a hand held 5ml glass 
homogeniser (Jencons, Leighton Buzzard. UK) at 4°C. Each sample received 40 turns, 
before being aliquoted into five labelled Eppendorf tubes. Due to the large numbers of 
samples obtained from the rat model, the pestle of the homogeniser was attached to an 
overhead stirrer in order to speed up the homogenization process, before being aliquoted 
into the Eppendorf tubes. All samples were then stored at -80°C until analysis.
2.2.3 Respiratory chain complex activities
The respiratory chain complex activities were performed using previously well 
described spectrophotometric assays (273). To control for mitochondrial enrichment, 
the activities are expressed as a ratio to citrate synthase activity. Citrate synthase is a 
mitochondrial matrix enzyme resistant to oxidant and free radical attack (274). The 
assays were performed at 30°C in a Uvikon XS spectrophotometer.
Immediately prior to analysis, tissue homogenates were freeze thawed three times in 
liquid nitrogen and a 30°C water bath so as to shatter cell membranes and expose the 
complexes for analysis.
Complex I activity
Principle: Mitochondrial complex I catalyses NADH oxidation to NAD. Electron 
transfer from NADH to ubiquinone is catalysed by complex I, though in the in-vitro 
assay, CoQi acts as the artificial electron acceptor. This activity is measured as the 
rotenone-sensitive decrease in NADH at 340nm, since rotenone is a specific inhibitor of 
complex I.
Method: Homogenates were diluted 1:5 in assay buffer. See section 5.2 for the 
composition and concentrations of solutions used.
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Samples and references were set up in plastic cuvettes (Sarstedt, Beaumont Leys, 
Leicester, UK) as follows:
Sample (pi) Reference (pi)
Phosphate buffer 800 800
BSA 50 50
NADH 30 30
KCN 10 10
Homogenate 20 20
Water 80 90
They were well mixed and left undisturbed for one minute. C0Q1 (10pl) was added to 
the sample cuvette and mixed. The disappearance of NADH was measured at 340nm 
over 5 minutes. After this time 20pl of rotenone was added to the sample cuvette, mixed 
and measured for a further 5 minutes. Calculations to determine activity are displayed in 
section 5.2.
The linearity of this technique is demonstrated in Figure 11 over a range of 
concentrations (Undiluted to 1:10, n=4 in each group).
Complex I 
activity 
(pmol/min/ml)
0.8 Rz= 0.998
0.6
0.4
0.2
T T
0 0.2 0.4 0.6 0.8 1.0
Concentration of original homogenate
Figure 11: Dose-response relationship of complex I activity
The rate of decrease that was insensitive to rotenone (therefore not due to complex I)
was 28% of the total rate in septic human muscle and 18% in the orthopaedic controls,
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this difference was not statistically significant (p=0.4). In the rat muscle at 24 hours the 
rotenone insensitive rate (as a percentage of total rate) was 7% in the septic muscle and 
13% in the sham controls (p=0.3). In the rat liver at 24 hours, this difference was 9% in 
the septic animals and 11% in the sham operated control animals.
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Complex II/III activity
Principle: Succinate is oxidised by complex II. Electrons are transferred from complex 
II to ubiquinone which is reduced to ubiquinol. Electrons are then passed to complex III 
which, in turn, reduces Cytochrome C. Complex II/III activity is therefore measured by 
the succinate-dependent, antimycin A-sensitive, reduction of cytochrome C observable 
at 550nm. Antimycin A is a specific inhibitor of complex III.
Method: Homogenates were diluted 1:5 in assay buffer. See section 5.3 for the 
composition and concentrations of solutions used.
Samples and references were set up in plastic cuvettes as follows:
Sample (pi) Reference (pi)
Phosphate buffer 600 600
EDTA 20 20
KCN 10 10
Cytochrome C 125 125
Homogenate 20 20
Water 185 225
The samples were well mixed and left undisturbed for two minutes. Succinate (40pl) 
was added to the sample cuvette and mixed. The reduction of cytochrome C at 550nm 
was measured over 6-7 minutes. After this time lOpl o f antimycin A was added to the 
sample cuvette, mixed and measured for a further 5 minutes.
Calculations to determine activity are displayed in section 5.3.
Figure 12 demonstrates the linearity (R2=0.999) of the method over a range of 
concentrations (undiluted to 1:10, n=4 in each group). The rate of cytochrome c 
reduction that was not sensitive to antimycin A (i.e. not due to the activity of complex 
II/III) was 1% in both septic and control patient groups. In the rat muscle taken at 24 
hours this was 1.8% in the sham control group and 1.7% in the severely septic group. In 
the rat livers at 24 hours this was 1.2% in the sham control group and 1.5% in the
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severely septic group. There were no significant difference in the antimycin A 
insensitive rates between septic and control subjects.
Complex II/III 
activity 
(pmol/min/ml)
0.1
0
Rz=  0.999
T T
0 0.2 0.4 0.6 0.
Concentration of original homogenate
Figure 12: Dose-response relationship of complex II/III activity.
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Complex IV activity
Principle: Cytochrome C oxidase transfers electrons from reduced cytochrome C to 
oxygen, reducing it to water. This assay measures the oxidation of reduced cytochrome 
C by monitoring its disappearance at 550nm. Activity is dependent on the concentration 
of cytochrome C and thus activity is expressed as a first order rate constant. The initial 
concentration of reduced cytochrome C was determined prior to the assay.
Preparation of reduced cytochrome C: Oxidized cytochrome C (Sigma, Gillingham, 
Dorset, UK) dissolved in water (lOmg/ml) was reduced with a few crystals of ascorbate 
and left for 10 minutes. To remove the ascorbate, the solution (maximum of 2.5ml) was 
passed through a PD10 gel filtration column (the column was previously washed with 
50ml of 1:10 dilution of the assay buffer). The fully reduced cytochrome C was 
collected from the bottom of the column.
Determination of cytochrome C concentration: The concentration was determined 
using a Uvikon XS spectrophotometer at 30°C at A, 550nm. 950pl of water and 50 pi of 
reduced cytochrome were dispensed into two cuvettes. One cuvette acts as a sample, the 
other acts as a reference. Both were placed in the spectrophotometer and 1 Opl of 
ferricyanide was added to the reference cuvette, the change in absorbance was noted. 
The concentration (molar) of cytochrome C was determined using the equation:
concentration= absorbance/8 (where 8 = 19.2xl03). 50pM was required for the assay.
Method to determine activity: homogenates were diluted 1:5 in assay buffer. See 
section 5.4 for the composition and concentrations of solutions used.
Sample (pi) Reference (pi)
Phosphate buffer 100 100
Reduced cytochrome C X X
Water 880-x 890-x
Where x = the volume of reduced cytochrome C solution required to give 50pM.
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Ferricyanide (lOpl) was added to the reference and the absorbance measured for several 
minutes. The tissue sample was then added to the sample cuvette, mixed, and the 
change in absorbance measured over five minutes.
Calculations to determine activity are displayed in section 5.4.
In order to evaluate that oxidation of cytochrome C was due to complex IV, lOpl of 
lOOmM KCN (an inhibitor of complex IV) was added to four rat liver homogenates. 
Compared to the rate prior to the addition of KCN, the rate of cytochrome C oxidation 
following its addition was 0.9%.
Citrate synthase activity
Principle: Citrate synthase catalyses the condensation of oxaloacetate and acetyl-CoA 
to form citrate and free CoA. Citrate synthase activity is assessed by the reaction of free 
Co A with DTNB (5, 5’ dithio-bis (2-nitrobenzoic acid)) which is observable at 412nm.
Method: Homogenates were diluted 1:5 in complex IV buffer. See section 5.5 for the 
composition and concentrations of solutions used.
Samples and references are set up in plastic cuvettes as follows:
Sample (pi) Reference (pi)
Buffer 950 960
Homogenate 20 20
Acetyl CoA 10 10
DTNB 10 10
The contents were mixed prior to the addition of lOpl oxaloacetate to the sample 
cuvette; the absorbance at 412nm was measured over 5 minutes.
Calculations to determine activity are displayed in section 5.5.
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2.2.4 Determination of adenine nucleotide concentration
Adenine nucleotide concentrations were determined using HPLC with UV detection 
(275). I would like to acknowledge the aid and assistance of Dr Ryszard Smolenski 
(Harefield Hospital, Middlesex) with this technique. Biopsies were initially freeze dried 
for 48hr. A sample of approximately 300mg dry weight was cut from the biopsy and 
added to a volume of 0.4M perchloric acid (PCA) equal to 25 times its weight. The 
sample was then homogenised in a ground glass homogeniser. The homogenate was 
transferred to an Eppendorf tube and then spun at 25,350g at 4°C for three minutes. The 
supernatant was transferred to another Eppendorf and then neutralised using 2M 
potassium hydroxide (pH was assessed using pH strips). The samples were then 
centrifuged for a further three minutes at 12,750g at 4°C and left on ice for a further 30 
minutes. 70pl of supernatant were then transferred to HPLC vials taking care to remove 
all bubbles. Nucleotide concentrations were then determined on a Hewlett-Packard 1100 
chromatography system (Hewlett Packard, Palo Alto, CA. USA) equipped with a cooled 
autosampler, an analytical column (150mm x 4.6mm) packed with 3pm Hypersil ODS 
(Hichrom, Reading, UK) and a Diode array detector. Data were collected and processed 
using an HpChemstation program operating on a PC-type computer. Results were 
expressed as nmol per mg of dry weight tissue.
2.2.5 Determination of GSH concentration
GSH concentration was determined by HPLC with electrochemical detection (276). 
Biopsy samples were homogenised as previously described for the complex activities. 
lOpl of homogenate was then added to 290pl of 0.1% orthophosphoric acid (BDH). The 
samples were then freeze-thawed twice as previously described. The samples were 
vigorously vortexed after each thaw. They were then spun in a microfuge at 12,750g for 
four minutes. The supernatant (minimum volume lOOpl) was pipetted into glass vials. 
GSH analysis was performed using HPLC coupled to an electrochemical detector, 
having been calibrated with standards of a known concentration, 5pM. The system 
consisted of an autosampler (HPLC autosampler 360, Kontron Instruments, Watford, 
Herts, UK), a pump (PU 1580 intelligent pump, Jasco, Victoria. Canada), an in-line 
degasser and a reverse phase column (Techsphere ODS 5pm 250x4.6mm column,
HPLC Technologies, Welwyn Garden City, Herts, UK) while electrochemical detection
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was performed using an ESA Coulochem II electrochemical detector using a model 
5011 analytical cell (Bedford, MA, USA). The potential at electrode 1 was lOOmV and 
600mV at electrode 2. The peaks were analysed with a computing integrator (SP4400, 
Thermo Separation Products, Hemel Hempstead, Herts, UK). The mean retention time 
was 11.1 minutes (standard deviation ± 0.008, n=12). Results were expressed as pM/mg 
of total protein. Figure 13 demonstrates a typical chromatogram while the linearity of 
the technique and the voltamagram are shown in Figure 14 and Figure 15.
In order to assess the recovery of GSH from the homogenate, 5pM standard and a 
homogenate whose GSH concentration had already been determined (25 pM) were 
added together in equal volumes. The expected GSH concentration would therefore be 
15pM. The measured concentration was 13.6pM ± 0.3 (n=4) giving a recovery of 91%.
103
GSH
peak
Solvent
front
1
Injection-------------►—>
n---------- i----------- 1—
0 10 20 
minutes
Figure 13: A typical chromatogram obtained from a GSH reference sample
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Figure 14: Linearity between increasing concentration of GSH and the current produced 
at the electrochemical detector.
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Figure 15: Voltamogram of current produced while varying the potential at electrode 2
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2.2.6 Determination of protein concentration
Principle: The assay is based on the reaction between protein and an alkaline copper 
tartrate solution (Solution A) and Folin reagent (Solution B) (277).
Method: The tissue was homogenised as previously described and diluted 1:5 in muscle 
isolation buffer. It was then diluted a further 1:20 in water (lOpl homogenate and 190pi 
of water). A standard curve was determined, using bovine serum albumin, for 
concentrations between 0 and 200pg/ml. lOOpl of reagent A and 800pl of reagent B 
were added to the samples and standards. They were vigorously vortex and left in the 
dark for 25 minutes. Absorption was then measured at 750nm on a Uvikon XS 
spectrophotometer.
2.2.7 Determination of total nitrite concentration
Principle: Total tissue nitrite concentrations were determined using a modified Griess 
method (278). The assay depends upon the enzymatic reduction of nitrate to nitrite, 
which can then be converted into a coloured azo compound and detected 
spectrophotometrically.
Method: Samples were homogenised and freeze thawed as described for the analysis of 
complex activities. They were further diluted 1:5 in phosphate buffered saline (PBS) 
and added to Ultrafree-MC filtration tubes before being spun in a refrigerated centrifuge 
at 21910g for 4 hours at 4°C (Hettich Universal 32R, Hettich Zentriflugen, Tuttlingen, 
Germany). 50pl of the filtrate was pipetted into the wells of a 96 well plate. A standard 
curve was determined for nitrite concentrations between 0 to 50pM. To each well, 25pi 
of nitrate reductase (300u/l) and 25 pi ofNADPH tetrasodium salt (Fw=905; 25 pM) 
were added. The plate was then completely covered with tin foil and incubated for three 
hours at room temperature. 50pl was then added to each well of a solution consisting of:
• 2.4ml L-glutamic dehydrogenase, 3U/ml in PBS.
• 2.4ml, 3mM a-ketoglutaric acid, disodium salt (Fw=190.1, 2.85mg/5ml in
PBS).
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• 1.2ml, 1.5M ammonium chloride (Fw=53.5, 8.03g/100ml PBS aliquoted into
1.2ml).
The plate was then incubated for a further ten minutes at 37°C. 50pl of Griess reagent 1 
(1% sulphanilamide (lg/lOOml) in 5% concentrated phosphoric acid) and 50pl of Griess 
2 reagent (0.1% N-ethylenediamine dihyrochloride in water) was then added to each 
well and Incubated for a further ten minutes at room temperature. The absorbance was 
then read on a plate reader at 540nm (Spectramax Plus, Molecular Devices, Sunnyvale, 
California, USA).
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2.3 Statistical analysis
Data are presented as mean ± standard error. Comparisons between the groups were made 
using a 1-way ANOVA and post-hoc LSD testing. Associations were assessed with 
Pearson’s correlation coefficient. Analysis was performed using SPSS 11.0 software (SPSS 
Inc, Chicago, IL).
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2.4 Patient results
2.4.1 Overview
Though the association between sepsis and organ dysfunction is well recognized 
(17;28), mechanisms by which it occurs have yet to be established. Findings of raised 
oxygen tension in the organs of both septic patients (101) and animals (99) suggest a 
defect in cellular oxygen utilization. Cell and animal models of sepsis have implicated 
an inhibition of the mitochondrial respiratory chain, and a consequent decrease in ATP 
production, as being causal. This inhibition may be mediated by various reactive 
nitrogen species.
There are little published data available on mitochondrial dysfunction in human sepsis, 
though small studies have found changes in complex activities (263;264) and lower 
ATP levels (269;270).
This present study aimed to address whether mitochondrial dysfunction does occur in 
human sepsis, and if this is related either to the severity of disease and/or the outcome 
of the patient. The study also investigated the relationship between NO production, 
GSH depletion, mitochondrial dysfunction and ATP levels.
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2.5 Patient survival and demographics
Vastus lateralis biopsies were obtained from a total of 29 septic patients. These were 
compared to nine orthopaedic control patients and five cardiogenic shock patients. For the 
septic and cardiac patients, biopsies were performed within 24 hours of ICU admission. 
Fifteen (eleven survivors) of the septic patients had further biopsies. A total of 72 biopsies 
were obtained with no complications seen in any of the patient groups. Due to variation in 
the amount of biopsy material obtained, not all of the analyses could be performed, as 
indicated in Figure 16.
Of the 29 septic patients, 16 survived the septic episode (survivors) though two of these 
survivors later died of unrelated causes. These were (1) hypoxia following 
pneumonectomy for a lung abscess caused by aspiration and (2) treatment withdrawal at 
the family’s behest following recovery from an episode of intra-abdominal sepsis and 
MODS, this patient subsequently died of an unrelated pneumonia. Patient demographics 
are displayed in Table 7. All patients had elevated cardiac outputs and all but two were 
requiring norepinephrine to maintain a mean blood pressure in excess of 60 mmHg. All 
were mechanically ventilated and twelve were haemofiltered. For patients not responding 
to high dose norepinephrine, a 16mg dose of dexamethasone had been administered within 
six hours of the biopsy to seven eventual survivors and two non-survivors. No significant 
difference was seen between septic survivors and non-survivors in terms of weight (p=0.8), 
age (p=0.9), norepinephrine requirement (p=0.9), blood pressure (p=0.06) and cardiac 
output (p=0.9)
Three of the five cardiogenic shock patients died as a direct result of their disease. Four of 
these patients were admitted to the ICU in cardiogenic shock following coronary artery 
bypass grafting; the fifth patient was admitted with an acute decompensation of a dilated 
cardiomyopathy. All patients required mechanical ventilation and an epinephrine infusion 
to maintain a mean blood pressure in excess of 60 mmHg. One patient required 
haemofiltration. There were no significant differences between the cardiac control group 
and the septic survivors and non-survivors with respect to weight (p=0.4), age (p=0.8),
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vasoactive drug requirement (assuming equivalence in potency between epinephrine and 
norepinephrine, p=0.3) and mean arterial blood pressure (p=0.4). Cardiac output was 
significantly lower in the cardiogenic shock group (p=0.01).
All nine control patients undergoing elective total hip replacement surgery were discharged 
home after an uneventful postoperative course. There were no significant differences 
between the orthopaedic control group, the septic and cardiac groups with respect to age 
and weight.
I l l
Septic
survivors
Septic
non­
survivors
Cardiac
controls
Orthopaedic
Controls
Number 16 13 5 9
Age 60 ±3.6 60 ± 4.6 58 ±6.8 69 ± 3.2
Gender (M/F) 8:8 8:5 5:0 5:4
Weight (kg) 74 ± 4.6 67 ±3.1 70 ± 7.4 63 ± 3.2
Source of sepsis: -
• chest 4 6 -
• abdominal 6 6 -
• septicaemia 4 0 -
• other 2 0 -
Prior surgery 5 5 4 -
Comorbid factors
• diabetes 2 1 0 0
• malignancy 0 1 0 0
•  ischaemic heart disease 1 0 4 1
1st 24 hour SAPS II score 42 ± 2.8 58 ±6.7 49 ± 4 -
1st 24 hour SOFA score 10 ± 1 11 ± 1 12 ± 1 -
Vasoactive drug 23.7 + 4.1 21.6 ± 1.7 33 ±8.8 0
requirement (pg/min)
Arterial base deficit 4.0 ± 1.9 6.7 ± 1.9 6.7 ± 0.8 -
(mEq/1)
Oxygen delivery (DO2) 1349 ± 89 1165 ± 174 1247 ± 98 -
ml/min
Cardiac output (1/min) 7.4 ± 0.6 7.4 ± 0.8 4.4 ± 0.8 -
Mean blood pressure 74 ± 5 67 ± 4 70 ±4.1 -
(mmHg)
SVR (dyn.sec.cm'5) 630 ± 42 553 ± 40 1176 ±276 -
Length of ICU stay (days) 13.6 ±2.9 6.8 ±1.2 5.8 ±1.4 -
Table 7: Demographic data of patients enrolled into study
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Total patients=43
Survivors=16
•  NOx=10
•  GSH=15
• Mitoch=16
• ATP=12
Non-survivors=13
• NOx=9
• GSH=12
• Mitoch=13
• ATP=9
2nd biopsy=ll
• NOx=6
• GSH=10
• Mitoch=ll
•  ATP=6
2nd biopsy=4
•  NOx=2
• GSH=4
• Mitoch=4
•  ATP=4
3rd biopsy=2
•  NOx=l
•  GSH=2
• Mitoch=2
• ATP=2
3rd biopsy=6
• NOx=3
• GSH=6
• Mitoch=6
•  ATP=3
4th biopsy=3
•  NOx=2
• GSH=3
• Mitoch=3
• ATP=2
5th biopsy=3
• NOx=2
• GSH=3
• Mitoch=3
• ATP=1
Septic=29
•  NOx=19
• GSH=27
• Mitochondria=29
• ATP=21
Cardiogenic shock=5
•  NOx=l
•  GSH=4
• Mitochondria=5
•  ATP=5
Surgical control=9
• NOx=7
• GSH=8
• Mitochondria=9
•  ATP=9
Figure 16: Number of patients recruited from each group and number of analyses 
performed.
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2.6 Biopsy 1
2.6.1 Skeletal muscle total NOx
Skeletal muscle NOx levels were measured using a modified Griess method as 
described in 2.2.7.
Skeletal muscle NOx concentrations were significantly raised in both the septic 
survivors (p=0.005) and non-survivors (p=0.0001) compared to orthopaedic controls. 
Non-survivors also had significantly higher NOx values compared to survivors 
(p=0.01). Due to the small amount of tissue obtained from the cardiac control patients 
NOx analysis was only performed on one sample, hence no comparisons were made.
[NOx] 
pmol/mg protein
250 i 
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0 i □
Orthopaedic
controls
Septic
survivors
Septic
non-survivors
Figure 17: Skeletal muscle NOx concentrations from the four patient groups.
There was a significant positive correlation (r=0.67, p=0.003) between total tissue NOx 
levels and norepinephrine requirement in the septic patients (Figure 18). This reflects 
the importance of NO in the vascular dilatation and hyporeactivity that is associated 
with sepsis.
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♦ Septic survivors 
n Septic non-survivors
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Norepinephrine requirement 
pg/min
Figure 18: Relationship between norepinephrine requirement and skeletal muscle [NOx]
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2.6.2 Skeletal muscle reduced glutathione
Skeletal muscle GSH content was measured by HPLC as described in 2.2.5.
Muscle GSH content was significantly lower in the cardiac controls (p=0.04), septic 
survivors (p=0.0001) and non survivors (p=0.00001) compared to orthopaedic controls 
(Figure 19). There were no significant differences between the septic and cardiac 
groups.
[GSH] 
nmol/mg protein
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T
Orthopaedic
controls
Cardiac
controls
Septic
survivors
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non-survivors
Figure 19: Skeletal muscle GSH concentrations from the four patient groups.
GSH showed a significant negative correlation (r=-0.67, p=0.0003) with tissue NOx 
levels, reflecting the increased oxidant stress in the acutely septic state (Figure 20).
[NOx] 
pmol/mg protein
♦ Septic survivors 
n Septic non-survivors 
A Orthopaedic controls
300
200
100
0 5 10 15
[GSH] 
nmol/mg protein
Figure 20: The relationship between skeletal muscle [NOxJ and [GSH]
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2.6.3 Skeletal muscle complex I activity
Complex I activity was determined as described in 2.2.3. It is expressed as a ratio to 
citrate synthase activity in order to correct for mitochondrial content of the tissue.
There was a trend to decreased complex I activity in both septic groups compared to 
both of the control groups (Figure 21). This was significant in the non-survivors who had 
lower values than the orthopaedic (p=0.005), cardiac (p=0.02) and septic survivor 
(p=0.05) groups.
Complex I activity/ 
CS activity
0.25 
0.2 
0.15 
0.1 
0.05 
0
Orthopaedic Cardiogenic Septic Septic non­
controls shock survivors survivors
Figure 21: Skeletal muscle complex I activity in the four patient groups.
A significant negative correlation (r=-0.44, p=0.03) was seen between complex I 
activity and tissue NOx levels (Figure 22) and a significant positive correlation (r=0.47, 
p=0.005) seen with tissue GSH (r=0.47, p=0.005, Figure 23) and ATP levels (r=0.4, 
p=0.03, Figure 24). Complex I activity also showed a negative correlation (r=-0.63, 
p=0.0001, Figure 25) with norepinephrine requirement.
These associations may reflect the ability o f NO to inhibit complex I when GSH levels 
are depressed.
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Figure 22: The relationship between skeletal muscle [NOx] and complex I activity
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Figure 23: The relationship between skeletal muscle [GSH] and complex I activity
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Figure 24: The relationship between skeletal muscle [ATP] and complex I activity.
Complex I activity/ 
CS activity 
0.4 i
r=0.-63
p=0.00010.3
0.2
T 1
10 20 30 40 50
Norepinephrine requirement 
pg/min
♦ Septic survivors 
n Septic non-survivors 
° Cardiogenic shock
60
Figure 25: The relationship between norepinephrine requirement and skeletal muscle 
complex I activity.
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Others have demonstrated that NO mediated inhibition of complex I can be reversed 
with the addition of exogenous GSH (194;213), suggesting nitrosylation of thiol groups 
on the complex. To investigate reversibility in the human septic muscle, homogenates 
were incubated in 5mM GSH for 40minutes. No reversibility of Complex I inhibition 
was achieved in the 10 septic patients examined (Figure 26)
Relative change in 
complex I activity
1.4
1.2
0.8
0.6
Figure 26: change in complex I activity with the addition of 5mM GSH to 10 skeletal 
muscle homogenates obtained from septic patients.
2.6.4 Skeletal muscle complex II/III activity
Complex II/III activity was determined as described in 2.2.3. It is expressed as a ratio to 
citrate synthase activity in order to correct for mitochondrial content of the tissue.
There were no significant differences between the four groups (p=0.3, Figure 27).
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Figure 27: Skeletal muscle complex II/III activity in the four patient groups.
However, there was a negative correlation (r=-0.4, p=0.05) between complex II/III 
activity and norepinephrine requirement (Figure 28). This suggests the complex may still 
be prone to inhibition but is less susceptible than complex I.
Complex II/III activity/ 
CS activity 
0.4
0.3
0 *
r=-0.4
p=0.05
20 40 60
♦ Septic survivors 
° Septic non-survivors 
° Cardiogenic shock
80
Norepinephrine requirement 
pg/min
Figure 28: The relationship between norepinephrine requirement and skeletal muscle 
complex II/III activity.
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2.6.5 Skeletal muscle complex IV activity
Complex IV activity was determined as described in 2.2.3. It is expressed as a ratio to 
citrate synthase activity in order to correct for mitochondrial content of the tissue.
Skeletal muscle complex IV activity was significantly higher in the cardiac controls 
(p=0.0002) and septic non-survivors (p=0.003) than the orthopaedic controls (Figure 29). 
The cardiac patients also had significantly (p=0.003) higher values than the septic 
survivors.
These results are contrary to the majority of studies of sepsis performed in cells and 
animals which show a rapid, but reversible inhibition of complex IV, mediated by NO. 
The reason may be methodological; as the assay is performed in buffers equilibrated in 
room air at 30°C, this high oxygen tension will displace the NO and thus reverse the 
inhibition. The apparent increase in activity seen in these patients may be due to an 
increase in complex IV though this was not measured.
Complex IV activity/ 
CS activity
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controls shock survivors survivors
Figure 29: Skeletal muscle complex IV activity in the four patient groups.
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2.6.6 Skeletal muscle ATP concentration
Skeletal muscle adenine nucleotide concentrations were determined by reverse phase 
HPLC with UV detection as described in 2.2.4.
The skeletal muscle ATP concentration was significantly lower in the septic non­
survivors compared to orthopaedic controls (p=0.05), cardiac controls (p=0.009) and 
septic survivors (p=0.0004) (Figure 30).
[ATP] 
nmol/mg dry wt
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1_1T._1hui 1__________
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Orthopaedic Cardiogenic Septic Septic non­
controls shock survivors survivors
Figure 30: Skeletal muscle ATP concentration in the four patient groups
123
2.6.7 Skeletal muscle ADP and AM P concentrations
There was no overall significant difference in skeletal m uscle ADP (p=0.6) and AM P 
(p=0.7) levels between the four patient groups (Figure 31 and Figure 32)
[ADP] 
nmol/mg dry wt
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controls shock survivors survivors
Figure 31: Skeletal muscle ADP concentration from the four patient groups
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Figure 32: Skeletal muscle AMP concentration from the four patient groups.
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2.6.8 Skeletal muscle adenylate energy charge
The adenylate energy charge represents the proportion of adenine nucleotides in a ‘high 
energy’ state. It is derived from the equation (ATP+0.5ADP)/(ATP+ADP+AMP) (279).
There were no significant differences in skeletal muscle energy charge between the 
orthopaedic controls and the other groups. However, the septic non-survivors had a 
significantly lower energy charge compared to both the septic survivors (p=0.01) and 
the cardiac patients (p=0.04) (Figure 33).
Adenylate energy 
charge 
1.0 i
Orthopaedic Cardiogenic Septic Septic non­
controls shock survivors survivors
Figure 33: Skeletal muscle energy charge in the four patient groups.
125
2.6.9 Skeletal muscle ATP:ADP ratio and total adenine content
The ATPiADP ratio, reflecting the proportion of adenine nucleotide readily available 
for metabolism, was significantly lower in the septic non-survivors compared to 
orthopaedic controls (p=0.03), cardiac patients (p=0.02) and septic survivors (p=0.003) 
(Figure 34).
ATP:ADP
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0 I
*
Orthopaedic Cardiogenic 
controls shock
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Septic non­
survivors
Figure 34: Skeletal muscle ATP:ADP ratio in the four patient groups.
Total adenine content was derived from the sum of the ATP, ADP and AMP 
concentrations.
There were no significant differences in skeletal muscle adenine content between the 
orthopaedic controls and cardiac controls (p=0.3), septic survivors (p=0.2) and non­
survivors (p=0.3). However, the septic non-survivors had significantly lower adenine 
nucleotide concentrations than either septic survivors (p=0.01) or cardiac patients 
(p=0.03), Figure 35.
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Figure 35: Skeletal muscle adenine nucleotide content in the four patient groups.
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2.6.10 Skeletal muscle phosphocreatine:creatine ratio
Phosphocreatine and creatine concentrations were determined by reverse phase HPLC 
with UV detection as described in 2.2.4.
Significantly lower phosphocreatine:creatine ratios were seen in the skeletal muscle of 
non-surviving (p=0.008) and surviving (p=0.05) septic patients compared to orthopaedic 
controls (Figure 36).
PC nCr
2
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1
0.5 
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Orthopaedic Cardiogenic Septic Septic non­
controls shock survivors survivors
Figure 36: Skeletal muscle PCrrCr ratio in the four patient groups.
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2.6.11 Summary
Skeletal muscle biopsies obtained from septic human patients demonstrated 
significantly higher levels of NOx than those obtained from elective surgical controls. 
Others have also demonstrated raised NOx levels in septic patients that have also 
correlated with systemic vascular resistance, blood pressure and cardiac output 
(280;281).The raised NOx levels were associated with lower levels of GSH, ATP and 
complex I activity. These were also related to sepsis severity (norepinephrine 
requirement) and outcome. Biopsies obtained from patients with cardiogenic shock with 
similar disease severity as the septic patients showed less GSH depletion and no 
evidence of neither respiratory chain inhibition nor low ATP levels.
Though the methods of analysis are different these findings are generally in keeping 
with the studies of Poderoso (264), Liaw (269) and Tresadem (270). The unexpected 
finding of an increase in complex IV activity maybe methodological or due to an 
increase in the quantity of complex IV protein. This must remain speculative at present, 
though one study exposing mouse macrophages to NO found an increase in the amount 
of mRNA for the complex IV subunit, COX 1 (282).
If the results found in skeletal muscle are repeated in other tissues, the hypothesis that 
mitochondrial dysfunction is an important mechanism underlying sepsis-induced organ 
failure is given further support.
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2.7 Sequential biopsies
Fifteen septic patients had repeat biopsies during their stay on intensive care. Eleven 
survived the episode of sepsis and related organ dysfunction, though two of these 
‘survivors’ subsequently died of unrelated causes. Prolonged critical illness is 
associated with a decrease in muscle bulk which made obtaining sufficient tissue for the 
analyses increasingly difficult. The number of analyses performed are displayed in 
Figure 16. No repeat biopsies were obtained from the orthopaedic or cardiac patients.
2.7.1 Organ dysfunction
Of the fifteen patients studied, all but one, remained intubated, ventilated and sedated 
during the course of the study.
Norepinephrine requirements fell sharply by the second biopsy (27.4 ± 3.7 v 3.7 ± 
2.4pg/min), with only four patients (two survivors) requiring continued vasoactive 
support by day 5. Three patients (one survivor) required intermittent vasoactive support 
beyond this time.
Six of the fifteen patients required initial haemofiltration (three survivors). Four (two 
survivors) required continued renal support beyond 15 days though only one patient 
required support beyond 20 days.
All patients received nutrition; 14 patients received enteral nutrition as tolerated while 
one patient required parenteral nutrition because of multiple small bowel fistulae.
The SOFA score was used to track organ dysfunction over the patient’s stay on the ICU. 
The mean SOFA score showed an overall significant (p=0.04) improvement over the 
period of ICU stay, (Figure 37), which was more clearly pronounced in eventual 
survivors (Figure 38).
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Figure 37: Mean SOFA score of all patients undergoing sequential muscle biopsies
Though there was an upward trend in the SOFA score of non-survivors, due to the small 
numbers (n=4) this was not significant (p=0.7) (Figure 38). Increases in SOFA score 
during ICU admission have been previously associated with a poor prognosis (32)
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n=3n=6n=l 1 n=3
1 5 10 15 20
Days of ICU stay
Figure 38: Sequential SOFA scores of septic survivors and non-survivors
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2.7.2 Sequential skeletal muscle NOx concentrations
The mean NOx skeletal muscle concentration was significantly lower in the post day-1 
biopsies compared to the day-1 value (Figure 39).
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Figure 39: [NOx] in skeletal muscle biopsies obtained from all patients undergoing 
sequential biopsies.
Only two of the four patients requiring continued vasoactive support had [NOx] 
analysed on day 5. Their NOx levels were higher (108 ± 20pmol/mg protein) than those 
found in the six patients analysed who were not requiring vasoactive support (75 ± 
7.5pmol/mg protein). This suggests persisting raised NO production may be associated 
with low blood pressure and the need for continued haemodynamic support.
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2.7.3 Sequential skeletal muscle reduced glutathione concentrations
Patient skeletal muscle concentrations rose significantly (p=0.005). Compared to day 1, 
GSH concentrations were significantly higher at days 5, 10 and 20. Between day 1 and 
day 5, there was no overall significant difference in GSH concentrations between 
survivors and non-survivors (p=0.08).
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Figure 40: GSH concentration in skeletal muscle biopsies obtained from all patients 
undergoing sequential biopsies.
Patients who were no longer requiring norepinephrine at day 5 showed a 95% increase 
in GSH levels (n=l 1) from day 1, compared to a 28% rise measured in three o f the four 
patients with persisting norepinephrine requirements (Figure 41).
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Figure 41: Sequential [GSH] in patients with and without persisting shock (as determined 
by a continuing norepinephrine requirement).
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2.7.4 Sequential skeletal muscle complex I activity
Complex I showed a progressive increase in activity over time (p=0.04). Compared to 
day 1 values, however, this was only significant by day 20 (p=0.01) (Figure 42). There 
were no differences between survivors and non-survivors (p=0.7).
Patients who were no longer requiring norepinephrine at day 5 showed a 14% increase 
in complex I activity (n=l 1) from day 1, compared to an 8% (n=4) rise in those with 
persisting norepinephrine requirements.
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Figure 42: Complex I activity in skeletal muscle biopsies obtained from all patients 
undergoing sequential biopsies.
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2.7.5 Sequential skeletal muscle complex II/III activity
There was no overall significant difference in skeletal muscle complex II/III activity 
over time (p=0.6). No difference in complex II/III activity was seen between survivors 
and non-survivors, nor in those with and without persisting shock.
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Figure 43: Complex II/III activity in skeletal muscle biopsies obtained from all patients 
undergoing sequential biopsies.
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2.7.6 Sequential skeletal muscle complex IV activity
There were no overall significant differences in skeletal muscle complex IV activity 
over time (p=0.6) (Figure 44). No difference in complex IV activity was seen between 
survivors and non-survivors, nor in those with and without persisting shock.
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Figure 44: Complex IV activity in skeletal muscle biopsies obtained from all patients 
undergoing sequential biopsies.
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2.7.7 Sequential skeletal muscle ATP, ADP and AM P concentrations
There were no significant differences in ATP (p=0.5), ADP (p=0.8) and AMP (p=0.9) 
concentrations over time (Figure 45). Nor were there any apparent trends between 
survivors, non-survivors and those with and without persisting shock.
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Figure 45: ATP, ADP and AMP concentrations in skeletal muscle biopsies obtained from 
all patients undergoing sequential biopsies.
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2.7.8 Summary
The SOFA score decreased over time signifying an improvement in organ function. 
Predictably this was greater in those who survived. This was associated with a 
downward trend in NOx levels and an increase in GSH levels and complex I activity. 
ATP levels were unaffected, though were high compared to the concentrations seen in 
all the non-survivors at day 1.
Though the numbers were small, the persistence of shock at day 5, as signified by 
continued norepinephrine requirements, was associated with smaller changes in these 
parameters. This may be due to the continued production of reactive nitrogen species 
e.g. NO, that have the capability of reducing vascular tone, decreasing GSH levels and 
inhibiting mitochondrial respiration.
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2.8 Discussion o f patient results
The study hypothesis stated that sepsis-induced MODS resulted from an inhibition of 
the mitochondrial respiratory chain related to over-production of reactive nitrogen 
species and a decrease in the protective antioxidant, GSH. Figure 46 depicts a possible 
schema.
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Figure 46: Schema of the proposed mechanism of respiratory chain inhibition and organ 
dysfunction
The results obtained from the septic patients support this hypothesis by demonstrating, 
for the first time, a relationship between the sepsis severity (adjudged by norepinephrine 
dose), NO production, antioxidant depletion, respiratory chain inhibition and ATP 
depletion. Despite being unable to clinically distinguish eventual survivors from their 
non-surviving counterparts, either by SOFA or SAPS II scores, statistically significant
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differences were seen in ATP levels, and in Complex I and IV activities obtained from 
skeletal muscle biopsy taken within 24 hours of ICU admission.
Overproduction of NO is central to the hypotension and vascular dysregulation seen in 
human sepsis (280;281). Injection of the non-specific NOS inhibitor, L-NMMA, into 
patients with septic shock resulted in an elevation of blood pressure and a decrease in 
norepinephrine requirements (174). However, until now, there has been minimal 
investigation into the role of NO as an inhibitor of cellular respiration in human sepsis. 
Indirect evidence supporting this theory includes a decreasing oxygen consumption in 
patients with an increasing severity of sepsis (55), a rise in tissue oxygen tension 
(101; 104) and a decrease in arterial ketone body ratio (a measure of hepatic 
mitochondrial redox state) which correlates with outcome and the plasma nitrite 
concentration (265;266). Muscle biopsies obtained from eight septic patients 
demonstrated an inhibition of complex I mediated respiration (264), while a case report 
demonstrated decreased complex III and IV activity (263).
Due to its short half-life, NO is difficult to measure directly in vivo. Nitrite/nitrate 
(NOx) levels are thus often used as a surrogate. Nitrite is the major oxidation product of 
NO metabolism, but is then further oxidized to nitrate. Nitrate is also generated by the 
interaction between NO and oxyhaemoglobin and through the decomposition of 
ONOO\ The sum of these nitrogen oxides is therefore used to quantify endogenous NO 
formation. NOx is heavily utilised in all areas of research as a marker of NO production 
as it is readily measurable in plasma and tissue, using simple and well-established 
methods. Unfortunately, the value gives no indication of NO turnover; as nitrate has a 
half life of between 5-8 hours in plasma, it is thus a poor marker of acute change. NOx 
values are dependent on both the rate of production and elimination. As the main route 
of elimination of NOx is renal, it is important to appreciate that a raised level may be 
caused, at least in part, by renal impairment (142;283). Other methods of assessing NO 
production, such as NO electrodes and the use of radio-labelled arginine are 
technologically demanding and not readily applicable to an ICU setting.
A number of studies have investigated the relationship between inflammation and NOx 
levels in ICU patients. Those with SIRS had higher NOx levels than those without 
(284). A comparison between healthy volunteers, patients with cardiogenic shock, 
bacterial pneumonia and septic shock demonstrated progressively higher plasma levels
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of both the pro-inflammatory cytokine, TNFa, and NOx (285). NOx values were higher 
in septic patients with shock compared to those without in both adult (286) and 
paediatric ICU populations (287).
NOx levels also correlate with the severity of a septic illness. In a study of septic adults, 
plasma NOx levels correlated inversely with systemic vascular resistance (SVRI) and 
the global O2 extraction ratio, and correlated directly with plasma lactate (280). In 
further septic patient studies plasma NOx levels correlated with the endotoxin level, 
cardiac output, vasopressor requirements and inversely with systolic blood pressure 
(281;286). NOx levels were also related to the severity of meningococcal sepsis (288), 
and to the severity of sepsis-induced organ dysfunction (289). Raised levels of iNOS 
protein have been reported in muscle biopsied from septic patients (143) This was 
associated with increased nitrotyrosine staining, suggestive of peroxynitrite formation, 
and a loss of contractile function.
Rabuel (working in the Intensive Care Unit, Lariboisiere University Hospital, Paris), 
using Western blotting techniques, investigated the concentration of iNOS protein in a 
proportion of the muscle biopsies obtained from this study. He demonstrated 
significantly higher levels of the iNOS protein (p>0.001) in both septic groups 
compared to orthopaedic controls (Table 8).
[iNOS] protein 
(arbitary units)
Orthopaedic 4.1 (0.9)
controls n=5
Septic 12 (2.2)
survivors n=8
Septic non­ 15.9 (3.9)
survivors n=5
Table 8: iNOS protein concentration in orthopaedic and septic patients
In agreement with other work, the present study has demonstrated that NOx levels 
(albeit in tissue and not plasma) are raised in patients with sepsis, and correlate with the 
severity of cardiovascular dysfunction as assessed by norepinephrine requirements.
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The increase in iNOS activity (143;290) and the raised NOx levels that are seen in 
human sepsis are also associated with higher levels of lipid peroxidation and protein 
nitration, and lower levels of reduced sulphydryl groups and total antioxidant capacity 
(143;284;291). These findings suggest that the rise in reactive nitrogen and oxygen 
species is associated with a decrease in antioxidant defences, and alteration in both cell 
structure and function.
In subsequent muscle biopsies taken at 5-day intervals, the decrease in NOx values was 
associated with an improvement in organ function. However, a persisting vasopressor 
requirement at day 5 was associated with higher NOx values (measured in only two 
patients), compared to those who no longer required haemodynamic support. Other 
studies have demonstrated similar trends; plasma NOx levels fell in septic survivors but 
remain elevated in non-survivors (292;293). Strand demonstrated plasma NOx and 
nitrotyrosine levels to be initially elevated in 16 patients with septic shock, but returning 
to control values on shock resolution (294). Two of their patients developed further 
episodes of shock, each time associated with a rise in plasma NOx concentrations.
These findings again implicate NO in the loss of vascular control seen in septic shock.
This study also demonstrated a significant inverse correlation between NOx and GSH 
levels. GSH is a major cellular antioxidant consisting of glutamate, cysteine and 
glycine. It protects the cell against modification by reactive species. GSH can detoxify 
ONOO", H2O2 and maintain protein thiol groups in a reduced form. During these 
reactions, two molecules of GSH are oxidized to one molecule of GSSG. The reduction 
of GSSG back to GSH is by the NADPH-dependent enzyme, GSSG reductase. This 
study and others have shown that concentrations of GSH are decreased in the critically 
ill. Nemeth found that whole blood GSH levels were approximately 40% lower in 31 
septic children compared to 30 surgical controls (121). Similar findings were reported 
by Lyons and colleagues (295). In a general ICU population, muscle GSH and total 
glutathione concentrations were significantly lower when compared to surgical controls 
(296). There was also a decrease in GSH:GSSG ratio. Numerous animal models have 
also demonstrated lower GSH levels during the septic process. In endotoxic rat models, 
Iqbal reported lower GSH concentrations in the left ventricle at 16 hours (180), El- 
Gawad found lower levels of brain GSH (297) while Portoles found a lower total 
hepatic GSH level at 48 hours (298). The loss of GSH witnessed in these studies
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decreases the rate of scavenging of ONOO' and increases the vulnerability of the cell to 
damage by reactive species (205). This is supported by the findings that deliberate 
depletion of glutathione prior to sepsis enhanced oxidant stress (299) and worsened 
organ dysfunction (300).
In keeping with these reported studies, the present study also found lower GSH levels in 
the septic patients. Only the reduced (GSH) component of glutathione was measured, 
and not the oxidised form, GSSG. Thus it is not known whether there has been a shift 
from the reduced to the oxidized form, and/or depletion of the whole glutathione pool.
A decrease in muscle GSH:GSSG ratio seen in ICU patients (296) and in blood taken 
from septic paediatric patients (121) suggests that critical illness is associated with a 
shift towards the oxidized form. This may be due to increased oxidative/nitrosative 
stresses associated with sepsis and MODS (121 ;301), or to a decrease in activity of 
glutathione reductase (302;303). The activity of this enzyme is decreased in GSH- 
depleted rat brains and is inhibited by ONOO' (302). However, in animal models of 
sepsis, glutathione reductase was increased in endotoxic rat hearts at 16 hours, despite a 
fall in GSH levels (180). Malmezat also demonstrated a rise in glutathione reductase 
activity in multiple tissues taken from bacteraemic rats at six hours (304).
A decrease in glutathione synthesis was inferred from Hammarqvist’s (296) findings of 
low GSH and GSSG in the muscles of critically ill patients. Lyons concluded that whole 
blood glutathione synthesis rates were 60% lower in septic children compared to 
controls (295). Possible reasons for this include an inhibition of the enzymes involved 
in the synthesis of glutathione or a lack of available substrate (305). Muscle 
concentrations of glutamine (primarily produced by skeletal muscle), cysteine and 
glycine are lower in the septic patient (296). Muscle production of glutamine was 
markedly decreased (48%) in hypercatabolic bums patients, irrespective of whether the 
patient was being fed (306), while the addition of glutamine to the TPN of trauma 
patients attenuated the fall in muscular GSH (307).
Glutamine is also an important fuel source for rapidly dividing cells such as 
lymphocytes and enterocytes. A fall in glutamine availability may therefore also reduce 
immune and gut function. This will partly contribute to the period of relative 
Immunosuppression and anergy that follows the initial inflammatory phase of a septic 
insult (41), thus increasing the risk of acquiring nosocomial infections. Supplementation
145
of glutamine in the critically ill reduces this risk (308) and has been shown to improve 
white cell function (309;310) in the high risk surgical patient.
Limited supplies of glutamine may also result in a loss of gut mucosal integrity (311), 
which may enhance the translocation of luminal bacteria into the portal circulation.
Some have proposed that this translocation promotes an excessive inflammatory 
response and may be the ‘motor’ of MODS (312).
A marked increase in tissue GSH concentration was noted in both septic groups in the 
second biopsy sample (taken at ICU Day 5) (Figure 40). This may reflect metabolic 
adaptation to sepsis, the provision of nutrition, or a reducing degree of inflammation. 
There is less oxidant stress as the acute septic episode resolves, but NADPH production 
via the pentose phosphate shunt also rises, hence increasing rates of GSSG reduction 
(180;304;313). Interestingly, the rise in GSH was lower in those with persisting 
norepinephrine requirements (Figure 41).
The septic patients in the present study had lower complex I activity associated with 
raised NOx levels and lower GSH levels. These findings support in vitro studies 
indicating that NO can inhibit the complexes of the respiratory chain and that GSH may 
protect the cell against this form of attack (193;205). Mitochondrial GSH depletion is 
associated with an increased production of reactive oxygen intermediates, a decrease in 
mitochondrial transmembrane potential and inhibition of respiratory chain complexes 
(314).
Mitochondrial inhibition may be rapid and reversible following a brief exposure to NO 
(complex IV) (188), or irreversible following a more prolonged exposure (complex I 
and IV) (196;204). The inhibitory effects of NO may also be a result of ONOO' 
generated by the reaction between NO and 02*. Preservation or restoration of Complex I 
activity with exposure to bright light (photolysis) or by addition of GSH suggests that 
nitrosylation of a critical thiol group may be the underlying mechanism.
(107; 194; 196;213). However, in the present study, no increase in complex I activity was 
found on addition of GSH to the tissue homogenates. This finding requires further 
investigation but possible reasons include:
1) Inhibition of complex I being not due to nitrosylation of thiol groups, but rather an 
irreversible nitration.
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2) GSH being unable to access the nitrosylated residue. This may be the case in intact 
cells or, possibly, mitochondria where GSH does not freely pass through 
membranes. However, as the samples were homogenised and then freeze-thawed, 
the membranes would have been fractured thus exposing the complex.
3) Complex I activity remaining unaffected but the total pool of complex I has been 
depleted.
Although complex I activity was lower in the septic patients at day 1 this demonstrated 
a trend toward increased activity over time (statistical significance was only achieved by 
Day 20). This increase was associated with a more rapid decrease in tissue NOx and 
increase in GSH concentrations. If GSH was able to reverse the inhibition of complex I 
in vivo, the increase in activity should have been more rapid, as GSH levels were similar 
to controls by Day 5. Though it is impossible to exclude a low intra-mitochondrial GSH 
concentration, despite a normal cellular GSH concentration, this finding again suggests 
that the inhibition of complex I is not through a nitrosylation mechanism.
The patients in cardiogenic shock also had significantly lower skeletal muscle GSH 
concentrations compared to the orthopaedic controls, albeit not as low as the septic 
patients (non-significant). Unfortunately, tissue NOx was only measured in one of the 
cardiac biopsies and it is thus impossible to compare NO production between these two 
groups. Four of these cardiac patients were recruited immediately post-surgery, and had 
undergone cardio-pulmonary bypass, a technique well known to initiate an 
inflammatory response and increase NO production (315). This may explain the lower 
GSH levels seen in these patients, though the intensity of the inflammation is considered 
less than that seen in sepsis (293). The lower intensity of inflammation and smaller 
decrease in GSH levels, compared to the septic patients, may have been sufficient to 
prevent the inhibition of complex I activity in these cardiac patients. It is noteworthy 
that these patients had a high mortality, with similar degrees of organ dysfunction and 
inotrope requirement, so the difference was not due to a less sick cohort of patients.
This suggests that organ dysfunction in sepsis arises from different mechanisms to 
organ dysfunction initiated by a low flow state.
The negative relationship between norepinephrine requirement and complex II/III 
activity suggested that NO may have an inhibitory effect on the enzyme. However, there 
was no significant difference in complex II/III activity, either between the patient
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groups studied or over time. This finding is in contrast to those demonstrating that NO 
or inflammation does inhibit these complexes (191;193;201;205;237). However, most 
of these studies have been carried out in cell culture and thus may not represent what 
happens in vivo. Secondly, different organs may be more or less susceptible to NO- 
mediated inhibition of the respiratory chain complexes (137). Thirdly, complex 
activities were expressed as a function of total protein which does not correct for 
mitochondrial density (137;316).
Complex IV activity (expressed as a first rate constant and corrected for mitochondrial 
mass) was significantly higher in the cardiogenic shock controls and septic non- 
survivors. The latter result is again contrary to many studies reporting inhibition of 
complex IV activity by NO or sepsis. While most investigators found NO rapidly 
inhibits complex IV activity, others report that NO can also rapidly (within 15 minutes) 
lead to an upregulation of transcription and translation of the COX-1 subunit of 
complex IV, which was associated with the maintenance of enzyme activity (282). 
Exposure of astroglial and mixed cortical cells to LPS and ylFN led to an increase in 
complex IV mRNA (COX-1 and 2, but not COX-4), albeit with a loss of complex IV 
activity (317). O2 itself may also exert an allosteric effect on complex IV; higher O2 
concentrations (as may be expected in sepsis) result in a higher Vmax and a lower Km of 
the enzyme (318).
Cell models have demonstrated that NO inhibition of complex IV is competitive with 
oxygen (188; 189). However, the assay used in this study assessed the activity of 
complex IV utilising buffers and reagents whose O2 content had equilibrated with room 
air. The high O2 content of these solutions would have led to the rapid displacement of 
NO from the complex. Thus, the raised activities may be a combination of an increase 
in Complex IV protein and the inability of the assay to measure the rapidly reversible 
inhibition.
It could be argued that the high complex IV activity may be an adaptive response to the 
low tissue oxygen tension seen in cardiogenic shock (30). Sauleda and colleagues found 
raised levels of COX-1 and complex IV activities in the skeletal muscle and 
lymphocytes of chronically hypoxic patients (319;320). In a similar fashion NO 
inhibition of complex IV may mimic tissue hypoxia; thus an increase in complex IV 
activity may also be an adaptive response. Both sepsis and hypoxia result in increased
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generation of reactive species by the respiratory chain (116;321), which may signal the 
cell to respond in a similar fashion. For example, both hypoxia and NO can up-regulate 
similar early response genes such as hypoxia inducible factor-1 (HIF-1) (322). Despite 
the findings of Sauleda (319;320), others have found that hypoxia results in either no 
change (323) or a decrease (324-326) in the amount of subunits or activity of complex 
IV, suggesting that hypoxia (or dysoxia) was not the trigger for the apparent increase in 
complex IV activity in these patients. This is supported by the finding that complex IV 
activity did not change over the course of the study, despite a decrease in NOx 
concentrations and an improvement in organ function. Further studies should thus 
include measurement of Complex IV protein levels.
Tissue phosphocreatineicreatine ratio and ATP levels were significantly lower in 
patients with fatal sepsis compared to their surviving septic counterparts, cardiac failure 
and orthopaedic controls. ATP levels were maintained in the cardiac group, even in the 
three non-survivors (15.3 nmol/mg dry weight), indicating a different pathological 
process than that seen in fatal sepsis. Maintenance of ‘high-energy’ phosphates is 
reported in the resting skeletal musculature of patients with heart failure (327) but this 
decreases in septic patients (269;270).
In the present study skeletal muscle ATP levels did not show any significant changes 
over time in the septic patients. However, only four of the septic non-survivors, the 
population with significant reductions in ATP, survived long enough to have a further 
biopsy taken.
The fall in muscle ATP: ADP ratio in the septic non-survivors can have effects on 
metabolic control. In health, a fall in ATP:ADP ratio can exert allosteric control on the 
activities of phosphofructokinase (PFK) and pyruvate dehyrogenase (PDH), increasing 
the activities of these key enzymes. During sepsis, this control may also be lost. PFK 
activity was lower in septic rats (328) while others have shown increased activity of 
pyruvate dehydrogenase kinase, an enzyme that can phosphorylate and inactivate the 
PDH complex (329).
The lower energy charge reflects the relative loss of ATP to the cells’ energy consuming 
processes. It is vital for cell survival that the adenylate energy charge be maintained. 
Thus in the face of limited supply, the cell can reduce ATP consumption by decreasing
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DNA and protein synthesis (330). However, this may also reduce the cells’ ability to 
resynthesise vital enzymes (including respiratory chain complexes) and thus delay 
recovery from an oxidant attack. The remaining major ATP consumers are the ion 
pumps, such as Na/K-ATPase, which help maintain intracellular ion homeostasis. The 
activity of this pump was decreased in the muscle of septic patients (331), the 
myocardium of septic rats (332) and mouse tubular cells exposed to pro-inflammatory 
cytokines (333). Activity in the latter study could be maintained with a NOS inhibitor. 
Others, however, have shown an increase in activity of this pump in the skeletal muscle 
of septic rats (334;335). James showed a relationship between the activity of the pump 
and lactate production (336). They speculated that ATP production may be 
compartmentalised, with glycolytic ATP being preferentially used for the Na+/K+- 
ATPase.
From the present study it is impossible to conclude whether the fall in ATP 
concentration was due to a decrease in ATP production and/or an increase in utilisation. 
However, the dependency of ATP concentration on complex I activity does suggest that 
supply may be limiting.
When oxidative phosphorylation becomes inhibited, e.g. in the presence of anoxia, the 
FiFo-ATPsynthase enzyme (complex V), which utilises the proton gradient across the 
inner mitochondrial membrane to synthesize ATP, reverses and becomes an ATP 
consumer in order to maintain the proton gradient. It is important to maintain this 
gradient in order to import proteins and ensure mitochondrial integrity. Collapse of this 
gradient triggers events leading to apoptosis (337). Thus, ATP created by accelerated 
glycolysis may be used to maintain this gradient (257). In addition, the permeability of 
the inner mitochondrial membrane increases as a result of damage by peroxynitrite 
(338). This would further impair ATP levels as electron transport would become 
increasingly uncoupled from ATP synthesis, with protons rapidly cycling in and out of 
the mitochondrial matrix. However, the lack of widespread cell death in post-mortem 
samples of failed vital organs (271) suggests the cell has managed to protect itself 
against this form of death.
In summary, this is the first study to demonstrate a relationship between the severity of 
sepsis, NO production, antioxidant depletion, mitochondrial inhibition, ATP depletion 
and outcome in human sepsis. An improvement in the patient’s condition was
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associated with a decrease in NO production, normalisation of GSH levels and an 
increase in complex I activity.
Though the numbers are small, the group of five cardiogenic shock patients with equal 
disease severity did not demonstrate these changes. This suggests that the findings in the 
septic patients were not just a reflection of being ‘unwell’ and may be specific to 
inflammatory conditions. These findings also suggest that the pathophysiology of organ 
dysfunction may also be different in these two groups of patients.
2.9 Future Work
Work to date does indeed support the hypothesis that mitochondrial dysfunction is an 
important mechanism underlying multiple organ failure in sepsis. However, evidence 
currently shows an association and causality has yet to be established.
Further studies are needed to translate the findings reported in skeletal muscle to more 
‘vital’ organs such as kidney and liver. Additional studies are needed in patients with 
varying levels of sepsis severity. More data are needed on changes over time within 
subgroups, e.g. survivors compared to non-survivors, and those with and without 
persisting vasoactive requirement. Further biopsies need to be obtained from patients in 
cardiogenic shock, particularly to compare tissue NOx levels. Patients at risk of sepsis 
e.g. emergency surgical admissions, need to be recruited to investigate the temporal 
sequence between development of sepsis, mitochondrial dysfunction and organ 
dysfunction.
It would be useful to isolate mitochondria from biopsy samples to determine whether a 
correlation exists between the activities of the isolated complexes and either NADH- or 
succinate-mediated respiration. This would also allow measurement of respiratory 
control ratios, thus providing an indication of how well coupled respiration is to ATP 
synthesis. A quantitative assessment of respiratory chain complex protein levels will 
address whether the different respiratory enzyme activities seen in the septic patients are 
due to inhibition and/or loss of the enzyme.
151
Likewise, the GSSG content in the biopsy should be measured to determine whether the 
lower GSH levels were due to increased oxidation and/or a reduction in the total 
glutathione pool. These measurements could be combined with plasma and tissue 
glutamine concentrations. Arterial ketone body ratios may also give an indication of 
hepatic mitochondrial function.
Though many of the techniques used to study mitochondrial function would be 
considered too invasive/unethical, it has been possible to measure tissue oxygen tension 
(101). A correlation between mitochondrial dysfunction and tissue oxygen tension 
would be supportive of the theory of cytopathic dysoxia. Near-inffa red spectroscopy 
(NIRS) could be used to probe the redox state of cytochrome aa3 (e.g. in the forearm 
muscle). Though NIRS cannot give a quantitative result, the response to an intervention 
(e.g. inflating a tourniquet to supra-systolic pressures) could also be instructive.
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Chapter 3:
Long Term Rat Model
153
3.1 Overview
The aim was to develop an adult rat model of sepsis and multi-organ dysfunction. The 
model was instrumented (venous and arterial lines) to allow continuous measurement of 
blood pressure and administration of intravenous fluid. The insult of faecal peritonitis 
was used as it reflects a more ‘realistic’ form of sepsis than endotoxin. Aggressive fluid 
resuscitation was started two hours after the induction of sepsis. Rats were clinically 
scored with respect to disease severity and sacrificed at pre-determined time points up 
to 72 hours. Muscle and liver were removed for the analysis of NOx, GSH, ATP and 
respiratory chain complex activities as described in Chapter 2.
3.2 Methodology
3.2.1 Instrumentation
These experiments were carried out in accordance with the Animals (Scientific 
Procedures) Act 1986. 250-275g male Wistar rats (Charles River, Margate, Kent, UK) 
were housed in the local animal unit for five days prior to use, with free access to food 
and water.
The venous and arterial lines used in these experiments were PVC tubing (Critchley 
electrical products Pty Ltd, Auburn, NSW. Australia), with an internal diameter of
0.28mm and an external diameter of 0.61mm. 400mm of this tubing was cut from a reel 
and inserted into a 50mm length of tubing (internal diameter=0.58mm, external 
diameter=0.96mm) with the join sealed with a drop of superglue. The finer tubing was 
passed through the metal sheath of the tether system (Figure 47) while the wider tubing 
allowed connection with the swivel system (Figure 47). The lines were then flushed 
with heparinized saline (1:1000) to remove all air, to check the system for patency and 
leaks. A 45° bevel was cut into the venous line and a 20° bevel cut into the arterial line.
The rats were anaesthetised in a box with isoflurane (Abbott Labs, Queenborough,
Kent, UK) using a Tec 4 vaporiser driven by 0.81pm of air. The rat was placed in the
supine position and maintained on a face mask. The right hind leg was extended and the
anterior and medial aspect of the thigh then swabbed with alcohol prior to the creation
of a 10mm transverse incision, made 5mm caudal to the groin crease. A hollow trochar
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was then inserted and tunnelled subcutaneously toward the nape of the neck, where it 
was pushed through a 3mm incision. Approximately 100mm of the lines (extending 
from the metal sheath of the tether) were inserted into the trochar, which was then 
withdrawn. This enabled the lines to be drawn, subcutaneously, from the neck to the 
incision in the leg for insertion into the femoral vein and artery.
Using a dissecting microscope, the femoral vein, artery and nerve were first identified, 
exposed and then separated with blunt dissection. Initially, approximately 4mm of the 
femoral vein was isolated using proximal and distal 5/0 silk ties. The vein was then 
opened with an oblique cut, which was made in the distal third of the isolated vein. The 
venous line was then inserted to a depth of approximately 10mm. The two ties, and one 
additional tie, were then used to secure the line. The arterial line was inserted in a 
similar manner. The lines were checked again for patency and the thigh wound closed 
using interrupted tichrom sutures (4/0). The button at the end of the tether system was 
secured to the rat using four 2/0 silk sutures.
The rat was then returned to his cage and the swivel system mounted to a 
counterbalanced, overhead arm on a universal joint. Upon recovery this system allowed 
the rat unimpeded movement around his cage with free access to food and water. Both 
lines were then flushed continuously with 0.15ml/h of heparinised saline (1:1000) using 
a KD scientific 101 syringe pump (KDScientific, New Hope, PA, USA). Mean arterial 
blood pressure was transduced using a Viggo-Spectramed P23XL (Viggo-Spectramed, 
Oxnard, Ca, USA) in-line transducer. These data were recorded using a Power Lab data 
collection system (AD Instruments, Castle Hill, Australia). This system was calibrated 
using a mercury sphygmomanometer at the beginning of every experiment.
In this way up to six rats at a time could be studied. A picture of the apparatus used is 
shown in Figure 48 demonstrating the cage, swivel system, tether and pressure 
transducer.
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Swivel system (see inset)
Flexible metal sheath
Button attachment to rat
To/from
To/from pumps and 
pressure transducer
Venous and 
arterial lines
Figure 47: Tether and swivel system used for mounting venous and arterial lines
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Syringe driver
Universal joint and 
counterbalance
Pressure
transducer
Food and water Heater mat 
hoppers
Figure 48: Apparatus used to house and monitor a rat during the course of the experiment
Swivel and 
tether system
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3.2.2 Induction of sepsis and fluid resuscitation
Twenty four hours after recovery from the anaesthesia, sepsis was introduced using an 
intraperitoneal injection of faecal slurry. This faecal slurry was obtained from the bowel 
contents of a rat from the same batch as those that had been instrumented. The rat was 
anaesthetised with isoflurane. Skeletal muscle, liver and blood were taken initially as 
these rats comprised the naive group. The preparation of these samples is described 
below. The bowel, from jejunum to descending colon, was then removed; the contents 
were placed in a beaker and weighed. The contents were then suspended in twice their 
weight with normal saline and agitated with a Whirli-Mixer for 60 seconds. The 
suspension was then strained through a coffee filter to remove large pieces of fibrous 
material. The remaining suspension was injected intraperitonally (0.625ml/100g) into 
the experimental animals only. Sham control animals received no i.p. injection to avoid 
accidental perforation of the bowel.
Fluid resuscitation was commenced two hours later via the venous line, using two 60ml 
syringes in parallel loaded onto a Harvard 22 syringe driver (Harvard Apparatus, 
Southnatick, Mass, USA). For the first 24 hours 20ml/kg/hr of a 1:1 solution of 
Elohaes/5% glucose was infused. This was reduced to 17.5ml/kg/hr between 24 and 48 
hours. This was further reduced to lOml/kg/hr between 48 and 72 hours. Sham control 
animals underwent the same fluid resuscitation regimen. During the fluid infusion 
(infused at room temperature) a heater mat, under the cage was used to aid the animals 
in maintaining their body temperature.
This method of sepsis induction and resuscitation regimen had been determined in a 
pilot study. Other forms of sepsis, including s.c. and i.v. Staphylococcus pyogenes and
i.v. endotoxin, were ineffective in generating a model that was severe enough to 
produce organ dysfunction, when the rat received i.v. fluid resuscitation, Table 9. It was 
found that faecal peritonitis, involving a polymicrobial insult and foreign material, 
produced a model with a high mortality and evidence of organ dysfunction as well as 
being more representative of a sub-group of the septic patient population. An i.p. 
injection of faecal slurry avoided the need for a laparotomy and caecal ligation and 
puncture. Doses of 0.5, 0.625 and 0.75ml faecal slurry/1 OOg of rat were given (n=8 in 
each group), without fluid resuscitation. The mortality in the 0.5ml/100g group was
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only 1 of 8 at 24 hours. In the 0.625ml/100g group the mortality was 6 but all 8 in the 
0.75ml/100g group.
Mortality at 
24 hours
Clinical signs of 
sepsis at 24 hours
Hypotension at 24 
hours
E.coli endotoxin 
20mg/kg
0 0 0
s.c. S.pyogenes 0 1 0
i.v. S.pyogenes 0 0 0
Faecal slurry
0.5ml/100g n=8 1 2 0
0.625ml/100g n=8 6 8 7
0.75ml/100g n=8 8 8 8
Table 9: Methods of sepsis induction and response at 24 hours.
The fluid resuscitation used in the rats involved fluid commonly used in the 
resuscitation of human patients. Elohaes (Fresenius-Kabi, Runcorn, Cheshire, UK) is 
commonly used as an intravascular volume expander in patients with inflammatory 
conditions who have lost some of the integrity of their vascular tight junctions, while 
5% glucose maintains both intra- and extracellular water content. Survival at 24 hours, 
was noted between septic rats (injected with 0.625ml/100g faecal slurry) resuscitated by 
a 1:1 solution with infusion rates of 10, 15, 20 and 25ml/kg/hr (n=8 in all groups). 
Survival data are shown in Table 10
Rate of fluid 
administration
Survival at 24 
hours (n)
10 ml/kg/hr 0
15 ml/kg/hr 2
20ml/kg/hr 4
25ml/kg/hr 4
Table 10: Number of septic rats surviving 24 hours with differing fluid regimens
The rate of fluid administration was reduced to 17.5ml/kg/hr between 24 and 48 hours 
and further reduced to 1 Oml/kg/hr between 48 and 72 hours. These rates were derived
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from observations that lower rates of administration led to rapid worsening in blood 
pressure in the sicker rats.
3.2.3 Clinical scoring, collection and processing of samples
In order to assess the effect of time on mitochondrial function it was necessary to 
sacrifice the rats at predetermined time points. These were 0 hour (just prior to the 
induction of sepsis) and at 4, 24, 48 and 72 hours after the induction of sepsis. However, 
the induction of sepsis with faecal slurry produced a broad range of clinical response, 
from rats showing only slight signs of illness through to rapid deterioration and death. 
As such, a scoring system was devised taking into account the most noticeable changes 
in appearance and behaviour, such as piloerection, bloating, conjunctival injection and 
lack of interest in the surroundings. As blood pressure often reflected the clinical 
condition it was also included in the score. The scoring system is shown in Table 11. 
The rat needed to show signs of at least two characteristics within the appearance and 
alertness group to obtain a score. The blood pressure was used providing the line was 
patent and the trace was stable for the 10 minutes prior to sacrifice. The final clinical 
score required the fulfilment of two of three of these characteristics. If the arterial line 
was occluded, scoring was performed on just appearance and alertness and final score 
based on the worst of the characteristics.
Mild Moderate Severe
Appearance
•  Hunched
•  Piloerection
•  No bloating
•  Hunched
•  M arked piloerection
•  Bloated abdomen
•  Sunken eyes
•  M arked 
piloerection
•  M arkedly bloated 
abdom en
•  Conjunctival 
injection
Alertness •  Alert
•  Occasional 
interest in 
environm ent
•  M oves freely
•  D epressed level o f  
alertness
•  Little interest in 
environm ent
•  M oves w ith 
difficulty
•  M arkedly (or 
absent) depressed 
level o f  alertness
•  No interest in 
environm ent
•  No m ovem ent
Mean blood 
pressure
• >90mmHg •  75-90mm Hg • <75m m Hg
Table 11: Scoring system for the septic rats
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At the appropriate time points the rats were removed from their cages and re­
anaesthetised. An incision was made in the medial aspect of the left hind leg and up to 
three samples of skeletal muscle were taken. Two were placed in labelled Eppendorf 
tubes and rapidly frozen into liquid nitrogen, while the third was placed in a universal 
container with 10ml of phosphate buffered formalin for histological analysis. A 
laparotomy was then performed and three samples of liver removed and processed in 
the same way as the muscle. Blood was then removed by cardiac puncture and aliquoted 
into Eppendorf tubes whereupon it was spun at 21000g in a refrigerated centrifuge for 
five minutes and the plasma removed and frozen at -80°C, for later biochemical analysis 
of organ dysfunction. Providing an adequate amount of blood was obtained rapidly with 
no evidence of coagulation, 80pl of blood was introduced into a Radiometer ABL300 
blood gas analyser (Radiometer, Copenhagen, Denmark), to obtain blood pH, base 
deficit and haemoglobin concentration.
Kidneys, heart, lungs, small and large bowel were also removed from a subpopulation 
of rats at 24 hours and placed in phosphate buffered formalin, for later histological 
analysis.
The experiment was terminated by removal of the heart.
Tissue samples frozen in liquid nitrogen were then later analysed for tissue NOx, GSH 
concentrations, respiratory chain activities and nucleotides as described in Chapter 2 .
Formalin-fixed tissues were routinely processed by the Department of Histopathology, 
UCL Hospitals NHS Trust, 4mm sections cut, and stained with haematoxylin and eosin. 
Histological sections were then examined by Dr Tom Jaques and Dr Marco Novelli, 
histopathologists experienced in rodent pathology, for evidence of architectural 
derangements and cell death. Both were blinded to the condition of the rats.
Blood taken by cardiac puncture was analysed by the Department of Chemical 
Pathology, UCL Hospitals NHS trust for urea, creatinine, sodium (Na+), potassium (K+) 
and hepatic profile (albumin (Alb), bilirubin (Bil), alkaline phosphatase (ALP), alanine 
aminotransferase (ALT) concentrations), using standard automated techniques.
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3.3 Statistical analysis
Data are presented as mean ± standard error. Overall comparisons over time and severity 
were made using 2-way ANOVA, while comparisons within each time point were made by 
1-way ANOVA and post-hoc LSD testing. Analysis was performed using SPSS 11.0 
software (SPSS Inc, Chicago, IL).
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3.4 RESULTS: Long term rat model
O verview
The patient study reported in Chapter 2, demonstrated a relationship between NO 
production, GSH depletion, lower complex I activities and lower ATP levels. These 
were related to severity of disease and outcome. An animal model was developed to 
investigate whether this mechanism affects organs more ‘vital’ than skeletal muscle, and 
how these may be affected by severity and duration of disease. The model closely 
simulates the human disease process, drawing parallels and highlighting differences, 
combining physiological and biochemical markers of organ dysfunction with markers of 
mitochondrial function and histology. Importantly, the duration of the model had to run 
over days (not hours), involve a true septic insult with a mortality similar to the human 
condition, be aggressively fluid resuscitated and have evidence of multi-organ 
dysfunction.
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3.5 Clinical scoring and survival
A total of 205 rats were operated upon. Two of these rats died intra-operatively, one 
from uncontrolled haemorrhage, the other from an accidental overdose of anaesthetic. 
The remaining 203 rats made uneventful post operative recoveries. The tether system 
allowed unimpeded movement around the cage with all rats exploring, eating and 
drinking freely. All rats looked clinically well prior to the start of the experiment and 
the induction of sepsis. Fifty seven rats were used as sham operated controls (299±2.2g) 
while sepsis was induced in 143 rats (303±1.5g). A further nine rats comprised the naive 
group.
During the course of the experiment three rats were noted to have occluded venous lines 
and were removed from the study.
The sham group became mildly oedematous with occasional piloerection but otherwise 
looked outwardly normal, continuing to eat and drink and maintaining an interest in 
their environment. All the septic animals displayed clinical manifestations of ill-health 
such as hunched appearance, piloerection, bloating and a loss of interest in their 
environment. However, it was not possible to categorise the severity of disease (as 
described in Table 11) until 24 hours. In addition, mean arterial blood pressure fell in the 
septic animals when compared with sham controls, this fall was most pronounced in the 
severely affected animal (Figure 52).
The proportion of septic rats classified as being mild, moderate or severe at each time- 
point are shown in Table 12
Mild Moderate Severe
24 hours 57% 14% 29%
48 hours 36% 40% 24%
72 hours 73% 27% 0%
Table 12: Proportion of rats classified as mild, moderate or severely septic at 24, 48 and 72 
hours.
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Of the twenty six surviving septic rats at 72 hours, none were classified as severe and 
eleven were showing signs of an improvement in their clinical condition improved. 
These signs included a decrease in piloerection and hunching and an increase in 
grooming, eating, drinking and interest in the environment. Figure 49 indicates the 
number of rats at each of these time points and demonstrates the number of samples 
taken for analysis.
165
Mild=19
• Biochemistry=l 3
• Mitochondria=10
• Nucleotide=9
Moderate=7
• Biochemistry=4
• Mitochondria=7
• Nucleotide=6
72 hours=2648 hours=29
Tota 1=209
4 hour=6
• Biochemistry=3
• Mitochondria=6
• Nucleotide=6
72hour=9
• Biochemistry=7
• Mitochondria=9
• Nucleotide=5
0 hour=6
• Biochemistry=4
• Mitochondria=6
• Nucleotide=4
Severe=7
• Biochemistry=5
• Mitochondria=7
• Nucleotide=6
24 hour=19
• Biochemistry=13
• Mitochondria=15
• Nucleotide=8
4 hours=7
• Biochemistry=6
• Mitochondria=7
• Nucleotide=6
48 hour=17
• Biochemistry=6
• Mitochondria=10
• Nucleotide=6
Mild=10
• Biochemistry=5
• Mitochondria=10
• Nucleotide=5
Moderate=6
• Biochemistry=6
• Mitochondria=6
• Nucleotide=5
Severe=12
• Biochemistry=6
• Mitochondria=12
• Nucleotide=5
Mild=24
• Biochemistry=12
• Mitochondria=10
• Nucleotide=8
Moderate=12
• Biochemistry=6
• Mitochondria=12
• Nucleotide=6
Septic animals that died 
prior to sampling=39
Sham controls=57Nai've=9
• Biochemistry=4
• Mitochondria=6
• Nucleotide=7
Septic animals 
sampled=104
Figure 49: Number of naive, sham and septic rats used at each time point. Biochemistry 
refers to number of blood samples taken for biochemical analysis. Mitochondria refers to 
the number of samples analysed for [NOx], [GSH] and respiratory chain activities. 
Nucleotide refer to number of samples taken for adenine nucleotide and phosphocreatine 
concentrations.
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The protocol demanded sacrifice at predetermined time points. Thirty nine rats died in 
between these points giving an observed mortality of 27%. Most of these rats (n=31) 
died between the 24 and 48 hour time points, three died before 24 hours and five died 
after the 48 hour time point. In addition, the preliminary studies to determine the dose of 
slurry showed that all severely affected animals died within six hours of the 
classification; this would give an overall mortality of 36%. This mortality figure is 
comparable to those quoted for human sepsis (3;9;15). The mortality in the sham control 
group was 0%.
During the harvesting of organs at the end of the experiment, all septic rats were noted 
to have macroscopic peritoneal inflammation. This ranged from ascites and 
inflammation of the serosal surface of the bowel in the mildly affected animals, to 
grossly dilated bowel with multiple adhesions, abscesses and gross purulent ascites in 
the severely affected animals. An example of the peritoneum and contents is displayed 
in Figure 50. Sham control rats looked macroscopically normal.
The kidneys isolated from severely affected septic rats were smaller than those obtained 
from sham controls (Figure 51). However, due to the need for rapid processing of the 
tissue, the organs retrieved from each rat were not weighed.
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a) An example of the peritoneum of a mildly rat animal at 24 hour. The wound on the 
hind leg is related to the sampling of skeletal muscle
b) An example of the peritoneum of a moderately septic rat animal at 24 hour. Note the 
dilated bowel and adhesions across the liver
c) An example of the peritoneum of a severely septic rat animal at 24 hour. Note the 
grossly dilated bowel and multiple thick adhesions across the bowel and lower part of 
the liver.
Figure 50: Macroscopic appearance of the peritoneal cavity of mild (a), moderate (b) and 
severely (c) septic rats.
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Figure 51: An example of the size (and colour) difference seen in the kidneys removed 
from a severely affected rat (left) and a sham operated control (right) at 24 hours.
3.6 Key to graphs
The graphs, in this chapter, used to display evidence of organ dysfunction, [NOx], 
[GSH], complex activities and adenine nucleotide concentrations use the following key:
□ Sham operated controls
□ 4 hour septic
m Mildly septic
□ Moderately septic
□ Severely septic
* Significant difference (p<0.05) 
compared to sham control
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5.7 Clinical and biochemical assessment o f organ dysfunction
Organ dysfunction was assessed by invasive measurement of mean arterial blood 
pressure and the determination of serum urea, creatinine, sodium, potassium, alanine 
aminotransferase, alkaline phosphatase and albumin. Statistical comparisons are made 
within the text, but more detailed statistical analyses are shown in section 6.
3.7.1 Mean arterial blood pressure
The collection of continuous blood pressure data was achieved in 52 of the septic rats 
and 25 of the sham operated controls. In the remainder, the arterial line occluded due to 
its fine calibre.
Values of mean arterial blood pressures obtained from rats culled at the 24,48 and 72 
hour time points are displayed in Figure 52.
Septic animals had significantly lower blood pressures than sham operated controls 
(pO.OOOOl). Though no difference was seen between septic and sham rats at 4 hours 
(p=0.4), the moderate and severely affected animals sacrificed at 24 hours had 
significantly lower blood pressures (both pO.OOOOl) compared to shams. Mild, 
moderate and severely affected rats sacrificed at 48 and 72 hours had significantly lower 
pressures than the sham controls (p=0.0001).
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MAP
mmHg
150
°  Sham 
♦  Mild 
D Moderate 
A Severe
Sham n=5 
Mild n=9 
Moderate n=8 
Severe n=4
Sham n=8 
Mild n=7 
Moderate n=6 
Severe n=6
Sham n=12 
Mild n=9 
Moderate n=4
50 , , ;
24 48 72
Hours
Figure 52: Mean arterial blood pressure obtained from rats sacrificed at 24, 48 and 72 
hours
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3.7.2 Renal function
Renal dysfunction was assessed by serum urea and creatinine as displayed in Figure 53 
and Figure 54. Both urea and creatinine reflect the dynamic equilibrium between 
production and renal excretion. A raised urea and creatinine is usually indicative of a 
fall in glomerular filtration rate of at least 50%, however urea production may also be 
increased by the septic process itself.
The serum urea was significantly higher in the moderate (p=0.0003) and severely 
(pO.OOOOl) affected rats at 24 hours. However, there were no statistically significant 
differences between the groups at any other time points (Figure 53).
Urea
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Figure 53: Urea concentration plotted over time and disease severity.
Similar changes were seen with serum creatinine, with significantly higher creatinine 
levels in the moderate (p=0.03) and severely (p=0.02) affected rats at 24 hours. Figure 
54.
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Figure 54: Creatinine concentration plotted over time and disease severity.
The improvement in renal function by 48 hours may reflect the natural course of the 
disease but could also be a result of selection pressure; i.e. only those rats with normal 
renal function survive to the 48 hour time point.
Hours of sepsis
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3.7.3 Serum electrolytes
Changes in serum sodium and potassium, the two most commonly measured cations in 
clinical practice, were assessed.
There were significantly lower serum sodium values in the moderate (p=0.01) and
severely septic rats (p<0.00001) at 24 hours compared to sham-operated controls.
However, no difference was seen between the disease groups beyond 24 hours (Figure
55).
Sodium
mmol/1
150
140
130
120
110 
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Figure 55: Sodium concentration plotted against time and disease severity.
At 24 hours, the potassium was significantly lower in the mild group compared to sham 
controls (p=0.02). It was, however, significantly elevated in the severe group at 24 
hours when compared to sham controls (p=0.0001) and the other septic groups 
(p<0.0001). There was also a trend towards an increased potassium with disease 
severity at 72 hours, with significantly higher levels in the moderate group (p=0.01), 
(Figure 56).
The significantly lower sodium and higher potassium seen in the sicker rats at 24 hours 
may be a result of deteriorating renal function or a shift in the intra/extra cellular 
balance that occurs during critical illness and acidosis (the sick cell syndrome).
Naive
*
4 24
Hours of sepsis
48 72
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Figure 56: Potassium concentration plotted over time and disease severity.
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3.7.4 Hepatic profile
This involved measurement of serum bilirubin, alkaline phosphatase (ALP), albumin 
and alanine aminotransferase (ALT). These markers reflect a disturbance in metabolic 
and excretory ability, hepatocyte integrity, and synthetic function. Significant 
derangements in hepatic profile were noted in the sicker rats at 24 and 48 hours
All rats had a bilirubin level at or below the limit of detection, <lpM ; as such no data 
are presented.
ALP activity is assumed to reflect the liver isoform of the enzyme as the model was one 
of generalized peritonitis and hepatic ALP is commonly elevated in sepsis. The ALP 
level was significantly higher in the severely septic animals at both 24 (pO.OOOOl) and 
48 hours (p=0.02). However, these values were significantly lower (p=0.007) at 48 
hours compared to the 24 hours in the severe group (Figure 57).
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Figure 57: Alkaline phosphatase plotted against time and disease severity.
Albumin demonstrated significant falls with both time (p=0.0001) and severity of 
disease (p=0.001). Both the moderate (p=0.0003) and severely (p=0.00004) affected rats 
had significantly lower levels than the sham operated rats (Figure 58).
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The fall in albumin in the sham control animals is likely due to the dilutional effect of 
the intravenous fluid administration.
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Figure 58: Albumin concentration plotted against time and disease severity.
ALT values changed with time (p<0.00001) but not with the severity of disease (p=0.3). 
There was a trend to decreasing ALT values with time after 0 hours, with all time points 
showing significantly lower values than the naive or rats at 0 hours (p<0.01) (Figure 
59).
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Figure 59: ALT concentration plotted against time and disease severity.
177
The raised alkaline phosphatase in the severely septic rats at 24 and 48 hours and 
depressed albumin levels in the sicker rats at 24 hours suggests a defect in hepatic 
excretory and synthetic functions. These results are compatible with findings in septic 
patients where derangements in the hepatic profile are common but fulminant liver 
failure is rare.
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3.7.5 Blood pH
Due to the fine calibre of the arterial line it proved difficult to obtain a sufficient sample 
to perform blood gas analysis. As such, samples were obtained by cardiac puncture at 
the end of the experiment. In the event of coagulation the sample was not introduced 
into the blood gas analyzer. Therefore blood Hb, pH and base deficit were measured in 
only 24 rats. The samples were taken from rats at different time points and have been 
grouped by severity alone.
Figure 60 shows the significantly higher base deficit (p<0.0001) and lower pH 
(p<0.0001) seen in the severely septic rats when compared to the other groups. This 
metabolic acidosis may be a result of anaerobic respiration from local hypoperfusion 
and/or increased ATP hydrolysis.
Base deficit
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0
Figure 60: Intracardiac blood base deficit and pH from rats with differing disease severity
No significant differences in Hb were seen across the groups, displayed in Table 13.
Sham Mild Moderate Severe
Hb (g/dl) 11.9 (0.2) 12.5 (0.6) 11.2 (0.6) 11.3(1.4)
Table 13: Hb concentration in rats with differing sepsis severity
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179
3.8 Histology
Organ histology was reported by Dr Tom Jaques and Dr Marco Novelli (Department of 
Histopathology, University College London). Samples were obtained from three rats in 
each group at 24 hours. A summary of these results are displayed in Table 14. Increasing 
severity of disease was associated with a more marked inflammatory response on the 
intestinal serosal surfaces, consistent with a faecal peritonitis. There was also evidence 
of mesothelial inflammation but no evidence of large scale mucosal cell death.
Liver sections demonstrated an infiltration of foamy macrophages in both sham and 
septic animals. Sections isolated from moderate and severely affected rats showed 
evidence of mild, active chronic portal inflammation but no evidence of large scale cell 
death or distortion to the architecture.
Lung sections showed evidence of intra-alveolar haemorrhage in all but the severely 
septic rats. Evidence of bronchial and mesothelial inflammation were noted in both 
sham and septic animals. Renal histology was unremarkable, though one moderately 
septic rat had evidence of interstitial inflammation, but none of the rats displayed signs 
tubular necrosis or obstruction. Skeletal and cardiac muscle were also unremarkable. 
Representative histology from myocardium, lung, liver and kidney and of sham- 
operated and severely septic animals is shown in Figure 61.
Lungs Liver KidneyM yocardium
Septic
Animals
Sham -
Animals
Figure 61: Representative histology from severely septic and sham control rats
180
Severity Sham controls Mild sepsis Moderate sepsis Severe sepsis
Number 3 3 3 3
Skeletal
Muscle
Normal Normal Normal Normal
Liver
Portal tract Foamy cells Foamy cells Foamy cells, 
chronic 
inflammatory 
cells (2)
Foamy cells, 
chronic 
inflammatory 
cells (1)
Bile duct Normal Normal Normal Normal
Fibrosis None None None None
Lobular
inflammation
None None Foamy cells (1) None
Capsule Normal Normal Inflammation (1), 
abscess(1)
Acute 
inflammation (2)
Kidney
Interstitium Normal Normal Mild interstitial 
inflammation (1)
Normal
Glomeruli Normal Normal Normal Normal
Vessels Normal Normal Normal Normal
Heart Normal Normal Normal Normal
Lung
Pleura Mild mesothelial 
reaction (1)
Mild mesothelial 
reaction (3)
Moderate 
mesothelial 
reaction (1)
Moderate 
mesothelial 
reaction (2)
Bronchi Mild 
inflammation (2)
Mild 
inflammation (3)
Moderate 
inflammation (1)
Mild (1), severe 
(1) oedema
Parenchyma Mild alveolar 
haemorrhage (1)
Focal alveolar 
haemorrhage (3)
Focal alveolar 
haemorrhage (1)
Normal
Bowel
Peritonitis None Mild (3)
Mild (1), 
moderate (2)
Moderate (1), 
severe (2)
Mesothelium Normal Normal Mild 
inflammation (1)
Mild (1), 
moderate (1) 
inflammation
Table 14: Histology of organs isolated from sham and septic rats at 24 hours.
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3.8.1 Summary of clinical, biochemical and histological findings
Increasing severity of disease was associated with increasing evidence of organ 
dysfunction. This was particularly marked at 24 hours, where severely affected rats had 
significantly lower blood pressure and albumin concentrations compared to sham or 
mildly affected rats. At 24 hours, the severely affected rats had significantly higher 
values for urea, creatinine, potassium and alkaline phosphatase. Renal and hepatic 
function were better at 72 hours compared to that measured at 24 and 48 hours. This 
may be due to resolution of the organ dysfunction. Alternatively, as a result of selection, 
only rats with the best organ function survived to 72 hours.
The cause of death of the 39 non-surviving rats is unclear. These rats had a clinical 
course similar to the severely affected rats with a blood pressure significantly lower 
than any other group. As such cardiovascular failure is assumed to be the primary cause 
of death. The degree of renal and liver dysfunction seen in the severely septic rats is 
unlikely to have contributed directly to their deaths.
Despite evidence of cardiovascular, renal and hepatic impairment, histology of the vital 
organs was unremarkable, showing no evidence of large scale cell death or architectural 
disturbance by which to explain the dysfunction.
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3.9 Hepatic tissue results
3.9.1 Hepatic NOx
Raised levels of nitric oxide have been well described in animal models of sepsis and 
inflammation. (79). Due to the difficulty in measuring NO directly a number of 
investigators use total tissue nitrite/nitrate as a marker of the level of NO production.
At 24 hours the severely septic rats had significantly higher hepatic NOx levels than 
either sham (p=0.004) or mildly affected rats (p=0.02), (Figure 62). NOx levels peaked 
at 48 hours, with both moderate (p=0.0005) and severely (p=0.0003) affected rats 
having higher levels than sham controls. NOx levels were similar to sham operated rats 
by 72 hours, at which point the septic animals were showing signs of recovery. Thus the 
increase in NOx with severity of disease is in agreement with other published material 
(179; 180).
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Figure 62: Changes in hepatic NOx concentration over time and with disease severity
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3.9.2 Hepatic GSH
GSH concentrations were determined using HPLC as described in Chapter 2.
Naive rats had significantly higher hepatic GSH concentrations compared to sham 
operated control rats at 4 (p=0.02), 24 (p=0.03) and 48 hours (p=0.02), (Figure 63).
Hepatic GSH values showed a downward trend with increasing disease severity. This 
was most marked at 24 and 72 hours. At 24 hours, severely affected rats had 
significantly lower GSH concentrations than the sham (p=0.004) or mildly (p=0.02) 
affected rats. At 72 hours both mild (p=0.006) and moderately (p=0.01) affected 
animals had lower levels than sham operate controls.
These findings of depressed GSH concentrations in sepsis are consistent with the 
findings in human skeletal muscle (125) reported in Chapter 2, and with work published 
by other groups (180).
[GSH]
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Figure 63: Changes in hepatic GSH over time and with disease severity.
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3.9.3 Hepatic complex I activity
Complex I activity is expressed as a ratio to citrate synthase activity to correct for
mitochondrial content of the tissue.
Hepatic complex I activity progressively fell with increasing disease severity at all time 
points Compared to sham controls this became significant in the severely affected rats at 
24 hours (p=0.03) and in the mildly affected rats at 72 hours (p=0.03), (Figure 64).
There was also a trend towards higher complex I activities in all groups over time. This 
was most marked in the sham control group where the complex I activity was 
significantly higher in the rats at 72 hours compared to those at 4 (p=0.00007), 24 
(p=0.00004) and 48 hours (p=0.003). This increase in activity with time was also seen 
(though less marked) in the sequential biopsies obtained from the septic patients 
(Chapter 2).
These findings of lower hepatic complex I activity in the sicker animals are similar to
those found in the septic human skeletal muscle described in the previous chapter.
Lower complex I activity has also been demonstrated in several cell models (137;205),
animal models (231;237) and patients (264).
Complex I activity/
CS activity
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Figure 64: Changes in hepatic Complex I activity over time and with disease severity.
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3.9.4 Hepatic complex II/III
Complex II/III activity is expressed as a ratio to citrate synthase activity to correct for
the mitochondrial content of the tissue.
There were no significant differences in hepatic complex II/III activity between or 
within the groups (p=0.3), (Figure 65). This is similar to the findings in skeletal muscle 
taken from septic patients.
Complex II/III activity/ 
CS activity
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Figure 65: Changes in hepatic Complex II/III activity over time and with disease severity
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3.9.5 Hepatic complex IV activity
Complex IV activity is expressed as a ratio to citrate synthase activity in order to correct
for the mitochondrial content of the tissue.
In the sham control animals, hepatic complex IV activity was lower at the 24 and 48 
hour timepoints compared to the 4 hour group (both p<0.0001). Although there was no 
significant difference between groups at each time points, there was a trend to increased 
activity in the milder septic animals compared to the shams. Figure 66.
Complex IVactivity/
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Figure 66: Changes in hepatic Complex IV activity over time and with disease severity.
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3.9.6 Summary of hepatic [NOx], [GSH] and complex activities.
Sepsis was associated with increased levels of hepatic NOx in the more severely 
affected animals at both 24 and 48 hours, though levels returned to sham control values 
by 72 hours. Hepatic GSH concentration and complex I activity were significantly 
lower in the severely affected rats at 24 hours. Complexes II/III and IV showed no 
significant differences at any time point. Though complex I activity was related to 
disease severity, there was an increase in activity over time in both sham and septic 
groups.
The findings of a raised tissue NOx and lower GSH levels and complex I activities at 24 
hours are consistent with the findings in septic human muscle described in Chapter 2. 
Others have shown impaired respiratory chain activity evidenced by a decrease in state 
3 respiration, associated with ultrastructural damage to the mitochondria (231). Though 
complex IV activity did not change, as measured by this ex vivo assay, this may reflect 
the rapidly reversible nature of NO inhibition of the complex (188), especially in room 
air where oxygen will more actively compete against NO.
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3.10 Hepatic nucleotides
Hepatic nucleotides are expressed as nmol/mg dry weight.
3.10.1 Hepatic ATP
Hepatic ATP concentrations were significantly lower in the more severely affected 
septic rats. This was statistically significant in the severe sepsis group at 24 hours 
compared to sham controls (p=0.02), mildly (p=0.002) and moderately (p=0.04) 
affected rats. At 72 hours moderately affected rats had significantly lower values than 
sham controls (p=0.01) and the mildly (p=0.02) affected rats (Figure 67).
Other investigators have also shown a decrease in hepatic ATP concentrations in the 
more severe models of sepsis (228).
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Figure 67: Changes in hepatic ATP concentration over time and with disease severity.
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3.10.2 Hepatic ADP
Hepatic ADP concentration was significantly raised by 4 hours within the septic animals 
(p=0.02), (Figure 68). Although the ADP concentration increased with disease severity 
at 48 and 72 hours, this was only statistically significant in the severe rats at 48 hours 
(p=0.05).
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Figure 68: Changes in hepatic ADP concentration over time and with disease severity.
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3.10.3 Hepatic AMP
Hepatic AMP concentrations rose with increasing severity of disease at 24, 48 and 72 
hours (Figure 69). This was significant in the severely affected rats at 24 hours 
compared to the sham (p=0.0003), mildly (p=0.00006) and moderately (p=0.009) 
affected rats. At 72 hours the moderately septic rats had significantly higher AMP 
concentrations compared to both sham (p=0.001) and mildly (p=0.0003) affected rats.
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Figure 69: Changes in hepatic AMP concentration over time and with disease severity.
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3.10.4 Hepatic energy charge
The ‘adenylate energy charge’ is the proportion of adenine nucleotides in a ‘high 
energy’ state. It can be represented by the equation (ATP+0.5ADP)/(ATP+ADP+AMP) 
(279).
Hepatic energy charge was significantly lower in the severely affected rats at 24 hours 
compared to sham controls (p=0.0002) and mildly affected rats (p=0.0001). At 72 
hours, moderately affected rats also demonstrated significantly lower hepatic energy 
charge than either sham controls (p=0.001) or mildly affected rats (p=0.001), (Figure 
70).
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Figure 70: Changes in hepatic adenylate energy charge over time and with disease 
severity.
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3.10.5 Hepatic ATP:ADP ratio and total adenine pool
The ATP:ADP ratio, reflecting the proportion of adenine nucleotide readily available 
for metabolism, was lower in the livers of the more severely affected rats. This was 
statistically significant in the severe group at 24 hours compared to the mildly (p=0.02)
and moderately affected rats at 48 (p=0.04), and at 72 hours (p=0.009) versus sham
*
controls (Figure 71).
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Figure 71: Changes in hepatic ATPrADP ratio over time and with disease severity.
The total adenine pool was higher in the 0 and 4 hour group than at any other time point 
though it did not vary with sepsis or severity of disease.
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3.10.6 Summary of changes in hepatic adenine nucleotide concentrations
Hepatic ATP values were significantly lower in the severely septic rats at 24 hours and 
the moderately affected rats at 72 hours; this was also associated with higher levels of 
AMP. A significant rise in ADP was only seen in the moderate group at 48 hours. These 
results suggest a rate of ATP hydrolysis in excess of production.
Energy charge and ATP:ADP ratios were also lower in the sicker rats. Thus, relatively 
less adenine nucleotide is in a form that will drive energetically unfavourable reactions. 
The lower ATP levels and energy charge seen in the severe as compared to the mild rats 
at 24 hours is similar to the changes seen in the skeletal muscle of the non-surviving 
patients. Other groups working with animal models have also measured lower ATP 
levels in the livers of septic rats compared to controls (228;239;242).
194
3.11 Skeletal muscle results
3.11.1 Skeletal muscle NOx
Compared to sham controls there were significantly higher NOx values in the muscle 
taken from each septic group at 24 hours. Moderate and severely septic rats at 48 hours 
had significantly higher NOx levels than sham controls (p=0.02 and p=0.001 
respectively). Muscle NOx concentrations were highest at 24 hours and were similar to 
sham control levels at 72 hours (Figure 72).
The muscle obtained from the septic rats shows a similar increase in NOx levels as 
those obtained in the septic patients reported in Chapter 2.
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Figure 72: Changes in skeletal muscle NOx over time and with disease severity.
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3.11.2 Skeletal muscle GSH
Sham control rats at 24 and 48 hours had significantly less muscle GSH than the sham
control rats at either 4 (p=0.01 for both) or 72 hours (p=0.004 for both), (Figure 73).
Muscle GSH values showed a downward trend with increasing sepsis severity. This was
significant at 24 hours for both moderate (p=0.007) and severely (p=0.001) affected
rats, and at 72 hours for the moderately septic rats (p=0.00002).
[GSH] 
nmol/mg protein
70 |
60 ■
50 t
40
30 j—
20 4 
10 
0 I
Naive 0 4 24 48 72
Hours of sepsis
Figure 73: Changes in skeletal muscle glutathione over time and with disease severity.
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3.11.3 Skeletal muscle complex I activity
Complex I activity is expressed as a ratio to citrate synthase activity to correct for 
mitochondrial content.
Skeletal muscle complex I activity trended downward with an increasing severity of 
disease at 24 and 48 hours (Figure 74). Complex I activity was significantly lower in the 
severely affected rats at 24 (p=0.002) and 48 hours (p=0.05) compared to sham controls. 
By 72 hours all groups had similar activities.
The 22% reduction in complex I activity seen in the severely septic rats is similar to that 
seen in the muscle biopsies taken from the non-surviving septic patients (-30%). Other 
investigators have reported evidence of complex I inhibition in skeletal muscle biopsies 
taken from bacteraemic baboons and endotoxaemic rabbits. (236;237).
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Figure 74: Changes in skeletal muscle complex I activity over time and with disease 
severity.
Naive
Hours of sepsis
197
3.11.4 Skeletal muscle complex II/III activity
Complex II/III activity is expressed as a ratio to citrate synthase activity in order to 
correct for mitochondrial content.
No significant differences were seen in muscle complex II/III activity over time (p=0.3) 
or with severity of disease (p=0.9), (Figure 75). This was similar to the findings in 
septic patients recorded in Chapter 2.
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Figure 75: Changes in skeletal muscle complex II/III activity over time and with disease 
severity.
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3.11.5 Skeletal muscle complex IV activity
Complex IV activity is expressed as a ratio to citrate synthase activity in order to correct 
for mitochondrial content.
Complex IV activity was significantly higher in the muscle of mild (p=0.006) and 
moderately (p=0.0003) affected rats at 24 hours as displayed in Figure 76.
Though these findings are similar to the data obtained from the patients’ skeletal muscle 
(Chapter 2), it is contrary to most published work which shows an inhibition of complex 
IV activity. This may be methodological and/or represent an upregulation in complex 
IV activity (282); this is discussed further in section 3.13.
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Figure 76: Changes in skeletal muscle complex IV activity over time and with disease 
severity.
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3.11.6 Summary of changes in skeletal muscle [NOx], [GSH] and complex
activities
Higher levels of muscle NOx were seen in all the septic rats at 24 hours, and in the 
moderate and severely affected rats at 48 hours. GSH levels were significantly 
depressed in the severely affected rats at 24 hours, and in the moderately affected rats at 
both 24 and 72 hours. Complex I activity was significantly lower in the severe groups at 
both 24 and 48 hours. Complex II/III showed no significant changes while complex IV 
activity was significantly elevated in the mild and moderately affected rats at 24 hours.
The changes seen in the muscle of the septic rats reflected similar changes seen in the 
rat liver and in the muscle biopsies obtained from septic human patients. Other groups 
have also demonstrated similar impairments in respiratory chain activity and oxidative 
capacity (241).
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3.12 Skeletal muscle adenine nucleotide levels
Hepatic nucleotides are expressed as nmol/mg dry weight.
3.12.1 Skeletal muscle ATP levels
Skeletal muscle ATP concentrations demonstrated a downward trend with increasing 
disease severity in the septic animals at each time point (Figure 77). However, this was 
only statistically significant in the moderately affected rats at 72 hours compared to 
sham controls (p=0.0004) and the mildly affected animals (p=0.01). ATP levels in the 
24 hour sham operated rats were significantly lower than both the mild (p=0.006) and 
moderately (p=0.008) affected rats at the same time point, and also lower than the sham 
operated rats at 48 (p=0.08) and 72 hours (p=0.04). Similar findings were also seen in 
the liver (section 3.10.1).
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Figure 77: Changes in muscle ATP concentration over time and with disease severity.
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3.12.2 Skeletal muscle ADP levels
Muscle ADP levels were significantly lower in the 24 hour sham operated controls 
compared to the mildly (p=0.007) and moderately affected rats (p=0.03) at the same 
time point. There were no other significant differences within the groups (Figure 78).
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Figure 78: Changes in muscle ADP concentration over time and with disease severity.
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3.12.3 Skeletal muscle AM P levels
Skeletal muscle AMP levels were significantly raised in the septic rats at 4 hours (Figure 
79). At 24, 48 and 72 hours there was a trend to increasing AMP levels with disease 
severity (significant in the severe rats at 24 hours (p=0.03) and the moderate rats at 72 
hours (p=0.04)). Similar trends were also seen in the livers taken from the same 
animals.
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Figure 79: Changes in muscle AMP concentration over time and with disease severity.
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3.12.4 Skeletal muscle adenylate energy charge
The ‘adenylate energy charge’ is the proportion of adenine nucleotides in a high energy 
state. It can be represented by the equation (ATP+0.5ADP)/(ATP+ADP+AMP) (279).
Compared to sham controls, the muscle adenylate energy charge was significantly lower 
in the septic rats at 4 hours (p=0.004), and both the mild and moderately affected rats at 
72 hours (p=0.03 and 0.0002 respectively), (Figure 80).
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Figure 80: Changes in muscle adenylate energy charge over time and with disease severity
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3.12.5 Skeletal muscle ATP:ADP ratio and total adenine pool
The muscle ATP: ADP ratio, reflecting the proportion of adenine nucleotide readily 
available for metabolism, was significantly lower in septic rats at 4 hours (p=0.02), and 
at 72 hours in the moderately septic rats (p=0.0002), (Figure 81).
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Figure 81: Changes in muscle ATP: ADP ratio over time and with disease severity
Similar to the changes in ATP levels, the total adenine pool (reflecting the amount of 
nucleotide available for phosphorylation) was significantly lower in the 24 hour sham 
control rats compared to the mild (p=0.003) and moderately (p=0.006) affected rats. The 
adenine pool was also smaller in the moderately affected rats at 72 hours compared to 
the sham controls (p=0.006) and mildly affected rats (p=0.02), (Figure 82).
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3.12.6 Skeletal muscle phosphocreatinercreatine ratio
Though there was a downward trend in skeletal muscle PCr:Cr ratio with disease
severity, there was no overall significant difference with time (p=0.9) or disease
(p=0.4), (Figure 83).
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Figure 83: Changes in muscle PCr:Cr ratio over time and with disease severity.
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3.12.7 Summary of skeletal muscle adenine nucleotide and phosphocreatine
concentrations
Skeletal muscle ATP levels were significantly higher than those found in the liver (and 
patient muscle) and were more resistant to change during the septic process. This may 
be the result of decreasing exercise activity of the sicker septic animals. At 24 hours, 
sham operated animals had lower skeletal muscle ATP and total adenine levels (but 
with conservation of energy charge) compared to the mild and moderately septic rats at 
the same time point. This finding is unexpected and may reflect the result of aggressive 
fluid resuscitation on a normal animal. Similar to liver, the muscle ADP values were 
unaffected while the AMP values were higher in the sicker rats, suggesting an increase 
in ATP hydrolysis. The unchanged PCr:Cr ratio confirms that rat skeletal muscle high 
energy phosphates are resistant to depletion during the septic process.
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3.13 Discussion o f long term rat model
The patient study dem onstrated that severity and outcom e o f  sepsis was associated with 
increased NO production, depressed levels o f  GSH, low  com plex I activity and low 
ATP levels. These findings support (but do not prove) the hypothesis that M ODS is a 
result o f  m itochondrial respiratory chain inhibition as depicted in Figure 84.
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Figure 84: Schema of the proposed mechanism of respiratory chain inhibition and organ 
dysfunction
H owever, a num ber o f  im portant questions arise. W hat is the relevance o f  skeletal 
m uscle data to m ore ‘v ital’ organs such as liver or kidney? Are these changes causal or 
sim ply epiphenom enal? Ethical and technical difficulties constrain the availability o f  
hum an ‘vital organ’ tissue, especially when repeated sampling is desirable to m onitor 
disease progression and concurrent m itochondrial function. It would also be difficult to 
initially test putative therapies in a hum an population w ithout first dem onstrating the 
efficacy and safety o f  the intervention in an anim al model.
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It was thus necessary to generate an animal model that simulated the human disease as 
closely as possible. This was achieved at a number of levels:
1. Sepsis was induced by an i.p. injection of faecal slurry, generating a faecal 
peritonitis, a common form of sepsis on the ICU (9). Live bacteria have the 
ability to replicate and have mechanisms to evade the host’s defences, thus 
providing a more realistic insult than endotoxin alone.
2. A mortality rate of 36% reflects crude ICU mortality rates (3;9; 15)
3. The duration of illness in the rats was short compared to that seen in the adult 
patient study and is more reflective of a septic paediatric ICU population (339). 
This may be, in part, due to the lack of comorbidity seen in young rats and 
children.
4. Aggressive fluid resuscitation was required to avoid hypovolaemia. 
Hypovolaemia results from a decrease in oral intake in the sicker animals, a 
relative increase in capacity of the circulation, and loss of intravascular fluid to 
the extra-vascular spaces due to increased microvascular leak. The fluids used 
were the same as those used on the UCL Hospitals ICU, though the relative 
amounts used were higher in the rats compared to the patients. The maintenance 
of Hb concentration across the spectrum of disease suggests intravascular fluid 
overload did not occur.
5. The patients who participated in this study also received a number of therapeutic 
interventions, such as midazolam for sedation, which may potentially confound 
the mitochondrial findings (340). To control for this variation, the rats received 
only fluid resuscitation. No antibiotics were given.
6 . Disease severity was assessed with a scoring system using clinical, physiological
and biochemical indices commonly used in intensive care patients.
This model of faecal peritonitis produced a spectrum of disease from mild to severe, 
despite using a standardized protocol on an outwardly homogenous population of rats of 
similar size and age. Although the bacterial load in the faecal slurry may have differed, 
there was still a marked variation in clinical response, even though the same slurry was 
used in up to six animals of the same litter at the same time. Possible reasons for this 
variation include:
• Significant level of phenotypic variability that would have dictated the animal’s
response to the septic insult, despite being an inbred population.
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• Previous acquisition of immunity; for example, development of high anti­
endotoxin antibody levels following previous bites/scratches that may have 
become infected.
• Variation in bacterial load could, conceivably, be due to injection of caecal 
slurry into the bowel lumen.
Though the course of an individual animal was unpredictable at the outset of the 
experiment, the clinical classification of mild, moderate or severe produced a 
comparable level of organ dysfunction with respect to raised levels of urea and 
creatinine (renal dysfunction), alkaline phosphatase (liver), and decreased albumin 
(liver, capillary leak). Though the rise in urea and creatinine seen in the severe rats was 
indicative of renal dysfunction, it was not severe enough to be considered life- 
threatening. A similar rise in a septic patient would not be sufficient to warrant renal 
replacement therapy. The raised ALP and lower albumin levels seen in the sicker rats 
also suggested significant liver dysfunction, however the bilirubin and ALT levels 
remained unchanged indicating an absence of fulminant liver failure. The essentially 
normal kidney and liver histology, even in the most severely affected rats, adds further 
support to the notion that neither renal nor hepatic impairment were sufficiently severe 
to be the direct cause of death. As death was usually preceded by a period of 
progressive hypotension, despite aggressive volume resuscitation, mortality is most 
likely to be related to cardiovascular failure, of which myocardial depression may be a 
significant component.
The apparent improvement in biochemical organ function seen at 48-72 hours may be 
due to either recovery or to selection bias as the rats with the most severely affected 
organ dysfunction had already died. To avoid excessive falls in haemoglobin we did not 
take sequential blood samples. The good agreement between physiological and 
biochemical dysfunction does nevertheless suggest that clinical improvement seen in 
surviving animals may also reflect recovery of any biochemical derangements.
Despite biochemical and physiological evidence of multi-organ dysfunction and 
histological evidence of inflammation (most marked in lung and gut serosa), the lack of 
gross histological damage is noteworthy. This lack of observable cell death is one of the 
intriguing characteristics of sepsis-induced organ failure, and mirrors the post-mortem 
findings of Hotchkiss and colleagues in both septic animals (260) and patients (271).
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Similar to findings made in both septic patients and other animal models (180), there 
were raised levels of NO metabolites at 24 hours in both skeletal muscle and liver, 
suggestive of increased NO production. The amount of NOx correlated with the severity 
of the disease at 24 and 48 hours. By 72 hours, NOx values were similar to the sham 
operated animals, reflecting either a cessation of the acute inflammatory phase or, again, 
a result of selection. A criticism of rodent models of sepsis is that NO production is far 
in excess of that seen in humans (341). However, in this study, the tissue NOx values 
were similar to those found in the septic patients. The range of reported plasma NOx 
values found in human sepsis is considerable; three studies found maximum values 
ranging from 450 to 622|iM (281;285;294). These values are comparable to, or in 
excess of, many of the values reported in rodent studies (123;167;179;299;342) In our 
patient study the highest NOx value found was 250pM/mg protein. As discussed, NOx 
levels may be compounded by renal dysfunction and thus may not be a good reflection 
of acute change; the resolution of NOx values by 72 hours was also associated with an 
improvement in organ dysfunction.
Basal GSH levels were approximately eight-fold higher in liver than in skeletal muscle. 
Similar proportions have also been reported in other models (343;344). The higher 
levels found in liver reflect its different metabolic roles and the higher probability of 
encountering oxidants or poisons absorbed from the gut. Rat skeletal muscle GSH levels 
were approximately six-fold higher than those found in the human orthopaedic controls. 
A difference of this magnitude may represent a difference in fibre types found in rats or 
a species difference.
Similar to the septic patients, GSH levels were lower in the sicker rats at both 24 and 72 
hours in both liver and skeletal muscle. This likely reflects the increased oxidant stress 
associated with sepsis. As only the reduced (GSH) and not the oxidised (GSSG) form of 
glutathione was measured, it is impossible to speculate whether the lower GSH levels 
were due to a loss of the total glutathione pool or a shift away from the reduced form. 
Findings in other animal models (180;297) and patients (295;296) suggest both 
mechanisms may occur.
A fall in GSH levels were also seen in the sham operated animals at 4, 24 and 48 hours, 
particularly in muscle. The stress of surgery and isolation may be implicated though no 
fall was seen in sham-operated animals at the 0 hour time point, i.e. 24 hours post­
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surgery. The fall may possibly be due to the large volume fluid resuscitation regimen as 
a trend towards recovery was seen at 72 hours when the rate of fluid administration was 
half that given at 24 hours. Mechanisms by which this could occur are unknown as there 
are no reports in the literature of hydroxyethyl starch causing enhanced oxidant stress. A 
washout of GSH or its precursors may be a possible explanation, though this has not 
been previously described in the literature. Other small molecules showed similar 
trends, particularly in the skeletal muscle where NOx, GSH, ATP, ADP and AMP 
concentrations were lower in the sham control rats during the period of aggressive 
resuscitation (2-48 hours).
Complex I activity was significantly higher in liver compared to the skeletal muscle. 
This likely reflects the different metabolic requirements of the two tissues, and may be 
possibly exaggerated in sedentary laboratory animals. Rat skeletal muscle complex I 
activity was also significantly higher than that found in patients, possibly due to a 
differing proportion of skeletal muscle fibre types between the two species. Despite this, 
the septic rats demonstrated a downward trend in complex I activity with increasing 
disease severity, similar to the septic patients. Complex I activity in the severely 
affected rats at 24 hours was 22% and 20% lower in liver and muscle, respectively, 
compared to sham controls. This difference is comparable to that seen in patients; septic 
survivors had a 15% lower activity than orthopaedic controls while the non-survivors 
had a 30% reduction in activity. The association of low complex I activity with low 
GSH and high NOx levels lends support to the in vitro findings that NO and/or its 
metabolites will depress GSH levels and inhibit the complex. Inhibition of Complex I 
by either NO or ONOO' may be via a reversible yet longer-acting nitrosylation of thiol 
groups in the complex (194;213), or, as suggested by the patient study, by an 
irreversible nitration via ONOO'or other nitrating species.
Hepatic complex I activity showed an increase in activity over time in both septic and 
control groups. It could be argued that selective pressures resulted in the rats with lower 
activities succumbing to the septic insult earlier, thus skewing the results. However, as 
the control group showed the same trend and had zero mortality, this explanation seems 
unlikely. This trend was not seen in skeletal muscle. Complex I can exist in either 
activated (A) or deactivated (D) forms, though control mechanisms (or even relevance) 
are not understood. A higher proportion of the deactivated form may be seen in
 ^I  ^i
conditions of anoxia (345), high Mg and high Ca , while low temperatures lead to a
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greater proportion of the active form. The deactivated form may still oxidize NADH but 
will be unable to reduce ubiquinone, similar to the rotenone-inhibited complex. This 
could increase the propensity of the enzyme to generate reactive oxygen species (346). 
Though the rats were housed in a room held at 21°C and heater mats were placed under 
their cages, it is possible that the aggressive fluid resuscitation (infused at room 
temperature) may have resulted in mild hypothermia. Thus the progressive increase in 
hepatic complex I activity may have been a response to this fall in core temperature. An 
increase in electron flux may be important for heat generation. However, these changes 
were not seen in the muscle which would be expected to increase rates of respiration 
and heat generation through shivering (347).
Complex II/III activity did not change with time or disease in either skeletal muscle or 
liver. These results are similar to the findings in the septic shock patients.
Compared to sham controls, complex IV showed a trend towards increased activity in 
the less sick animals at 24 hours in both liver (non-significant) and muscle. Though 
similar to our findings in septic patients, it is contrary to most published data (reviewed, 
(348). It could simply reflect the inability of the assay to detect the rapidly reversible 
inhibition of complex IV mediated by NO however the increase in activity does imply 
an increase in Complex IV protein and/or enzyme activity. It is conceivable that this 
may represent an adaptive response (282).
Skeletal muscle ATP levels were significantly higher than hepatic ATP levels. This has 
previously been demonstrated (244) and may be a reflection of an organ that was 
metabolically inactive but with the need for a high reserve. Rat skeletal muscle ATP 
levels were also three-fold higher than those seen in elective orthopaedic patients. This 
suggests either a difference in the relative proportion of muscle fibre types or a species 
difference. During sepsis, adenine nucleotide concentration in skeletal muscle was more 
resistant to change than liver, with significantly depressed ATP and energy charge only 
becoming apparent at 72 hours in the moderately affected animals. From this study, it is 
impossible to conclude whether the lower ATP and energy charge seen in the sicker 
animals, together with the concurrent rise in AMP, was a result of decreased production 
or increased utilization of ATP. It could be argued that ATP utilization may be 
decreased in an attempt to offset the fall in ATP production, thereby preventing a fall in 
the adenylate energy charge to a critical threshold sufficient to trigger apoptotic or
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necrotic cell death pathways. This would support the histological absence of cell death 
in the multiple organs examined. ATP turnover would be an ideal, though practically 
taxing, measurement to address this question.
In summary, the rodent model of sepsis developed during the course of this study 
reflects the human condition in a number of ways. These include disease severity as 
well as physiological and biochemical evidence of organ dysfunction. The model is 
associated with increased levels of nitric oxide metabolites, GSH depletion, loss of 
complex I activity and lower tissue ATP levels. The magnitude of these changes were 
related to the severity of disease and occurred in both skeletal muscle and liver. Though 
the changes were similar between both species, absolute values were markedly 
different, with rats having significantly higher complex I and II/III activities, GSH and 
ATP levels than the human patients. As the rats only received fluid resuscitation and not 
vasoactive drugs or other forms of organ support, the changes seen are likely to be a 
result of the pathological process rather than potentially confounding factors such as 
drug administration.
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3.13.1 Future Work
Further characterisation of the model further could include implantation of chronic flow 
probes around major arteries such as the abdominal aorta or renal artery to enable 
continual assessment of blood flow, and to thus determine temporal and absolute 
changes in cardiac output. This would help to determine the relative contribution of 
vascular dysregulation and myocardial depression in the aetiology of the cardiovascular 
failure manifest as shock. Information obtained from flow probes would also aid 
accurate titration of fluid resuscitation. This would more accurately reflect ICU practice 
and avoid any concerns of fluid over-load or under-load. It would be interesting to 
extend the model for a further two days to investigate whether moderately affected rats 
at 72 hours would continue to deteriorate thereafter, as may be predicted by their lower 
GSH and ATP levels. This would also enable the further investigation of recovery from 
sepsis.
Cells exposed to NO or endotoxin often show a decrease in O2 consumption 
(106; 107; 196). However, tissues isolated from septic animals may show either increases 
(221;225;226) or decreases (118;221;230) in cell or organ O2 consumption. This 
confusion arising from the animal literature is probably a result of investigators 
examining different organs, species, conditions and, importantly, at different time 
points. This model allows the assessment of O2 consumption over time and with 
increasing disease severity. Preliminary work has demonstrated a fall in O2 consumption 
from renal tubules isolated from septic animals at 24 hours (349). An assessment of O2 
consumption in isolated organs, permeabilised cells and mitochondria would also assess 
the impact of the multiple techniques used in isolating samples on oxygen consumption.
Investigation of underlying pathophysiological mechanisms could be continued by
altering potential disease processes. An obvious intervention would be to inhibit iNOS
activity, and thus reduce nitrosative stress. This could be achieved with specific iNOS
inhibitors such as 1400W. Numerous investigators have already shown that inhibition of
NO production prevents organ failure, mitochondrial dysfunction and improves survival
(167;185;192;350;351). However, others have found deleterious effects on eliminating
iNOS (352;353). In models involving live bacteria, NO produced by iNOS may have an
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important role in the cytotoxic abilities of immune effector cells such as macrophages; 
inhibiting this enzyme may thus reduce the effectiveness of the immune system. Other 
therapeutic strategies that could be investigated with this model include modulation of 
the oxidant response, either by enhancing GSH levels or boosting other antioxidant 
defences. N-acetyl cysteine (NAC) is an antioxidant and a donor of cysteine, an amino 
acid used in GSH synthesis. In a small study, administration of GSH or NAC to patients 
with septic shock led to a decrease in the indices of lipid peroxidation, an increase in 
plasma GSH levels and an improved mortality at ten days (354). NAC also increases 
hepatic blood flow and function in septic patients (355). A further small study 
demonstrated that NAC given to septic patients improved respiratory function and 
decreased ICU stay, though not mortality (356). Unfortunately, no large scale trial has 
been performed to assess the efficacy of either NAC or GSH. The results obtained from 
the septic patients in the present study suggest that GSH would be unable to reverse the 
complex I, inhibition however early/prophylactic administration may prevent/delay 
inhibition from occurring (196). As the cell is unable to take up GSH as a whole 
molecule, it is split into two components (cysteinyl-glycine and y-glutamyl amino acids) 
by the enzyme y-glutamyl transpeptidase (yGT) prior to uptake. GSH is then 
resynthesized in the cytoplasm by GSH synthetase. yGT is upregulated by nitric oxide 
and is an important means of maintaining intra-cellular GSH levels (357). However, 
cysteinyl-glycine can reduce ferric iron to ferrous iron, which may then set up redox 
reactions to produce oxidant species (358). Indeed, inhibition of yGT led to a decrease 
in lipid peroxidation and cell swelling in a model of renal ischaemia (359). As such, it 
may be more appropriate to explore the possibility of administrating more lipophilic 
forms of GSH such as glutathione ethyl ester. This is of particular relevance if the 
decrease in GSH synthesis is a result of GSH synthetase inhibition (295). The activity of 
the enzyme glutathione peroxidase is dependent on selenium; this element is depleted 
during the septic process (360). By replacing selenium in septic patients, the activity of 
glutathione peroxidase was shown to increase (360). This was associated with a lower 
incidence of acute renal failure and death compared to conventionally treated patients. 
The authors suggest this may be due to enhanced antioxidant capability.
The model may also be used to investigate the role of glycolysis in the provision of 
ATP during a period of prolonged respiratory chain inhibition. Preliminary studies 
suggest that glycolysis may be upregulated (257). Though practically difficult, the 
investigation of ATP turnover would provide important information on rates of
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synthesis. This would determine whether ATP utilization was increased, to cope with 
increased metabolic demand, or decreased, possibly as an adaptation to the septic state.
One of the remarkable aspects of sepsis-associated organ dysfunction is that despite 
often profound dysfunction, organ function may be completely restored should the 
patient/animal survive (361;362). The normal histology of the failed organs is also an 
intriguing paradox (271). The organs may be deliberately ‘shutting down’ to preserve 
their long-term integrity while awaiting an improvement in the local milieu prior to 
restoring function. In essence, the organs may enter a state of hibernation. Though little 
evidence currently exists for this in sepsis, analogies can be drawn from the 
myocardium. With partial ischaemia, cardiomyocytes decrease their contractile function 
but remain viable and recover fully on reperfusion. This is known as short-term 
myocardial hibernation (363), where contraction matches perfusion and there is a 
recovery of metabolic parameters. The molecular mechanisms behind this contractile 
dysfunction remains unclear. Myocardial hibernation is associated with alterations in 
calcium handling, a change in a  and p adrenoreceptor density (364), and an initial 
upregualtion of stress proteins e.g. p38-MAPK (365) and heat shock proteins (366). 
Evidence of iNOS induction and peroxynitrite generation has also been obtained from 
human ventricular biopsies (367). Similar responses may be found in sepsis with 
internalisation of p adrenoreceptors, enhanced NO, P38-MAPK (368) and HSP (369) 
expression.
Encouraging mitochondria to continue functioning normally in these circumstances may 
simply enhance damage and hasten the cell’s demise from an irreversible loss of energy 
supply.
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4 Conclusion
The original hypothesis of this study was that MODS associated with sepsis was a result 
of NO-mediated inhibition of the mitochondrial respiratory chain. This study has 
succeeded in demonstrating that severity of sepsis is indeed associated with evidence of 
increased NO production, GSH depletion, lower complex I activity and decreased ATP 
levels. These trends can be seen in the skeletal muscle of septic patients, and in the 
skeletal muscle and liver of septic rats. Though absolute values are different across 
organs and species, the trends are similar, suggesting a conserved mechanism. As such, 
it would be reasonable to expect the same changes in the vital organs of septic patients. 
Though causation has yet to be established, these findings do strongly support the 
hypothesis.
This work also resulted in the development of a long term rodent model of sepsis and 
MODS that reflects the human condition in a number of ways. The model could be used 
for the further investigation of mechanisms, and for the testing of novel therapies.
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5 Appendix 1; Solutions and calculations.
5.1 Isolation buffers
All solutions were made up in distilled water (Milli Q water purification system) unless 
otherwise stated. Buffer reagents are all BDH analar quality unless otherwise stated.
Skeletal muscle mitochondria isolation buffer: 320mM sucrose (Fw=342.3, 107g/l, 
BDH); ImM EDTA (ethylenediaminetetra-acetic acid dipotassium salt; Fw= 404.47, 
0.4047g/l, BDH); lOmM Trizma base (Fw=121.1, 1.211 g/1, Sigma), adjusted to pH 7.4 
with 2M HCL (BDH), made up in fresh distilled water, Adjusted again to pH 7.4 at 4°C 
with 2M HCL and stored at 4°C for up to four weeks.
Liver mitochondria isolation buffer: 250mM sucrose (Fw 342.3, 85.58g/l, BDH), ImM 
EDTA (Fw 404.47, 0.404g/l, BDH), lOmM Trizma base (Fw 121.1, 1.21 lg/1, Sigma). 
Adjust to pH 7.4 with 2M HCL (BDH). Readusted to pH 7.4 at 4°C with 2M HCL and 
stored at 4°C for up to four weeks
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5.2 Complex I  activity
Buffer: potassium phosphate (25mM)/ MgCl2 (lOmM); pH 7.2: Mix 25mM KH2P04 
(Fw=136.1, 3.402g/l, BDH) and 25mM K2HP04 (Fw=174, 4.354g/l, BDH) to obtain pH 
7.2. AddlOmM MgCl26.H20  (Fw=203.3,2.033g/l, BDH), adjust to pH 7.2.
KCN lOOmM: Fw=65.12; 65.1mg/10ml, Aldrich 
BSA (fatty acid free): 50mg/ml, Sigma 
Coenzyme Qj: 5mM, Fw=250.3, Sigma
Rotenone: ImM, Fw=394.4; 4mg/10ml ethanol, warm to 50°C to solubilize, Sigma 
NADH, tetrasodium salt: 5mM, Fw=905, add 1.4 ml H20  to 5mg pre-weighed vial. Protect 
from light by covering with silver foil, Sigma
Determination of coenzyme Qi concentration
Coenzyme Qi is a member of the ubiquinone group. All ubiquinones contain the same 2,3- 
dimthoxy-5-methylbenzoquinone nucleus but have differing lengths of prenyl side chain. 
Coenzyme Qi absorbs light at 275nm, thus using the Beer-Lambert law, the concentration 
of pure coenzyme Qi can be determined.
2ml of ethanol is added to 2mg (1 vial) CoQi. 990pl of ethanol and lOpl of this solution is 
added to two quartz cuvettes and mixed. One cuvette is placed in the sample position of a 
Uvikon XS spectrophotometer (Fixed wavelength: 275nm) the other in the reference 
position. The spectrophotometer is auto-zeroed. A few granules of sodium borohydride, 
which reduces ubiquinone to ubiquinol, is added to the reference cuvette the contents then 
mixed. After 5 minutes the absorbance is read. This is repeated 3 times and the average 
absorbance taken.
The concentration (molar) of CoQi was determined using the equation: Absorbance/ 8
(S=12.25xl03). 5mM was required for the assay and aliquoted into 0.5ml. This was 
calculated in the following way
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Unknown volume=5mM x 0.5ml/concentration of CoQi
The remaining volume of the aliquot was made up to 0.5ml with ethanol 
Calculation of complex I activity (at 340nm)
Calculation: AAl=change in absorbance min' 1 before the addition of rotenone 
AA2= change in absorbance min' 1 after the addition of rotenone
AA=AA1 - AA2
AA/e=C (cone)
(e = 6.81xl03)
=mole/min/l
x50 (dilution factor of sample (20pl in lOOOpl), x5 (dilution factor of sample prior to assay. 
The result was expressed as a ratio to citrate synthase activity to account for mitochondrial 
content of the sample.
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5.3 Complex II/III activity
Reagents for Complex II/III:
Buffer: potassium phosphate (166mM); pH 7.4: Mix 166mM KH2PO4 (Fw= 136.1, 22.5g/l) 
and 166mM K2HPO4 (28.9g/l) to obtain pH 7.4.
EDTA (K+): 15mM Fw=404.47: (BDH); 6.1 mg/ml 
Cytochrome C0.8mM, Fw=12,384, 10: mg/ml, Boehringer 
KCN lOOmM: Fw=65.12; 65.1mg/10ml, Aldrich 
Succinate (disodium salt): Fw=270.1, 0.5M; 135mg/ml, Sigma 
Antimycin A: 2mg/2ml ethanol, Sigma
Calculation of complex II/III activity (at 550nm)
Calculation: AAl=change in absorbance min' 1 before the addition of antimycin A 
AA2= change in absorbance min' 1 after the addition of antimycin A
AA=AA1 - AA2
AA/s=C (cone)
(s = 6.61xl03)
=mole/min/l
x50 (dilution factor of sample (20pi in 1000pl),x5 (dilution factor of sample prior to assay. 
The result was expressed as a ratio to citrate synthase activity to account for mitochondrial 
content of the sample.
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5.4 Complex IV activity
Complex IV reagents
Phosphate buffer: potassium phosphate buffer (lOOmM); pH 7.0: mix lOOmM K2HPO4 
(17.4g/l) and lOOmM KH2P0 4 (13.6g/l) to obtain pH 7.0.
Ferricyanide (K*): lOOmM, Fw=329.2, 32.93 mg/ml (Sigma)
Calculation of complex IV activity
Calculation from authentic sample (In = natural log)
Example:
Realtime Reaction time Absorbance kmin' 1
0.9 0 0.9220 ln(0.9220/0.8775)/l=kl
1.9 1 0.8775 ln(0.9220/0.8246)/2=k2
2.9 2 0.8246 ln(0.9220/0.7763)/3=k3
3.9 3 0.7763
Take mean value of kl, k2 and k3=mean rate constant, k
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Multiply k by dilution factors; x50 (dilution factor of sample (20pl in lOOOpl), x5 (dilution 
factor of sample prior to assay) = rate constant per minute= kmin'1.
The result was expressed as a ratio to citrate synthase activity to account for mitochondrial 
content of the sample.
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5.5 Citrate synthase activity
Preparation of Citrate synthase reagents
Buffer: pH 8.0; Mix lOOmM Trizma base (Fw=121.1, 12.11 g/1, Sigma), and 0.1%(v/v) 
Triton X-100 adjusted to pH 8.0 at 30°C. Store at 4°C.
Acetyl-CoA (sodium salt): lOmM, Fw=809.6, 8.96mg/ml, Sigma.
Oxaloacetate: 20mM; Fw=132.1, 5.3mg in 2ml, Sigma.
DTNB [5,5’ dithio-bis (2-nitrobenzoic acid)]: 20mM, (Fw=396.3, 7.9mg/ml Sigma), 
add a few crystals of KHCO3 to help solubilise.
Calculation of citrate synthase activity
A= absorbance min' 1
A/e=C (cone)
(e = 13.6 xlO3)
=mole/min/l
x50 (dilution factor of sample (20pl in lOOOpl), x5 (dilution factor of sample prior to 
assay, best expressed as nmole/min/ml.
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6 Appendix 2: Statistics
Statistical comparisons of the measured variables made between the rat groups at 
different time points are shown below. The important differences have been referred to 
in results, section 3.4.
6.1 Organ dysfunction
24 hours Sham Mild Moderate
Severe <0.00001 <0.00001 0.0001
Moderate <0.00001 0.00001
Mild 0.4
48 hours Sham Mild Moderate
Severe <0.00001 <0.00001 <0.00001
Moderate <0.00001 0.03
Mild 0.0001
72 hours Sham Mild
Moderate <0.00001 0.0002
Mild <0.00001
Levels of significance (p value) between the blood pressures in the different groups of 
rats culled at 24 hours, 48 and 72 hours.
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Urea with with sham v sham v mild v mild v moderate v
comparison time severity moderate severe moderate severe severe
Time - - 24 24 24 24 24
P value 0.002 0.001 0.0003 <0.00001 <0.00001 0.01 0.03
Levels of significance (p value) between the urea values in the different groups of rats 
culled at 24 hours, 48 and 72 hours.
Creatinine
comparison
with time with
severity
sham v 
moderate
sham v 
severe
mild v
severe
Time - - 24 24 24
P value 0.00001 0.001 0.03 0.02 0.05
Levels of significance (p value) between the creatinine values in the di 
rats culled at 24 hours, 48 and 72 hours.
ferent groups of
Na+ with with sham v sham v mild v mild v moderate
comparison time severity moderate severe moderate severe v severe
Time 24 24 24 24 24
P value 0.0001 0.001 0.01 <0.00001 0.03 <0.00001 0.0001
Levels of significance (p value) between the sodium values in the different groups of 
rats culled at 24 hours, 48 and 72 hours.
K + 
comparison
with
time
with
severity
sham v 
mild
sham v 
severe
mild v
severe
mod v 
severe
sham v 
mod
mild v 
mod
Time 24 24 24 24 72 72
P value 0.001 0.0005 0.02 0.0001 0.00001 0.00006 0.01 0.01
Levels of significance (p value) between the potassium values in the different groups of 
rats culled at 24 hours, 48 and 72 hours.
ALP
comparison
with
time
with
severity
sham v 
severe
mild v
severe
mod v 
severe
sham v 
severe
mild v
severe
mod v 
severe
Time 24 24 24 48 48 48
P value 0.001 0.00001 <0.00001 <0.00001 <0.00001 0.02 0.02 0.03
Levels of significance (p value) between the ALP values in the different groups of rats 
culled at 24 hours, 48 and 72 hours.
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Alb
comparison
with
time
with
severity
sham v 
moderate
sham v 
severe
mild v 
moderate
mild v
severe
Time 24 24 24 24
P value 0.0001 0.001 0.0003 0.00004 0.006 0.001
Levels of significance (p value) between the albumin values in the different groups of 
rats culled at 24 hours, 48 and 72 hours.
ALT
comparison
with
time
with
severity
Time - -
P value 0.00001 0.3
Levels of significance (p value) between the ALT values in the different groups of rats 
culled at 24 hours, 48 and 72 hours.
Comparison overall sham v 
severe
mild v
severe
moderate v 
severe
PH 0.00003 0.00002 <0.00001 0.0001
Base deficit 0.00003 0.00004 <0.00001 0.0001
Levels of significance (p value) between the pH and base deficit values in the rats of 
differing severities.
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6.2 Hepatic [NOx], [GSHJ and mitochondrial complex activities
[NOx|
comparison
with
time
with
severity
sham v 
severe
mild v
severe
sham v 
mod
sham v 
severe
mild v 
mod
mild v
severe
Time - - 24 24 48 48 48 48
P value 0.0002 0.02 0.004 0.02 0.0003 0.0005 0.001 0.001
Levels of significance (p value) between the hepatic NOx values in the different groups 
of rats culled at 24 hours, 48 and 72 hours.
|GSH1
comparison
with
time
with
severity
sham v 
severe
mild v
severe
sham v 
mild
sham v 
moderate
Time - - 24 24 72 72
P value 0.05 0.009 0.004 0.02 0.006 0.01
Levels of significance (p value) between the hepatic GSH values in the different groups 
of rats culled at 24 hours, 48 and 72 hours
Complex I with with sham v mild v sham v
comparison time severity severe severe mild
Time - - 24 24 72
P value <0.00001 0.6 0.03 0.09 0.03
Levels of significance (p value) between the hepatic complex I activity values in the
different groups of rats culled at 24 hours, 48 and 72 hours
Complex II/III 
comparison
with
time
with
severity
Time - -
P value 0.7 0.9
Levels of significance (p value) between the hepatic complex II/III activity values in the 
different groups of rats culled at 24 hours, 48 and 72 hours
Complex IV 
Comparison
with time with
severity
Time - -
P value 0.02 0.6
Levels of significance (p value) between the hepatic complex IV activity values in the 
different groups of rats culled at 24 hours, 48 and 72 hours
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6.3 Hepatic adenine nucleotide concentrations
|ATP|
comparison
with
time
with
severity
sham v 
severe
mild v
severe
moderate 
v severe
sham v 
moderate
mild v 
moderate
Time - - 24 24 24 72 72
P value 0.1 0.008 0.02 0.002 0.04 0.01 0.02
Levels of significance (p value) between the hepatic ATP values in the different groups 
of rats culled at 24 hours, 48 and 72 hours.
[ADP]
comparison
with
time
with
severity
sham v 
sepsis
sham v 
severe
Time - - 4 48
P value 0.09 0.03 0.02 0.05
Levels of significance (p value) between the hepatic ADP values in the different groups 
of rats culled at 24 hours, 48 and 72 hours.
|AMP]
comparison
with
time
with
severity
sham v 
severe
mild v 
severe
moderate 
v severe
sham v 
moderate
mild v 
moderate
Time - - 24 24 24 72 72
P value 0.04 0.00002 0.0003 0.00006 0.009 0.001 0.0003
Levels of significance (p value) between the hepatic AMP values in the different groups 
of rats culled at 24 hours, 48 and 72 hours.
Energy charge 
comparison
with
time
with
severity
sham v 
severe
mild v
severe
sham v 
moderate
mild v 
moderate
Time - - 24 24 72 72
P value 0.04 0.00002 0.0002 0.0001 0.001 0.001
Levels of significance (p value) between the hepatic energy charge values in the 
different groups of rats culled at 24 hours, 48 and 72 hours.
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ATP:ADP
comparison
with
time
with
severity
mild v
severe
sham v 
moderate
sham v 
moderate
mild v 
moderate
Time - - 24 48 72 72
P value 0.1 0.002 0.02 0.04 0.009 0.03
Levels of significance (p value) between the hepatic ATP: ADP ratios in the different 
groups of rats culled at 24 hours, 48 and 72 hours.
Adenine pool 
comparison
with time with
severity
Time - -
P value 0.04 0.2
Levels of significance (p value) between the hepatic adenine pool values in the different 
groups of rats culled at 24 hours, 48 and 72 hours
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6.4 Skeletal muscle [NOx], [GSH] and complex activities
|NOx)
comparison
with
time
with
severity
sham v 
mild
sham v 
mod
sham v 
severe
mild v
severe
mod v 
severe
sham v 
mod
sham v 
severe
Time - - 24 24 24 24 24 48 48
P value 0.006 0.00003 0.01 0.03 0.0001 0.05 0.04 0.02 0.001
Levels of significance (p value) between the skeletal muscle NOx values in the different 
groups of rats culled at 24 hours, 48 and 72 hours.
|GSH1
comparison
with
time
with
severity
sham v 
mod
sham v 
severe
sham v 
mild
sham v 
mod
mild v 
mod
Time - - 24 24 72 72 72
P value 0.001 0.0001 0.007 0.001 0.001 0.00002 0.01
Levels of significance (p value) between the skeletal muscle GSH values in the different 
groups of rats culled at 24 hours, 48 and 72 hours.
Complex I 
comparison
with
time
with
severity
sham v 
severe
mild v
severe
sham v 
severe
Time - - 24 24 48
P value 0.03 0.01 0.002 0.009 0.05
Levels of significance (p value) between the skeletal muscle comp 
in the different groups of rats culled at 24 hours, 48 and 72 hours.
ex I activity values
Complex II/III 
comparison
with time with
severity
Time - -
P value 0.3 0.9
Levels of significance (p value) between the skeletal muscle complex II/III activity 
values in the different groups of rats culled at 24 hours, 48 and 72 hours.
Complex IV 
comparison
with time with
severity
sham v 
mild
sham v 
moderate
moderate v 
severe
Time - - 24 24 24
P value <0.00001 0.02 0.006 0.0003 0.007
Levels of significance (p value) between the skeletal muscle complex IV activity values 
in the different groups of rats culled at 24 hours, 48 and 72 hours.
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6.5 Skeletal muscle adenine nucleotide concentrations
[ATP|
comparison
with
time
with
severity
sham v 
mild
sham v 
moderate
sham v 
moderate
mild v 
moderate
Time - - 24 24 72 72
P value 0.9 0.002 0.006 0.008 0.0003 0.01
Levels of significance (p value) between the skeletal muscle ATP values in the different 
groups of rats culled at 24 hours, 48 and 72 hours.
[ADP]
comparison
with
time
with
severity
sham v 
mild
sham v 
moderate
Time - - 24 24
P value 0.7 0.04 0.007 0.03
Levels of significance (p value) between the skeletal muscle ADP values in the different 
groups of rats culled at 24 hours, 48 and 72 hours.
|AMP]
comparison
with
time
with
severity
sham v 
severe
sham v 
moderate
Time - - 24 72
P value 0.01 0.0004 0.03 0.04
Levels of significance (p value) between the skeletal muscle AMP values in the 
different groups of rats culled at 24 hours, 48 and 72 hours.
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Energy charge 
comparison
with
time
with
severity
sham v 
septic
mild v
severe
sham v 
mild
sham v 
moderate
mild v 
moderate
Time - - 4 24 72 72 72
P value 0.1 0.001 0.004 0.04 0.03 0.0002 0.007
Levels of significance (p value) between the skeletal muscle energy charge values in the 
different groups of rats culled at 24 hours, 48 and 72 hours.
Adenine pool 
comparison
with
time
with
severity
sham v 
mild
sham v 
moderate
sham v 
moderate
mild v 
moderate
Time - - 24 24 72 72
P value 0.6 0.5 0.003 0.006 0.006 0.02
Levels of significance (p value) between the skeletal muscle adenine pool values in the 
different groups of rats culled at 24 hours, 48 and 72 hours.
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PATIENT/RELATIVE INFORMATION SHEET CONFIDENTIAL
Title of study: Changes in mitochondrial activity and density during critical illness 
Investigators: Dr D Brealey, Dr M Singer, Dr A Nathan, Dr A O’Brien Dr S Heales and 
Dr J Land.
Contact Number: ICU - 020 7380 9012 Office - 020 76799 6 6 6
The body’s cells contain specialized systems (mitochondria) which produce energy 
from fuels such as glucose. Most of the body’s oxygen demands are used for this 
energy production which enables the body to carry out its everyday functions. In 
critical illness the body does not seem fully able to utilize the available oxygen and the 
cells may not work properly as a result. This may be due to a breakdown in the 
function of the mitochondria, which we would like to study in detail.
We wish to compare normal patients undergoing surgery with patients on the 
intensive care unit being treated for severe infection, poor heart function and/or low 
oxygen levels in their blood. We would like to take a syringe-full of blood (20 ml) and 
a small biopsy of muscle tissue from the outer thigh though a small incision in the 
skin. For patients on intensive care we would like to repeat this at 4-5 day intervals to 
a maximum of 5 biopsies. This procedure takes only a few minutes and is associated 
with minimal complications, minor bleeding being the most frequent seen. However, 
this has not been found to be problematic in the hundreds of patients who have 
undergone this procedure. Nearly all the biopsies will be taken while the patient is 
sedated and asleep on the ventilator and will thus not be felt. If  the patient is awake, 
local anaesthetic is given to minimize any possible discomfort.
We would thus like to enrol you / your relative into this study, (delete as 
applicable). [For relatives: as your relative is currently unable to give consent, we 
seek your agreement. You do not have to give assent for your relative to take part in 
this study i f  you do not want to] You may withdraw at any time without giving a 
reason. Your decision whether to take part or not will not affect the care and 
management being given in any way. All proposals for research using human subjects 
are reviewed by an Ethics Committee before they can proceed. This proposal was 
reviewed by the Joint UCL/UCLH/NHNN Committees on the Ethics of Human 
Research.
Patient Consent / Relative Assent form CONFIDENTIAL
Title of study: Changes in mitochondrial activity and density during critical illness
Investigators: Dr D Brealey, Dr M Smith, Dr. M Singer Dr A Nathan, Dr A O’Brien, Dr S
Heales and Dr J Land.
To be completed by the patient/ next o f kin Delete as necessary
1. Have you read the information sheet about this study? YES/NO
2. Have you had an opportunity to ask questions and discuss this study? YES/NO
3. Have you received satisfactory answers to all your questions? YES/NO
4. Have you received enough information about this study? YES/NO
5. Which investigator have you spoken to about this study? _______________
6 . Do you understand that you are free to withdraw assent from this study
♦at any time
♦without giving a reason for withdrawing
♦without affecting the future medical care of your relative? YES/NO
7. Do you agree for you/your relative to take part in this study? YES/NO
Signed ---------------------------------------------  Date -------------------
Name in Block Letters ------------------------------------------------------------
Relationship to patient_____________________________________
Investigator _________  D ate___________
MECHANISMS OF DISEASE
M echanism s o f disease
Association between mitochondrial dysfunction and severity and 
outcome of septic shock
David Brealey, M ichael Brand, lain Hargreaves, Simon Heales, John Land, Ryszard Smolenski, Nathan A Davies,
Chris E Cooper, Mervyn Singer
Summary
Background Sepsis-induced multiple organ failure is the 
major cause of mortality and morbidity in critically ill 
patients. However, the precise m echanism s by which this 
dysfunction is caused remain to be elucidated. We and 
others have shown raised tissue  oxygen tensions in septic 
anim als and human beings, suggesting reduced ability of 
the organs to use oxygen. B ecause ATP production by 
mitochondrial oxidative phosphorylation accounts for more 
than 90% of total oxygen consumption, we postulated that 
mitochondrial dysfunction results in organ failure, possibly 
due to nitric oxide, which is known to inhibit mitochondrial 
respiration in vitro and is produced in excess in sepsis.
Methods We did skeletal muscle biopsies on 28 critically ill 
septic patients within 24 h of admission to intensive care, 
and on nine control patients undergoing elective hip surgery. 
The biopsy sam ples were analysed for respiratory-chain 
activity (complexes I—IV), ATP concentration, reduced 
glutathione (an intracellular antioxidant) concentration, and 
nitrite/nitrate concentrations (a marker of nitric oxide 
production).
Findings Skeletal muscle ATP concentrations were 
significantly lower in the 12 patients with seps is  who 
subsequently died than in the 16 septic patients who 
survived (p=0-0003) and in controls (p=0-05). Complex I 
activity had a significant inverse correlation with 
norepinephrine requirements (a proxy for shock severity, 
p=0-0003) and nitrite/nitrate concentrations (p=0-0004), 
and a significant positive correlation with concentrations of 
reduced glutathione (p=0-006) and ATP (p=0-03).
Interpretation In septic patients, we found an association 
between nitric oxide overproduction, antioxidant depletion, 
mitochondrial dysfunction, and decreased ATP concentrations 
that relate to organ failure and eventual outcome. These data 
implicate bioenergetic failure a s  an important patho­
physiological mechanism underlying multiorgan dysfunction.
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Introduction
Sepsis is the systemic inflammatory response associated 
with an infectious insult. It is the leading cause o f 
death in critically ill patients, and the predominant cause 
of multiple organ dysfunction.1 However, precise 
mechanisms through which organ dysfunction develops 
remain unknown, as do reasons for its persistence long 
after cessation o f the acute inflammatory phase. Although  
microvascular flow redistribution undoubtedly occurs,2 
we and others have shown increased tissue oxygen  
tension in the organs o f animals and patients with 
sepsis.34 This finding suggests that the predominant 
defect might lie in cellular oxygen use (tissue dysoxia) 
rather than in oxygen delivery per se.
Mitochondrial o x i d a t i v e  p h o s p h o r y l a t i o n  is 
responsible for over 90% o f total body oxygen 
consumption and ATP generation. The r e s p i r a t o r y  
c h a i n  (electron-transport chain) includes four individual 
enzyme complexes (I-IV). These enzyme complexes, 
notably NADH -ubiquinone oxidoreductase (complex I) 
and cytochrome C oxidase (complex TV), can be inhibited 
by reactive oxygen and nitrogen species such as nitric 
oxide.5 7 These reactive species are produced in substantial 
excess during sepsis and are also generated by the 
mitochondria.8 Complex I inhibition by nitric oxide is 
facilitated, in vitro, by depletion o f the intracellular 
antioxidant reduced glutathione.5,6 Concentrations o f this 
antioxidant are also known to decrease in septic states.910
N o  study has yet addressed whether alterations in 
BIOENERGETIC s t a t u s  in severe sepsis are associated with 
increased nitric oxide production, mitochondrial 
dysfunction, and antioxidant depletion, and whether these 
abnormalities relate to organ failure and to outcome. T o  
address these questions, we undertook a systematic study 
o f mitochondrial dysfunction in critically ill patients with 
sepsis admitted to intensive care.
Methods
Patients
After obtaining approval from the ethics comm ittee o f the 
University College London Hospitals National Health 
Service Trust, patients were recruited from the intensive- 
care unit or from the orthopaedic department. Patients 
(or their next-of-kin) were asked for informed consent (or 
agreement) before enrolment.
Patients with recent-onset severe sepsis or septic shock 
(as defined by standard criteria11) were enrolled. Those  
with severe coagulopathies (platelet count < 30X 109/L  or 
international normalised ratio >2), immunosuppression 
(endogenous or long-term chemotherapeutic), or both, 
were excluded. Routine physiological and biochemical 
variables were recorded, and scores on the simplified 
acute physiology score (SAPS II) and sequential organ 
failure assessment (SOFA) calculated. T he control group 
consisted o f otherwise healthy patients undergoing
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G L O S S A R Y
BIOENERGETIC STATUS
Energy "stored" in a form (ATP) that is readily available for cellular 
metabolism.
OXIDATIVE PHOSPHORYLATION
The coupling of energy released from substrate oxidation by the 
respiratory chain to the synthesis of ATP.
RESPIRATORY CHAIN
Terminal pathway of oxidative phosphorylation, a series of mitochondrial 
oxidoreductive molecules including cytochromes responsible for the 
stepwise transfer of electrons from substrates to oxygen.
elective total hip replacement surgery for degenerative 
arthropathy.
Procedures
W ithin 24 h o f patients’ admission to the intensive-care 
unit, a vastus lateralis muscle biopsy was done with 
H enckel Tilley forceps via a small incision in the 
lateral thigh. This procedure is safe for critically ill 
patients.12 Five to six biopsy samples (averaging 750 mg 
total) were frozen immediately in liquid nitrogen. 
In the controls, muscle biopsies were taken through 
the operation site from the vastus lateralis thigh 
m uscle at the beginning o f surgery and processed as 
above.
M itochondrial com plex activities were measured by 
well described spectrophotometric m ethods.13 Tissue 
samples were hom ogenised on ice with a hand-held glass 
hom ogeniser, then underwent three episodes o f rapid 
freeze-thawing to ensure cell lysis. Com plex activities 
were measured as the inhibitor sensitive rates (rotenone 
for com plex I and antimycin A for com plexes II and III). 
T o correct for mitochondrial enrichm ent (or depletion) 
within the sample, results were expressed as a ratio o f 
citrate synthase activity.14 C om plex I activity was also 
measured after addition o f reduced glutathione 
(hom ogenates were incubated in up to 5 m m ol/L  
reduced glutathione for up to 40 min) to determine 
whether inhibition could be reversed.5
C oncentrations o f reduced glutathione were measured 
in m uscle by reverse-phase high-performance liquid 
chromatography and electrochemical detection;15 results 
were expressed as a ratio o f total protein. Adenine 
nucleotide (ATP, A D P, and A M P), phosphocreatine, 
and creatine concentrations were measured in the 
m uscle samples by reverse-phase high-performance 
liquid chromatography after freeze-drying;16 results were 
expressed as nm ol/m g o f dry-weight tissue. M uscle 
nitrite/nitrate concentrations were measured by a 
m odified Griess reaction as a marker o f nitric oxide 
production.17 T hese results were expressed as a ratio of 
total w et weight protein.
Septic survivors Septic Controls
(n=16) non-survivors (n=9)
___________________ ________________ (n=12)
Age
Sex (male/female)
Weight (kg)
Source of sepsis 
Chest 
Abdominal 
Septicaemia 
Other 
Prior surgery 
Comorbid factors 
Diabetes 
Malignancy 
1st 24 h SAPS II score 
1st 24 h SOFA score 
Vasoactive drug 
requirement (pg/min)
Arterial base deficit 
(mEq/L)
Blood glucose 
(mmol/L)
Oxygen delivery 
(mL/min)
Cardiac output (L/min)
Mean blood pressure 
(mm Hg)
SVR (dyn.s.cnrr5)
Length of ICU stay
(days)______________
Data are numbers of patients or median (IQR). SAPS=simplified acute physiology 
score. SOFA=sequential organ failure assessment. SVR=systemic vascular 
resistance. ICU=intensive-care unit.
Table 1: Demographic and clinical characteristics at the time of 
biopsy
Statistical analysis
Data are expressed as median (IQR). Overall statistical 
significance between the groups was tested with a one­
way ANO VA or Kruskal-Wallis test, depending on 
normality o f distribution. Post-hoc analyses with 
correction for multiple comparisons were done with least 
significant difference or Dunnett tests, as appropriate. 
Correlations were calculated with a Spearman correlation 
coefficient (two-tailed test o f significance).
Role o f the funding source
T he sponsors o f the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing o f the report.
Results
O f the 28 patients with sepsis, 16 survived the septic 
episode (survivors). Non-survivors died in the intensive- 
care unit, with a median stay o f 6 days. All patients had 
increased cardiac outputs and all but two were requiring 
norepinephrine to maintain a mean blood pressure in 
excess o f 60 mm Hg. All were mechanically ventilated 
and 12 underwent haemofiltration. For patients who did
65 (46-71)
8 /8  
80 (58-90)
4
6
4 
2
5
2
0
42 (31-50)
8 (7-13)
22-3 (7-2-35-7)
5-8 (1-7-7-8)
5-6 (5-2-S-2)
64 (47-73)
7 /5  
65(59-73)
6
6
0
0
5
1
1
53 (37-79)
11 (8-14)
23 (19-28)
7-0 (2-7-10-1)
6-3 (3-9-8-8)
70 (65-73) 
5 /4  
64 (57-68)
1404 1132
(1040-1634) (715-1404)
7-1 (4-9-9-3) 7-2 (6-0-8-6)
66 (60-5-70-0) 73 (6&-80)
630 (339-699) 630 (449-691)
9-0 (4-0-18-5) 6-0 (4-0-8-8)
Septic survivors (A) Septic non-survivors (B) Controls (C) p (A vs B vs C)
ATP (nmol/mg dry weight) 15-8 (12-1-18-6), n=12 7-6 (6-6-10-0), n=9 12-5 (9-7-13-7), n=8 0-001
ADP (nmol/mg dry weight) 2-3 (1-6-2-7), n=12 2-3, (1-5-5-4), n=9 2-6 (1-2-3-1), n=8 0-83
AMP (nmol/mg dry weight) 0-12 (0-06-0-23), n=12 0-44 (0-1-0-8), n=9 0-2 (0-09-0-4), n=8 0-22
ATP:ADP ratio 7-44 (5-2-8-7), n=12 4-39 (1-4-5-1), n=9 5-5 (4-1-8-0), n=8 0-02
Total adenine content 18-2 (14-0-22-0), n=12 12-5 (9-9-13-6), n=9 16-1 (13-4—16-5), n=8 0-02
(nmol/mg dry weight) 
Phosphocreatine 47-1 (47-1-65-3), n = l l 36-1 (28-4-45-7), n=9 62-4 (56-8-63-9), n=8 0-02
(nmol/mg dry weight)
Creatine (nmol/mg dry weight) 43-2 (36-3-50-3), n = l l 41-5 (35-2-46-8), n=9 31-6 (28-3-43-0), n=8 0-24
Phosphocreatine:creatine ratio 1-28 (0-76-1-6), h = l l 0-98 (0-84-1-1), n=9 1-88 (1-4-2-2), n=8 0-006
Data are median (IQR). n=number of patients on whom sample analysis was done.
Table 2: Concentrations in sk ele ta l m uscle of ATP, ADP, AMP, phosphocreatine, and creatine
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Figure 1: Tissue ATP concentrations in patients with se p s is  
and in controls
Horizontal lines=medians, boxes=quartiles, whiskers=ranges.
not respond to high-dose norepinephrine (seven eventual 
survivors and two non-survivors), a 16 mg dose of 
dexamethasone was given within 6 h o f the biopsy. N o  
significant difference was seen between septic survivors 
and non-survivors in terms o f demographics, comorbid 
and other factors, cause o f sepsis, severity o f organ 
dysfunction, and physiological variables at the time o f 
biopsy (table 1). All nine control patients undergoing 
elective total hip replacement surgery were discharged 
home after an uneventful postoperative course.
Owing to variation in the amount o f tissue obtained, 
we were unable to do a full set o f analyses on all patients. 
M uscle A TP concentrations were significantly lower in 
septic non-survivors than in either septic survivors 
(p=0-0003) or controls (p=0-05; table 2, figure 1). AM P  
concentrations were slightly higher in non-survivors than 
survivors, and the total adenine pool was significantly 
lower, suggesting increased A TP hydrolysis. Complex I 
activity was significantly lower in septic non-survivors 
than controls, and reduced glutathione concentrations 
were significantly lower in both septic groups (table 3). 
N o reversibility o f complex I inhibition was achieved by 
addition o f exogenous glutathione. N o  difference 
between the groups was seen in the activities o f complex  
II and III, whereas complex IV activity was significantly 
higher in septic non-survivors than controls. The 
phosphocreatine:creatine ratio was also lower in the 
septic patients than controls (table 2).
We found significant positive correlations between 
tissue concentrations o f nitrite/nitrate and severity o f  
disease (norepinephrine requirement and SAPS II) and 
between complex I activity and both A TP and reduced 
glutathione concentrations (figures 2 and 3). Significant 
negative correlations were seen between norepinephrine 
requirement and both complex I activity and ATP  
concentration (figure 2); and between nitrite/nitrate 
concentrations and both complex I activity and reduced
n=0-68
O  Septic survivors 
•  Septic non-survivors
I I I i
0 20 40 60
Norepinephrine requirement (p,g/min)
0-3-,
0 -2 -
0 - 1 -
r T
Norepinephrine requirement (|xg/min)
60-,
4 0 -
20 -
0-1
0 5 10 15 20 25
ATP (nmoL/mg)
0-3-,
o
0 -
i--------------- 1---------------- 1------------------ 1------------------1------------------1
0 5 10 15 20 25
ATP (nmoL/mg)
Figure 2: Correlation betw een norepinephrine requirement, 
t is su e  nitrite/n itrate concentration, com plex I activity, and 
ATP concentration
Septic survivors (A) Septic non-survivors (B) Controls (C) p (A vs B vs C)
Complex 1 activity* 0 1 8  (0-14-0-23), n=16 0-15 (0-11-0-18), n=10 0-21 (0-18-0-24), n=8 0-03
Complex II and III activity* 0-13 (0-10-0-16), n=16 0-13 (0-12-0-15), n=12 0-12 (0-11-0-14), n=9 0-35
Complex IV activity* 0-014 (0-01-0-02), n=16 0-020 (0-013-0-02), n=12 0-011 (0-01-0-017), n=8 0-05
Reduced glutathione 5-0 (3-5-5-8), n=13 3-9 (2 -2- 4 -8 ), n = l l 9-8 (8-4-11-0), n=8 0-0004
(nmol/mg total protein)
Nitrite/nitrate 118 (99-159), n=8 176 (173-197), n=7 86 (45-103), n=6 0-001
(p.mol/mg total protein)
♦Expressed as a ratio of citrate synthase activity. Data are median (IQR). n=number of patients on whom sample analysis was done.
Table 3. Activities of mitochondrial com plexes and concentrations of reduced glutathione and nitrite/nitrate in skeletal m uscle
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Figure 3: Correlation between tissu e  nitrite/nitrate 
concentration, simplified acute physiology score (SAPS II), tissue  
reduced glutathione (GSH) concentration, and complex I activity
glutathione concentration (figure 3). N o  correlation was 
found between complex II and III or com plex IV activity 
and any other variable investigated.
Discussion
We have shown, in patients with sepsis and multiple 
organ failure, a relation between shock severity (as 
gauged by norepinephrine requirements to maintain  
an adequate blood pressure), mitochondrial dysfunction, 
A TP depletion, intracellular antioxidant (reduced  
glutathione) depletion, and nitric oxide production (as
gauged by nitrite/nitrate concentrations) in skeletal 
muscle. D espite being unable to distinguish clinically 
between eventual survivors and non-survivors, 
significant differences were seen in muscle bioenergetic 
status taken within 24 h o f intensive-care admission.
Although the number o f patients is relatively low and 
multiple comparisons were made on the data, the findings 
are nevertheless in keeping with cellular, animal, and the 
sparse human data previously reported. Short-term (<6 h) 
laboratory models o f sepsis have shown variable changes 
in mitochondrial respiration, whereas longer term 
models (>12 h) consistently reveal decreases in 
mitochondrial activity or ATP concentrations as the 
predominant finding.18 ATP depletion19-20 and inhibition of  
the mitochondrial respiratory-chain complexes have been 
shown separately in small case series o f patients with 
sepsis.21,22
T he respiratory chain is located in the mitochondrial 
inner membrane and consists o f the four complexes plus 
specialised electron carriers. Passage o f electrons down 
the chain creates a proton gradient across the inner 
membrane sufficient to drive A TP synthase (complex V) 
to phosphorylate A D P to ATP. T hese complexes can be 
inhibited by nitric oxide and its congeners,5 7 which are 
produced in excess during sepsis.23 Although studies o f 
nitric oxide have focused heavily on its role in inducing 
vascular hyporeactivity, little attention has been paid to 
its role as a mitochondrial inhibitor.
Cell models have shown rapidly reversible inhibition o f  
complex IV by nitric oxide competitive with oxygen 
tension.7 Because nitric oxide is unstable, free nitric oxide 
concentrations that remain in the homogenates are 
unlikely to be high enough to allow observation o f this 
reversible inhibition, especially at the much higher 
oxygen partial pressures (room air) under which the 
assay is done. However, the observed rise in complex IV 
activity was unexpected, although nitric oxide has been 
shown to induce the transcription o f complex IV.24
Nitric oxide has a longer-lasting effect on complex I 
than on complex IV.5-6 Our finding o f low complex I 
activity in combination with raised nitrite/nitrate concen­
trations and low reduced glutathione concentrations are 
in keeping with these in-vitro data. However, unlike cell 
m odels,5 we were unable to detect any reversibility 
on addition o f exogenous glutathione. We presume 
that the lengthy course of sepsis and extended exposure to 
reactive nitrogen species results in irreversible inhibition 
or permanent damage to the enzyme complex.
We cannot exclude a norepinephrine effect on 
mitochondria, but we consider this possibility unlikely. 
Animal and cellular studies o f sepsis show mitochondrial 
dysfunction in the absence of vasopressor agents,18 
whereas preliminary data (not shown) from four o f our 
patients with cardiogenic shock who required similar 
doses o f epinephrine revealed no fall in ATP compared 
with the controls.
Absolute muscle A TP concentrations and ATP:ADP  
ratios were significantly lower in non-surviving septic 
patients than survivors. The rise in AM P (and a lower 
adenine nucleotide pool) suggests an imbalance in ATP  
turnover, which could be a result o f decreased ATP  
production, although an increase in A TP use might also 
be contributory. ATP turnover cannot be readily 
elucidated by an ex-vivo assay; however, cells must 
maintain steady-state ATP concentrations above those 
that trigger apoptosis or necrosis.25
Damage or inhibition of complex I could decrease 
mitochondrial capability to generate ATP. The 30% 
decrease seen in the present study is similar to that
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associated with diseases known to be associated with 
mitochondrial dysfunction, such as Parkinson’s disease.26
T w o unresolved issues are the need to establish that 
mitochondrial dysfunction is causative rather than 
epiphenomenal, and to determine how relevant these 
findings in skeletal muscle are to other, more vital, organs 
such as liver and kidney. W e are currently studying long­
term laboratory models o f sepsis that seek to address 
these questions. Nevertheless, our findings implicate 
bioenergetic failure as an important pathogenetic 
mechanism underlying sepsis-induced multiple organ 
failure that could offer new therapeutic avenues.
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